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Background 
 
Hypospadias is a congenital malformation of the male external genitalia resulting from 
developmental arrest of the urethral fusion. The term hypospadias is derived from the prefix 
hypo- (under) and the verb spadonizo (to tear)1, referring to the displacement of the urethral 
opening at the ventral side of the penis. The displacement can be small, with the opening being 
located in the glandular region, or more substantial, with a penile, scrotal, or perineal opening. 
Consequently, hypospadias can be classified into different subgroups, which are depicted in 
Figure 1. 
 
 
Figure 1.  The different hypospadias subgroups. 
 
 
 
 
Hypospadias is a frequently occurring birth defect, affecting approximately 0.3 to 0.7% of 
newborn boys in Europe2,3. Generally, surgery is the treatment of choice, unless there is only a 
minimal displacement. The operation is usually performed in the first two years of a child’s life, 
and more than 250 techniques have been described. Local skin, buccal mucosa, or tissue from 
another site of the body is often used to create a tube that increases the length of the urethra, 
allowing it to open at the tip of the penis. Complications can occur in up to half of the patients4, 
and although most studies conclude that psychosocial development is not seriously altered, 
patients do suffer from negative genital appraisal5,6, sexual inhibition5, and more erection and 
ejaculation problems6. The high prevalence, invasive treatment, and dissatisfactory treatment 
results warrant aetiological research, with the ultimate aim of providing preventive measures 
for hypospadias. 
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In only a few hypospadias cases, a cause of the disorder can be identified, such as a steroid-5-
alpha-reductase type II deficiency or partial androgen insensitivity due to androgen receptor 
mutations. Alternatively, hypospadias can be part of a complex genetic syndrome with a known 
cause, such as the Smith-Lemli-Opitz or Denys-Drash syndrome7,8. In most cases, however, the 
aetiology has not been unravelled yet, and segregation analysis suggests a multifactorial 
aetiology, involving both genetic and environmental factors, for the majority of patients9.  
 
 
Objectives 
 
The aim of this research project was to obtain more insight into the genetic and environmental 
risk factors contributing to the development of hypospadias. We hypothesized that the various 
forms of hypospadias may have a different aetiology, and took this into account in all studies. 
Concerning genetic factors, we focused on: 
- previously reported associations with single nucleotide polymorphisms (SNPs) in 4 
genes: steroid-5-alpha-reductase (SRD5A2), oestrogen receptor 1 (ESR1) and 
2 (ESR2), and activating transcription factor 3 (ATF3); 
- gene-environment interactions between these SNPs and endocrine-related or stress-
inducing environmental factors; 
- identification of novel hypospadias candidate genes. 
Concerning environmental factors, we concentrated on: 
- demographic factors, such as familial occurrence of hypospadias and parental age; 
- pregnancy-related factors, such as subfertility and pregnancy complications; 
- lifestyle factors, such as exposure to endocrine disruptors, smoking, and alcohol use.
  
 
Populations and study design  
 
The findings described in this thesis are based on the integration of different studies and study 
populations (Fig. 2). The Regional Committee on Research Involving Human Subjects approved 
all studies. In 2002, questionnaire data were collected for a pilot study and subsequently, in 
2005, for the ZOON study (Zoon Ouder Onderzoek Nijmegen). DNA collection from patients 
and their parents for the AGORA data- and biobank (Aetiologic research into Genetic and 
Occupational / environmental Risk factors for Anomalies in children) started in December 
2004, while in 2006, questionnaire data were collected for the included patients. From 2006 
onwards, DNA and questionnaire data were collected simultaneously in AGORA. In 2006 and 
2007, a retrospective DNA collection effort was performed among the participants of the pilot 
study and the ZOON study. From all patients, clinical information was collected from the 
medical records.  
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Using these data, we tried to replicate previously reported associations for four SNPs, we 
performed gene-environment interaction analyses, and we carried out the first genome-wide 
association study (GWAS) for hypospadias. In addition, we performed two studies on environ-
mental factors contributing to this anomaly. In the first one, we used the questionnaire data 
collected in the ZOON study, while in the second one, we tried to replicate these findings in the 
patients collected in AGORA, supplemented with cases from the pilot study (Fig. 2). 
 
 
Figure 2.  Schematic representation of data collection and analyses among the different 
study populations. 
 
 
 
ZOON (Zoon Ouder Onderzoek Nijmegen); AGORA (Aetiologic research into Genetic and Occupational 
/ environmental Risk factors for Anomalies in children); NBS (Nijmegen Biomedical Study); GWAS 
(genome-wide association study); *the collection of DNA for the AGORA data- and biobank started in 
December 2004. Questionnaire data for the patients included in AGORA during 2004 and 2005 were 
collected retrospectively in 2006. From 2006 onwards, DNA and questionnaire data are collected at 
the time of hospitalisation. 
 
 
Outline of this thesis 
  
After an extensive review of the literature on the aetiology of hypospadias described in 
Chapter 1.2, Part 2 of this thesis focuses on genetic risk factors for hypospadias, whereas Part 3 
concentrates on the environmental contribution to this malformation. Chapter 2.1 describes 
our efforts to replicate previously reported associations for four SNPs in endocrine-related 
genes. The gene-environment interaction analyses that we performed in an attempt to 
reconcile our findings with those of others, mainly studying hormone-related risk factors, are 
presented in Chapter 2.2. The genome-wide association study is described in Chapter 2.3. 
Chapter 3.1 concentrates on environmental factors contributing to hypospadias, while Chapter 
3.2 focuses on their involvement in the different hypospadias subgroups in particular. A 
general discussion of methods, findings, and perspectives is included in Chapter 4.1. 
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Abstract 
 
Background  
Hypospadias is a common congenital malformation of the male external genitalia. Most cases 
have an unknown aetiology, which is likely to be a mix of monogenic and multifactorial forms, 
implicating both genes and environmental factors. This review summarizes the current 
knowledge about the aetiology of hypospadias. 
 
Methods  
Pubmed was used to identify studies on hypospadias aetiology published between January 
1995 and February 2011. In addition, reference lists of the selected manuscripts were searched 
to identify additional studies, including those published before 1995. 
 
Results  
Studies screening groups of hypospadias patients for single gene-defects found mutations in 
WT1, SF1, BMP4, BMP7, HOXA4, HOXB6, FGF8, FGFR2, AR, HSD3B2, SRD5A2, ATF3, MAMLD1, 
MID1, and BNC2. However, most investigators are convinced that single mutations do not 
cause the majority of isolated hypospadias cases. Indeed, associations were found with 
polymorphisms in FGF8, FGFR2, AR, HSD17B3, SRD5A2, ESR1, ESR2, ATF3, MAMLD1, DGKK, 
MID1, CYP1A1, GSTM1, and GSTT1. In addition, gene expression studies indentified CTGF, 
CYR61, and EGF as candidate genes. Environmental factors consistently implicated in 
hypospadias are low birth weight, maternal hypertension, and preeclampsia, suggesting that 
placental insufficiency may play an important role in hypospadias aetiology. Exogenous 
endocrine disrupting chemicals have the potential to induce hypospadias, but it is unclear 
whether human exposure is high enough to exert this effect. Some other environmental factors 
have been associated with hypospadias, but for most, results are inconsistent.  
 
Conclusions  
Although a number of contributors to the aetiology of hypospadias have been identified, the 
majority of risk factors remain unknown. 
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Introduction 
 
Hypospadias is a congenital hypoplasia of the penis, with displacement of the urethral opening 
along the ventral surface, often associated with dorsal hooded foreskin and chordee. More 
than 50% of cases have anterior hypospadias, with a small displacement of the meatus in the 
glandular region1,2. Other patients have more substantial displacements, with middle (penile) 
or posterior (penoscrotal, scrotal, and perineal) openings (Figure I). Hypospadias is usually 
diagnosed during physical examination of the newborn, but localization is best established 
during surgery, after chordee release. Compared to healthy children, boys born with 
hypospadias more often have additional congenital anomalies3-6, an association that appears to 
be stronger for posterior compared to anterior cases3,4,7. Especially cryptorchidism and other 
urogenital anomalies are frequently found with hypospadias4,8-10.  
 
 
Figure I. Hypospadias subgroups. 
 
 
 
Even when patients receive surgery in their first two years of life, they may encounter severe 
medical, social, and sexual problems later in life. After long-term follow-up (10 years) of mainly 
anterior hypospadias patients who underwent 1-stage repair, different rates of complications 
up to 50% were reported, depending on inclusion of different aspects11. Although most studies 
conclude that psychosocial development is not seriously altered, patients do suffer from 
negative genital appraisal, sexual inhibition, and more erection and ejaculation problems12,13.  
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Prevalence 
Figures on the birth prevalence of hypospadias vary considerably across countries, ranging 
from four to 43 cases per 10,000 births4,14. Hypospadias occurs most frequently in whites, less 
frequently in blacks, and rates are lowest among Asians and Hispanics15-23. There is debate 
about whether or not the prevalence of hypospadias is increasing. Some researchers reported 
increasing prevalences in China24,25, Australia4, the USA20,26, and Europe27, whereas others did 
not find an increase in Canada, the USA17,18,28, Europe29-31, and Japan14. However, results of 
different studies are difficult to compare because some are based on hospital discharge 
registries, including only surgically treated patients or all newborns diagnosed with 
hypospadias, whereas others are based on birth defects surveillance systems, including all 
registered hypospadias cases or excluding cases with glandular hypospadias. In addition, the 
diagnosis and definition of hypospadias may have changed over time.  
 
Embryology of the male external genitalia 
 
Indifferent stage 
Early development of the external genitalia is similar for males and females. The embryonic 
cloaca, the far end of the hind gut, is separated from the amniotic cavity by the cloacal 
membrane. Early in the fifth week of development, a swelling develops on both sides of this 
membrane, the cloacal folds, which meet in the midline anterior to the cloacal membrane, 
forming the genital tubercle32 (Figure II). At the same time, the genital ridges, the precursors of 
the gonads, develop. Studies in mice showed that this process requires Wilms tumour 1 (Wt1) 
activity, which activates splicing factor 1 (Sf1)33, thus preventing degeneration of the develop-
ping gonads34. During the seventh week of human development, the urorectal septum fuses 
with the cloacal membrane, dividing the cloaca into the primitive urogenital sinus and the 
rectum, and dividing the cloacal membrane into the urogenital and the anal membrane. The 
swellings next to the urogenital membrane are then called the urogenital folds, and a new pair 
of swellings, the labioscrotal swellings, appear on either side of these folds. In addition, the 
urogenital membrane breaks down32. 
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Figure II. Simple schematic drawing of the normal embryology of the male external 
genitalia, which is disturbed in case of hypospadias development.  
 
Early patterning 
The genital tubercle (GT) masculinises if exposed to androgens, but early patterning is 
androgen-independent. Studies on genes and proteins involved in this patterning process have 
mainly been performed in mice, and showed that the distal urethral plate epithelium is the 
signalling centre regulating GT outgrowth35. Fibroblast growth factor protein (Fgf) and 
wingless-type MMTV integration site family member 5A (Wnt5a) signalling have a growth-
promoting role in this outgrowth36, whereas bone morphogenetic proteins (Bmps) stimulate 
apoptosis37,38. Expression of Fgf8 in the urethral plate is regulated by sonic hedgehog (Shh) and 
homeobox A13 (Hoxa13)35,37,39, while Hoxa13 also regulates expression of Bmp737. Shh induces, 
either directly or via Fgf8 or other factors, expression of Fgf10, Bmp2, Bmp4, Wnt5a, Patched 1 
(Ptch1), Msh homeobox 1 (Msx1), and Hoxd1335,39. Shh thus modulates the balance between 
proliferation and apoptosis39, and regulates the initiation of GT outgrowth35. Immunohisto-
chemical staining of human foetal penises showed expression of SHH, its receptor PTCH1, and 
its downstream genes smoothened, frizzled family receptor (SMO) and GLI family zinc finger 1 
(GLI1) around the time of urethral closure40. Studies in mice showed that Wnt-β-catenin 
signalling also seems to play a role in GT development, either in early androgen-independent 
GT development41, or as a downstream effector of androgen signalling essential for GT 
masculinisation42.  
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Masculinisation 
Subsequent masculinisation relies on hormones produced by the testes. Expression of the sex 
determining region Y gene (SRY) induces a cascade of gene-interactions, involving SRY-box 9 
(SOX9)32, resulting in differentiation of the gonads into the testes43. SRY leads to the 
differentiation of Sertoli cells32, which secrete anti-Müllerian hormone (AMH). Studies in mice 
showed that AMH secretion happens under influence of Sf144. AMH causes regression of the 
Müllerian ducts that would otherwise form part of the female genital structures32. Human 
chorionic gonadotropin (hCG), produced by the placenta, controls foetal Leydig cell growth and 
stimulates foetal testicular steroidogenesis, the generation of steroids from cholesterol45. The 
enzymatic steps of steroidogenesis, mainly taking place in the Leydig cell, are well 
documented, and expression of key genes in this pathway is dependent on expression of SF146 
(Figure III). Testosterone leaves the Leydig cell and is converted into dihydrotestosterone (DHT) 
by steroid-5-alpha-reductase (SRD5A). Testosterone promotes formation of the internal 
reproductive structures from the Wolffian ducts, whereas DHT induces development of the 
external genitalia32, both through their effect on the androgen receptor (AR). Expression of 
oestrogen receptors (ESR) in male genital tissue during development suggests that the balance 
between androgens and oestrogens is important as well47. 
 
Figure III. Steroidogenesis in the mitochondrium (top) and smooth endoplasmic reticulum 
(bottom) of the foetal Leydig cell. 
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During masculinisation of the external genitalia, between the 12th and 14th week after 
conception32, the GT develops into the penis, the labioscrotal swellings fuse to form the 
scrotum32,48, and the urogenital folds close in a proximal to distal direction to form the penile 
urethra32,48-51 (Figure II). Several hypotheses have been proposed about formation of the 
glandular portion of the urethra. One of these states that, while the penile urethra is created 
by fusion and primary luminisation, the glandular urethra develops by fusion and secondary 
luminisation51. According to another hypothesis, the complete urethra arises by fusion of the 
urogenital folds48,52. Still others believe that the glandular portion of the urethra originates 
from a different set of folds53, ingrowth of surface cells54, or canalization of the urethral plate32.  
 
As a result, the development of hypospadias is also controversial. From a clinical point of view, 
development of the urethra, corpora, glans, and penile skin are directly correlated. In posterior 
hypospadias, there is non-fusion of the labioscotal swellings with a distal dysplasia of the 
urethral plate and corpora, as well as non-fusion of the glans and skin in the midline. In middle 
hypospadias, the distal part of the penis shows a persistence of the urethral plate and non-
tubularisation of the glans with disturbed penile skin formation. In glandular hypospadias, 
there is a dimple or a short tubular tract with a septum in between this tract and the urethral 
plate or tube and no closure of the skin in the midline. In the most minimal form, hypospadias 
sine hypospadias, only non-fusion of the preputial skin on the ventral side is seen, with dorsal 
hooded foreskin with or without some chordee.  
 
Aim of this review 
In 30% of the least frequently occurring posterior hypospadias cases, a cause can be identified, 
for example a complex genetic syndrome, partial androgen insensitivity due to androgen 
receptor mutations, or steroid 5 alpha reductase type II deficiency55,56. The aetiology of most 
other hypospadias cases, however, is not yet solved in spite of intensive research. In this 
review, we will summarize the current knowledge about the causes of the isolated, non-
syndromic form of this common birth defect in humans, from both a genetic and an 
environmental point of view. In addition, we will provide recommendations for further 
research. 
 
 
Methods 
 
Pubmed was used to identify all relevant manuscripts on the aetiology of hypospadias. We 
searched for papers published between January 1995 and February 2011 in the English 
language using the following keywords in the title or abstract: “(hypospadia OR hypospadias) 
NOT surgical NOT surgery NOT reconstruction NOT repair NOT incised NOT procedure”. This 
search provided 922 articles, of which we used the titles and abstracts to identify relevant 
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papers. We focussed our review on the aetiology of isolated hypospadias in humans. 
Therefore, we excluded all animal studies (N = 99), articles that were not about hypospadias or 
the aetiology of hypospadias (N = 235), and articles or case-reports that described the 
phenotype of patients suffering from syndromes including hypospadias, or that investigated or 
described the most likely cause of the syndrome in these boys (N = 308). To systematically 
exclude articles with a lesser degree of evidence, we excluded all ecological studies (N = 11). 
For epidemiologic studies reporting negative findings, we took the power into consideration 
before reporting that it showed no association. In general, we excluded negative studies 
describing <100 cases, as these have e.g. only 37% power to statistically significantly (P<0.05) 
detect a two-fold increased risk, assuming a prevalence of 10% (N = 15). To guarantee that all 
information was included only once in the article, we excluded all reviews and meta-analyses 
(N = 79). In addition, when a study was supplemented with new data in a later publication (N= 
3), we only included the article reporting the most complete data. Finally, all commentaries 
were excluded (N = 32). Reference lists of the selected manuscripts were searched to identify 
additional studies, including those published before 1995, although these were only included if 
they reported results that were not found in one of the more recently published articles (N = 
29). This selection process resulted in 169 original articles that were included in this review and 
are described below. 
 
 
Results 
 
Aetiology of hypospadias is multifactorial 
Hypospadias shows familial clustering, with 7% of cases having affected first, second, or third 
degree relatives2. Familial occurrence seems to be more common for anterior and middle 
forms of hypospadias than for posterior types2,57. The chance that a brother of an affected boy 
will also have hypospadias is 9 to 17%58-60. In two family studies and one small twin study, the 
heritability of hypospadias was estimated to be 57 to 77%58-60, meaning that 57 to 77% of the 
phenotypic variability can be attributed to genetic variability. Because hypospadias is equally 
transmitted through the maternal and paternal sides of the family, and recurrence risks for 
brothers and sons of hypospadias cases are similar, genetic rather than shared environmental 
factors may play a principal role in familial hypospadias58. Segregation analysis, however, 
suggested that the majority of cases have a multifactorial aetiology, involving both genes and 
environmental factors61.  
 
Genes implicated in the aetiology of isolated hypospadias 
Much of the genetic research on hypospadias has been focused on identification of causal 
mutations. In Table I, we summarize the exonic (including 3’-UTR and splice acceptor sites) 
mutations found in studies screening candidate genes in groups of hypospadias patients, 
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ordered according to the different stages of embryonic development. Whether these 
mutations have functional consequences remains unclear in most cases, as only few studies 
reported conservation and function of the region in which the mutation is located, or predicted 
potential influence of the mutation on protein function using bioinformatics. The majority of 
mutations were found only once and were identified in posterior or penile cases. The latter has 
contributed to the view that there is a difference in the genetic models underlying posterior 
versus anterior hypospadias, with more posterior cases being enriched in monogenic forms of 
hypospadias and anterior cases having a polygenic or multifactorial aetiology. The studies 
investigating associations between genetic polymorphisms and hypospadias are summarized in 
Table II, following the same order as Table I. 
 
Indifferent stage 
All genes involved in the development of the male external genitalia are obvious candidate 
genes for hypospadias. Because Wt1 and Sf1 play major roles in early embryonic development 
of the kidneys and the urogenital system, mutations in these genes are likely to cause not only 
hypospadias but also more severe defects. Indeed, SF1 mutations were found in severe 
penoscrotal hypospadias cases with cryptorchidism62, while a mutation in WT1 was described 
in a boy with penoscrotal hypospadias and micropenis63, and also in three boys with isolated 
penile or glandular hypospadias63 (Table I). 
 
Early patterning 
Genes involved in GT patterning are additional candidates for hypospadias. Mutation screening 
in hypospadias cases revealed mutations in BMP4, BMP7, HOXA4, HOXB6, FGF8, and the 
fibroblast growth factor receptor FGFR264,65 (Table I), while associations with hypospadias were 
also observed for polymophisms in FGF8 and FGFR265 (Table II).  
 
Masculinisation 
Expression of the SRY gene, located on the Y chromosome, is crucial for development of the 
testis from the indifferent gonad43,66. Sex chromosome abnormalities were noticed in four out 
of 100 hypospadias patients67, but no mutations in SRY were found in 90 patients in another 
study63. In addition, screening Yq for microdeletions in 44 cases did not reveal any 
abnormalities68, and neither did screening the segments of the Y chromosome associated with 
infertility in 20 cases with middle or posterior hypospadias and cryptorchidism69. 
 
Genetic research has strongly been focused on the hormone-dependent stage of sexual 
development as well. Especially the gene encoding the AR, which is expressed in the 
developing human penis and urethra70, was investigated extensively. Several studies reported 
rare mutations in this gene in hypospadias patients63,71-75 (Table I). In addition, polymorphisms 
in AR have been investigated for associations with the anomaly and may increase hypospadias 
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risk. For example, expansion of the polyglutamine (CAG) repeat in the N-terminus of AR, shown 
to decrease AR transactivation function76, was not found to be associated with hypospadias in 
three studies77-79. Two of these studies reported that longer GGN repeat length increased risk 
of penile hypospadias77,78 (Table II). DHT binding capacity of the AR in genital skin fibroblasts 
was reported to be decreased in some hypospadias patients71,80, whereas normal binding 
capacity was found in others81,82. In addition, AR levels were similar in foreskin samples of 
hypospadias cases and controls83. 
 
Several proteins are needed for AR function. FK506 binding protein 4, 59kDa (FKBP4, also 
known as FKBP52), for example, is a component of AR complexes, enhancing AR-mediated 
transactivation84. However, no differences in FKBP4 expression were noted between 
hypospadias patients and controls, and no mutations in FKBP4 were observed85. 
 
As normal male urethral development requires testosterone and DHT, defects in 
steroidogenesis could also account for hypospadias. One article stated that up to 50% of 
hypospadias patients have a testosterone biosynthesis defect86, a conclusion that could not be 
confirmed in two other studies that found no enzymatic defects87,88. Nevertheless, mutations 
have been found in hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-
isomerase 2 (HSD3B2)89 and steroid 5 alpha reductase type II (SRD5A2)63,75,90.  
 
The gene encoding SRD5A2 is particularly interesting because this enzyme is expressed during 
male genital development around the ventral part of the remodelling urethra and it converts 
testosterone to the more potent androgen DHT, which induces formation of the external 
genitalia70. Two single nucleotide polymorphisms (SNPs) in this gene seemed to be associated 
with hypospadias in some but not all studies1,63,75,90,91 (Table II). One of these SNPs (rs523349) 
causes a valine to leucine substitution (V89L), resulting in a decrease in enzyme activity by 
approximately 30%92,93, whereas the other SNP (rs9282858) results in an alanine to threonine 
replacement (A49T), which causes an increase in enzyme function93. Another SNP that seems 
to be associated with hypospadias and to have functional consequences is rs2066479 in 
HSD17B3. The glycine to serine substitution (G289S) caused by this SNP results in reduced 
HSD17B3 mRNA expression levels in utero91. 
 
Other genes 
Not only steroidogenesis but also the balance between androgens and oestrogens appears to 
be important in development of the male external genitalia. The oestrogen receptors ESR1 and 
ESR2 are expressed in the developing human male GT47, and associations have been reported 
between hypospadias and several SNPs in the genes encoding these receptors, as well as with 
the CA-repeat in ESR21,94-97 (Table II). One of the SNPs in ESR1, rs9340799, was shown to 
increase enhancer activity of ESR198.  
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Some additional genes are also suggested to be involved in development of hypospadias. 
Activating transcription factor 3 (ATF3) is an oestrogen-responsive gene showing strong up-
regulation in hypospadias99-102. Studies focusing on the relation between this gene and 
hypospadias found mutations and associations with several SNPs100,103, but not all associations 
could be replicated1 (Tables I and II). Recently, mastermind-like domain containing 1 (MAMLD1, 
previously known as CXorf6) was identified as a causal gene for hypospadias. MAMLD1 
contains the SF1 target sequence104, and mutations and polymorphisms in MAMLD1 have been 
found in hypospadias patients105-107 (Tables I and II). A recent genome-wide association study 
using pooled DNA samples identified diacylglycerol kinase, kappa (DGKK) as a major risk gene 
for hypospadias108. An intronic SNP was associated with a 2.5 times increased hypospadias risk, 
while DGKK expression in preputial skin was shown to be lower in boys carrying the risk allele. 
In this study, additional candidate genes, i.e. peroxisome proliferator-activated receptor 
gamma, coactivator 1 beta (PPARGC1B), glutamate receptor, ionotropic, delta 1 (GRID1), and 
KIAA2022 were also identified, but these still need to be confirmed. One study investigated 
MID1 in relation to hypospadias and found mutations in hypospadias patients, as well as a SNP 
in this gene to be associated with the disorder109 (Tables I and II). Insulin-like 3 (INSL3) 
mutations have been found in patients with cryptorchidism, but no alterations were detected 
in 94 hypospadias cases110 (Table I). 
 
Expression studies have also identified some candidate genes. Using prepuce samples of 
hypospadias patients and controls, Wang et al. not only found ATF3 to be upregulated in 
patients, but also connective tissue growth factor (CTGF) and cysteine-rich, angiogenic inducer, 
61 (CYR61), two other oestrogen-responsive genes102. In addition, epidermal growth factor 
(EGF) staining in prepuce showed less expression of EGF within the penile skin adjacent to the 
urethra in hypospadias patients compared to controls111.  
 
A balanced translocation in a man with hypospadias and other congenital anomalies indicated 
basonuclin 2 (BNC2) as candidate gene. This gene is expressed in developing human 
periurethral tissue, and mutations were found in 6 out of 48 hypospadias patients, but also in 2 
out of 23 controls112 (Table I). 
 
As exposure to environmental toxicants has also been suggested to cause hypospadias, and 
cytochrome P4501A1 (CYP1A1) and glutathione S-transferases (GSTM1 and GSTT1) are 
involved in the metabolism of various toxicants, two studies evaluated the effect on 
hypospadias risk for polymorphisms in the genes encoding these enzymes. One study found an 
association with hypospadias for concomitant deletion of GSTM1 and GSTT1113 (Table II). The 
other study investigated associations between maternal smoking, maternal SNPs in the genes, 
and hypospadias risk in offspring. They found an association between a SNP in CYP1A1 and 
hypospadias, which was not modified by smoking behaviour114. 
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One genome-wide linkage analysis in 69 families with at least 2 members with hypospadias 
found suggestive linkage at 9q22, 2p11, 10p15, and 10q21115, while another linkage study in a 
three-generational family showing autosomal dominant inheritance of hypospadias found a 
peak on 7q32.2-q36.1116. Mutation analysis of two genes in this region, AKRID1 and PTN failed 
to reveal any mutations116. 
 
Screening 17 isolated hypospadias patients and 12 patients with associated anomalies for copy 
number variants (CNVs) revealed clinically significant CNVs in 3 patients with isolated 
hypospadias (5p15, 12p13, and Xq28) and 2 patients with an associated anomaly, which were 
cryptorchidism (2q22) and cleft palate (16p11)117.     
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Table I.    Mutations found in studies screening candidate genes in groups of hypospadias patients. 
Gene Locus 
N 
ca-
ses 
N 
con-
trols Ethnicity Mutation  Phenotype 
Hetero-
zygosity  Remarks 
Refe-
rence 
 
Indifferent stage of development 
 
WT1 11p13   35     - different ethnicities -    73 
  90 276 Chinese N130N 
 
A131T 
S159S 
• penoscrotal, micopenis 
• penile 
• penile 
• glandular, also has BMP7 mutation 
hetero 
hetero 
hetero 
hetero 
 
 
 
 
63 
WTAP 6q25-q27   37   20 controls are Caucasian,  
ethnicity cases ? 
-    256 
SF1 11q13   60a 100 ? Q107X 
 
c.103-3C>Ab 
 
E11X 
• penoscrotal, bilateral cryptorchidism 
 
• scrotal, micropenis, bilateral 
 cryptorchidism 
• penoscrotal, micropenis, bilateral 
 cryptorchidism 
hetero 
 
hetero 
 
hetero 
•  showed that variant impairs 
 transcriptional activity 
 
 
• showed that variant impairs 
 transcriptional activity 
62 
 
Early patterning stage of development 
 
BMP4 14q22-
q23 
  90 190 Chinese H207D  
R223H 
H251Y 
• penoscrotal, micropenis 
• penoscrotal 
• penile, micropenis 
hetero 
hetero 
hetero 
 64 
BMP7 20q13   60c   96 different ethnicities -    65 
  90 190 Chinese R303C  
Q199Q 
c.1465T>Ad 
c.1567A>Gd 
• glandular, also has WT1 mutation 
• penile 
• penoscrotal, micropenis 
• penile 
hetero 
hetero 
hetero 
hetero 
 64 
HOXA4 7p15.2   90 190 Chinese G129C 
S290C 
 
• penoscrotal, micropenis 
• penile, bifid scrotum, cryptorchidism 
• penile, micropenis, also has SRD5A2 
 mutation 
hetero 
hetero 
hetero 
 64 
HOXB6 17q21.3   90 190 Chinese P42T  
 
 
C123R 
• scrotal, micropenis, bifid scrotum, 
 cryptorchidism, also has SRD5A2 
 and MID1 mutations 
• penile 
hetero 
 
 
hetero 
• mother heterozygous 64 
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Table I. (continued)  Mutations found in studies screening candidate genes in groups of hypospadias patients. 
Gene Locus 
N 
ca-
ses 
N 
con-
trols Ethnicity Mutation  Phenotype 
Hetero-
zygosity  Remarks 
Refe-
rence 
HOXA13 7p15.2   37   20 controls are Caucasian, 
ethnicity cases ? 
-    256 
FGF8 10q24   60 c   96 different ethnicities c.590C>Ge • ? homo • Swedish patient 65 
FGF10 5p13-
p12 
  60 c   96 different ethnicities -    65 
FGFR2 10q26   60 c   96 different ethnicities M186Tf 
c.2454C>Te 
• midpenile 
• ? 
hetero 
hetero 
• Swedish patient 
• Swedish patient 
65 
 
Masculinisation stage of development 
 
SRY Y   90 276 Chinese -    63 
SOX9 17q23   90 276 Chinese -    63 
AR Xq12 
 
 
 
  21   90 ? V870A • penoscrotal, bilateral cryptorchidism hemi  72 
    9g     - ? G566V • perineal hemi • family history suggested 
 familial component  
71 
  40h     - ? P546S • distal penile shaft hemi  74 
  35     - different ethnicities F725V 
 
 
 
 
S597T 
• hypospadias and cryptorchidism, 
 clinically diagnosed with PAIS based 
 on sparse body hair, gynaecomastia 
 and heredity for intersex malfor-
 mations 
• severe hypospadias, cryptorchidism, 
 bifid scrotum 
hemi 
 
 
 
 
hemi 
 
 
73 
  21 100 Japanese -    79 
  90 276 Chinese I664T 
R840H 
 
 
 
 
 
I842T   
• glandular, gynecomastia 
• perineal, micropenis, bifid scrotum 
 
 
 
 
 
• scrotal, micropenis, bifid scrotum 
hemi 
hemi 
 
 
 
 
 
hemi 
 
• mother heterozygous, variant 
 previously described in ambi-
 guous genitalia patient and 
 shown by others to reduce 
 androgen-binding affinity and 
 transcriptional activity 
• mother heterozygous 
63 
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Table I. (continued)  Mutations found in studies screening candidate genes in groups of hypospadias patients. 
Gene Locus 
N 
ca-
ses 
N 
con-
trols Ethnicity Mutation  Phenotype 
Hetero-
zygosity  Remarks 
Refe-
rence 
AR Xq12   90 276 Chinese R855H   
 
 
 
 
 
L859L 
• perineal, micropenis, bifid scrotum 
 
 
 
 
 
• penile 
hemi 
 
 
 
 
 
hemi 
• mother heterozygous, uncle has 
 same mutation and phenotype, 
 variant previously described in 
 2 brothers with perineal hypo-
 spadias, bilateral cryptor-
 chidism, and micropenis 
63 
  37i     - different ethnicities Q798E • scrotal hemi • variant previously described in 
 various genital defects and 
 shown by others to affect AR 
 transactivation function 
75 
  92 190 Iranian -    77 
FKBP4 12p13.33   91     - different ethnicities -    85 
HSD3B2 1p13.1   90g  101 ? S213T 
 
 
S284R   
 
A238A   
T259T  
 
T320T   
• scrotal, bilateral cryptorcidism 
 
 
• midshaft 
 
• midshaft 
• proximal penile, micropenis and 
 Wilms’ tumour (no WT1 mutation) 
• subcoronal 
hetero 
 
 
hetero 
 
hetero 
hetero 
 
hetero 
• mother and brother hetero-
 zygous, showed that variant 
 reduces enzyme activity 
• de novo, showed that variant 
 reduces enzyme activity 
 
• de novo  
 
• father heterozygous, has bifid 
 preputium and a wide meatus 
89 
HSD17B3 9q22   19j     - different ethnicities -    75 
SRD5A2 2p23   35     - different ethnicities -    73 
  81k 100 different ethnicities L113V 
H231R 
• penoscrotal 
• scrotal 
hetero 
hetero 
 
• variant previously described in 
 5α-reductase deficiency 
90 
  90 276 Chinese L224H 
 
 
• scrotal, micropenis, bifid scrotum, 
 also has G203S variant  
 
hetero 
 
 
• father heterozygous, 2 brothers 
 of patient have same geno-
 type and phenotype as patient 
63 
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Table I. (continued)   Mutations found in studies screening candidate genes in groups of hypospadias patients. 
Gene Locus 
N 
ca-
ses 
N 
con-
trols Ethnicity Mutation  Phenotype 
Hetero-
zygosity  Remarks 
Refe-
rence 
SRD5A2 2p23   90 276 Chinese R227Q 
 
 
 
 
 
 
R246Q 
 
 
 
 
 
Q6X     
  
 
 
 
 
656delT 
• penile, bifid scrotum, also has HOXA4
 mutation 
• scrotal, micropenis, bifid scrotum 
• glandular 
 
 
 
• scrotal, bifid scrotum, cryptorchidism 
 
 
 
 
 
• scrotal, micropenis, bifid scrotum, 
 cryptorchidism 
• scrotal, micropenis, bifid scrotum, 
 cryptorchidism, also has G203S 
 variant (also found in controls) and 
 HOXB6 and MID1 mutation 
• perineal, micropenis, bifid scrotum, 
 cryptorchidism 
homo 
 
homo 
hetero 
 
 
 
homo 
 
 
 
 
 
homo 
 
hetero 
 
 
 
hetero 
• variant previously described in
 patient with scrotal hypospa-
 dias, bifid scrotum, and micro-
 penis and shown by others to 
 inhibit NADPH binding, 
 reduce testosterone binding, 
 and reduce enzyme half-life  
• variant previously described in 
 2 patients with perineoscrotal 
 hypospadias, micropenis, and 
 cryptorchidism and shown by 
 others to reduce enzyme 
 activity 
 
 
• father heterozygous 
 
 
 
 
63 
  37i     - different ethnicities G196S 
 
 
 
• scrotal 
 
 
 
hetero 
 
 
 
• mother heterozygous, variant 
 previously described in homo-
 zygous form in 8 patients with 
 scrotal hypospadias and micro-
 penis and shown by ohers to 
 partly disrupt NADPH binding 
75 
SRD5A1 5p15   10l   49 ? -    257 
 
Other genes 
 
ESR1 6q25.1   60   94 different ethnicities -    97 
ESR2 14q23.2   60   94 different ethnicities -    97 
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Table I. (continued)   Mutations found in studies screening candidate genes in groups of hypospadias patients. 
Gene Locus 
N 
ca-
ses 
N 
con-
trols Ethnicity Mutation  Phenotype 
Hetero-
zygosity  Remarks 
Refe-
rence 
ATF3 1q32.3   93   96 different ethnicities A90G 
c.817C>Td 
 
• moderate 
• moderate/severe 
• moderate/severe 
? 
? 
? 
• Swedish patient 
• Middle Eastern patient 
• Swedish patient 
103 
  41   30 ? L23M • anterior hetero  100 
MAMLD1 Xq28 166 460 different ethnicities E124X 
 
 
 
Q197X 
R653X 
• penoscrotal, cryptorchidism, bifid 
 scrotum 
 
 
• penoscrotal, micropenis, bifid scrotum 
• penoscrotal, micropenis, cryptor-
 chidism, bifid scrotum 
hemi 
 
 
 
hemi 
hemi 
• Japanese patient, mother 
 heterozygous, maternal 
 half-brother has same mutation 
 and similar phenotype 
• Japanese patient 
• Japanese patient, mother 
 heterozygous 
106 
  41   30 ? V432Am 
L121X 
 
p.531ins3Qn 
• proximal penile 
• proximal penile, cryptorchidism 
• penoscrotal 
• coronal 
hemi 
hemi 
hemi 
hemi 
 
 
• de novo 
 
107 
  99o   95 ? Q529K 
D686D 
• severe, bilateral cryptorchidism 
• ? 
hemi 
hemi 
 
 
105 
MID1 Xp22 114   95 ? E238X 
 
 
 
K560R 
• penoscrotal, hypertelorism 
 
 
 
• penoscrotal, hypertelorism 
hemi 
 
 
 
hemi 
• mother heterozygous, brother 
 has same mutation and 
 phenotype, variant previously 
 described in Opitz syndrome 
109 
INSL3 19p13.2-
p12 
 94 270 Moroccan -    110 
BNC2 9p22.2   48p   23 different ethnicities A923V 
 
L414V 
P306A 
P579L 
E240G, 
 R283G, & 
 Q152R 
• distal 
• distal 
• distal 
• distal 
• distal 
• distal 
hetero 
hetero 
hetero 
hetero 
hetero 
hetero 
hetero 
hetero 
• Caucasian patient 
• African-American patient 
• Caucasian patient 
• Caucasian patient 
• Caucasian patient 
• Caucasian patient 
 
112 
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All studies included in this table screened hypospadias patients for mutations in specific genes. Most studies checked whether mutations were present in 
healthy controls. The table includes only exonic (including 3’-UTR and splice acceptor sites) mutations that were not found in healthy controls, were not 
previously reported polymorphisms, and were not described as a polymorphism by the authors of the article. Results from functional analyses, either 
performed by the study reporting the mutation or performed by earlier studies and referred to by the study reporting the mutation, are included in the 
table. Most studies included hypospadias patients with different degrees of hypospadias or information about phenotype was not reported. Most studies 
excluded syndromal patients, but did not exclude patients with cryptorchidism, micropenis, bifid scrotum, or other associated anomalies, or information 
about associated anomalies was not reported. Most studies did not exclude patients with affected relatives or information about affected relatives was not 
reported. Family members carrying the same mutation were unaffected, unless indicated differently.  
 
N, number; hetero, heterozygous; homo, homozygous; hemi, hemizygous; PAIS, partial androgen insensitivity syndrome; 
a
only DSD (disorders of sex 
development) patients with severe penile to penoscrotal hypospadias included; 
b
splice acceptor site; 
c
only patients with at least one affected relative 
included; 
d
3’-UTR; 
e
synonymous variant, not mentioned in which amino acid; 
f
variant is known as rs755793, but with allele frequency of 0% in Caucasians; 
g
only severe hypospadias patients included;
 h
only patients without other genitourinary abnormalities included; 
i
only patients with severe hypospadias or a 
familial form included;
 j
only patients from families contributing most to a linkage peak in the vicinity of HSD17B3 included;
 k
patients with cryptorchidism, 
intersex condition, or endocrine abnormalities excluded; 
l
only patients with elevated testosterone/DHT ratios without mutations in AR or SRD5A2 included; 
m
variant was later found in 2 more patients and in 2 controls
105
;
 n
variant was later found in 3 more patients and in 1 control
105
;
 o
only sporadic patients 
included; 
p
only patients with distal hypospadias included. 
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TABLE II.   Genetic association results for hypospadias. 
Gene Locus SNP 
N 
cases 
N 
controls Controls Ethnicity 
Genotypes / alleles associated 
with increased risk (P < 0.05) Reference 
 
Early patterning stage of development 
 
FGF8 10q24 rs3218238 or    
    rs3218233a 
  60b   96 healthy voluntary blood donors different ethnicities A allelec 65d 
FGFR2 10q26 c.382+52→G 
c.550+27T>C 
c.727+180T>G 
  60b   96 healthy voluntary blood donors different ethnicities G allele of c.382+52→Ge 
C / T allele of c.550+27T>Ce 
G allele of c.727+180T>Gc 
65d 
 
Masculinisation stage of development 
 
AR 
  
Xq12 CAG repeat   21  100 boys with short stature and normal external 
genitalia and fertile males 
Japanese no association 79 
  51  210 males from military service, no history of 
hypospadias or cryptorchidism 
cases are Caucasian,  
controls have Swedish  
mothers 
no association 78 
  92  190 fertile males Iranian no association 77 
GGN repeat   51  210 males from military service, no history of 
hypospadias or cryptorchidism 
cases are Caucasian,  
controls have Swedish  
mothers 
longer repeatf 78 
  92  190 fertile males Iranian longer repeatf 77 
FKBP4 12p13.33 rs1062478 
rs3021522 
333  380 voluntary blood donors different ethnicities no association 85 
HSD17B3 9q22 rs4743709 
rs2066476 
rs2066474  
rs2066480 
rs2066479 
  89g  291 male newborns without malformations Japanese A allele of rs2066479 
AA genotype of rs2066479 
91 
SRD5A2 2p23 rs9282858   81h 100+ normal controls different ethnicities T allele 90i 
rs523349   90    87 normal males Chinese G allele 
CG and GG genotypes 
63 
158    96 unaffected persons cases have different 
ethnicities, controls 
are Caucasian 
G allele  
CG and GG genotypes 
75 
  89g  281 male newborns without malformations Japanese CG genotypej 91 
620  596 unaffected males Caucasian no association 1k 
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TABLE II. (continued)  Genetic association results for hypospadias. 
Gene Locus SNP 
N 
cases 
N 
controls Controls Ethnicity 
Genotypes / alleles associated 
with increased risk (P < 0.05) Reference 
 
Other genes 
 
ESR1 6q25.1 rs6932902l   43  135 boys with short stature and normal external 
genitalia and fertile males 
Japanese A allele 
AA genotype 
95 
620  596 unaffected males Caucasian A allele 1k 
TA repeat 
rs1801132 
  90    94 voluntary blood donors different ethnicities no association 97 
rs2234693 
rs9340799 
  59g  286 boys without malformations Japanese A allele of rs9340799 94 
ESR2 14q23.2 CA repeat   90    94 voluntary blood donors different ethnicities longer repeat 97 
354  380 healthy voluntary blood donors different ethnicities longer repeat 96 
rs1887994 
rs1256040 
rs1256062 
rs10483774 
rs1271572 
354  380 healthy voluntary blood donors different ethnicities G allele of rs10483774 
AG genotype of rs10483774 
96 
rs944050   90    94 voluntary blood donors different ethnicities AG genotypem 97 
  59g  286 boys without malformations Japanese AG genotypen 94 
rs2987983 354  380 healthy voluntary blood donors different ethnicities G allele  
GG genotype 
96 
620  596 unaffected males Caucasian AG genotypen 1k 
rs1256049 
rs4986938 
  51  186 control males from military service without 
genital anomalies and with sperm 
concentrations  >5×106 spermatozoa/ml 
cases are Caucasian,  
controls have Swedish  
parents 
no association 258 
ATF3 1q32.3 rs2137424 
rs3125289 
rs1877474 
rs10735510 
rs9429889 
rs12070345 
rs10475 
330  380 healthy voluntary blood donors different ethnicities T allele of rs3125289 
TT genotype of rs3125289  
T allele of rs1877474 
TT genotype of rs1877474 
strongest association for com- 
 bination of risk alleles: 
 rs3125289 (T), rs1877474 
 (T), and rs11119982 (C)  
103 
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TABLE II. (continued) Genetic association results for hypospadias. 
Gene Locus SNP N 
cases 
N 
controls 
Controls Ethnicity Genotypes / alleles associated 
with increased risk (P < 0.05) 
Reference 
ATF3 1q32.3 rs11119982 330  380 healthy voluntary blood donors different ethnicities C allele 
CC genotype 
103 
620  596 unaffected males Caucasian T allele  
TT and CT genotypes 
1k 
MAMLD1 Xq28 rs61740566 370  380 healthy voluntary blood donors ? no association 105 
rs41313406 
rs2073043 
370  418 male healthy voluntary blood donors ? T allele of rs41313406  
G allele of rs2073043 
105 
DGKK Xp11.22 rs1934179 
rs7063116 
436o 
133o 
266o 
449 
133 
402 
healthy control males 
mothersp 
male healthy voluntary blood donors 
Caucasian A allele of rs1934179 
A allele of rs7063116 
108q 
MID1 Xp22 rs16986145 366 405 male controls ? A alleler 109 
CYP1A1 
GSTM1 
GSTT1 
15q24.1 
1p13.3 
22q11.23 
? 
gene deletion 
gene deletion 
  31s    64 mothers of boys without any malformation Japanese heterozygous CYP1A1 genotypen 114 
CYP1A1 
GSTM1 
GSTT1 
15q24.1 
1p13.3 
22q11.23 
? 
gene deletion 
gene deletion 
  80  120 age-matched boys ? concomitant deletion of GSTM1 
 and GSTT1 
113 
Most studies were association studies with a case-control design. Most studies included hypospadias patients with different degrees of hypospadias. Most 
studies excluded syndromal patients, but did not exclude patients with cryptorchidism, micropenis, bifid scrotum, or other associated anomalies or 
information about associated anomalies was not reported. Most studies did not exclude patients with affected relatives or information about affected 
relatives was not reported. Deviations from these statements are included in the specified footnotes. 
 
N, number; 
a
the SNP reported in the text was different from the SNP reported in the table; 
b
all patients have at least one affected relative; 
c
this SNP was 
found in heterozygous form in 3 patients, while it was not found in controls; 
d
this was not an association study, but a study screening FGF8 and FGFR2 for 
mutations; 
e
these SNPs were found in heterozygous form in 1 patient, while they were not found in controls. For c.550+27T>C it is not clear whether T or C 
is the risk allele because the SNP reported in the text was different from the SNP reported in the table (c.550+27T>C and c.550+27C>T); 
f
only penile patients 
have longer repeats; 
g
patients with affected family members excluded; 
h
patients with cryptorchidism, intersex condition, or endocrine abnormalities 
excluded; 
i
this was not an association study, but a study screening SRD5A2 for mutations. This SNP was found in homozygous form in 2 patients and in 
heterozygous form in 3 patients, while it was not found in controls. In another study, this SNP was found in 1 out of 37 patients, but as that study did not 
genotype controls to perform an association analysis, it was not included in the table
75
; 
j
only associated with severe hypospadias; 
k
this was an association 
study with a case-parent triad design analyzed using the transmission disequilibrium test; 
l
SNP tagged the ‘AGATA’ haplotype of rs926779, rs3020364, 
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rs6932902, rs3020371, and rs3020375; 
m
all six patients with this genotype had affected family members, and the SNP was inherited from the affected line 
twice; 
n
associated with decreased risk; 
o
only anterior and middle hypospadias patients included; 
p
this part of the study was an association study with a 
case-parent triad design analyzed using the transmission disequilibrium test, but as this in an X-chromosomal SNP, only mothers were taken into account; 
q
this was a genome wide association study with a case-control design, suggesting more associations with hypospadias than reported in this table; 
r
four 
cases were familial. Two affected relatives carried the variant, and one did not. Five of the nine cases with the variant had at least one parent born in North 
Africa, where the A allele is more prevalent; 
s
mothers of hypospadias patients.  
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The role of environmental factors in the aetiology of hypospadias 
While genes involved in the aetiology of hypospadias have received a considerable amount of 
attention, research on environmental factors has been even more extensive. Despite the large 
number of studies, however, clear evidence for causal environmental factors is still lacking, 
although some consistent associations have been reported. Table III gives a summary of 
environmental factors investigated in relation to hypospadias. 
 
Introduction 
Testicular dysgenesis syndrome 
In 2001, Skakkebæk et al. suggested that poor sperm quality, testicular cancer, undescended 
testes, and hypospadias are symptoms of one underlying entity, the Testicular Dysgenesis 
Syndrome (TDS)118. They were convinced of its existence because countries with high 
incidences of testicular cancer also had high prevalence rates of hypospadias, cryptorchidism, 
and poor sperm quality119. Other researchers wonder whether TDS actually exists since there is 
little evidence of shared causes120, only few patients display all features, and incidences of the 
four components of the syndrome did not increase over time at the same rate121. Although 
testicular germ cell cancer risk was increased in patients with hypospadias or undescended 
testis, risk was not increased in their family members. This does not support the hypothesis of 
shared heritability122. Recently, Skakkebæk et al. concluded that TDS does exist, but that it 
encompasses only a fraction of hypospadias and impaired spermatogenesis cases123.  
 
Oestrogen hypothesis  
In 1993, Sharpe and Skakkebæk already hypothesized that the increasing incidence of 
reproductive abnormalities in males may have a common cause, namely increased oestrogen 
exposure in utero, leading to disturbances in AMH secretion or impairment of Leydig cell 
development124. Ten years after the introduction of this hypothesis, Sharpe concluded that 
evidence for foetal oestrogen exposure inducing TDS had strengthened125. New pathways were 
identified through which oestrogens could induce TDS, including suppression of testosterone 
production, AR expression, and INSL3 secretion. Whether increased oestrogen exposure will 
turn out to be an important aetiologic factor for TDS is not so certain, however.  
 
The initial ‘oestrogen hypothesis’ was superseded by a more refined definition of endocrine 
disrupting chemicals (EDCs), suggesting that chemicals may act on the endocrine systems in a 
plethora of ways126. In 2008, Sharpe and Skakkebæk highlighted the central role of deficient 
androgen production or action during foetal testis development in the origin of the 
downstream disorders of TDS127. However, the question remains whether levels of exposures 
to EDCs are sufficient to influence male reproductive health126, and several reviews concluded 
that there is not much evidence for a role of environmental EDCs128-133.  
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Exogenous exposure to oestrogens 
Oral contraceptives 
Although oral contraceptives probably cause the strongest oestrogen exposure that humans 
can experience, an association between hypospadias and use of oral contraceptives during 
pregnancy was not found in most studies57,134-138.  
 
Assisted reproductive techniques 
Assisted reproductive techniques (ART) frequently involve hormonal stimulation, and some 
studies showed an increased hypospadias risk for ART16,57,136. More specifically, intracyto-
plasmic sperm injection (ICSI) increased hypospadias risk in most139-144 but not all studies145,146, 
whereas studies on in vitro fertilisation (IVF) did not report increased risks or were inconclusive 
134,139,144-146, except for one study that did not report whether ICSI was excluded147. In one study, 
increased hypospadias risk was associated with hormonal stimulation148, but this was not 
confirmed in other studies134,149,149-151. Other authors assumed that the increased hypospadias 
risk may be explained by reduced maternal or paternal fertility. Fathers of hypospadias cases 
were reported to have lower sperm concentrations, sperm counts152, and sperm motility, as 
well as higher proportions of abnormal sperm morphology153. In addition, several studies 
reported a prolonged time to pregnancy (TTP) for parents of hypospadias patients57,152,154,155, 
and only one study did not confirm these results6. The fact that ICSI, rather that IVF, and sperm 
quality are associated with hypospadias supports the idea that especially paternal fertility 
problems play a role in hypospadias57,136.  
 
Endogenous hormone levels 
Endogenous oestradiol levels 
Endogenous levels of free oestradiol increase with increasing body mass index (BMI) and are 
elevated in women with an early age at menarche156,157. Several studies found associations 
between hypospadias and mothers being overweight (25≤BMI<30 kg/m2)158 or severely 
overweight or obese (BMI>29 or 30 kg/m2)135,158-160, but one study did not57. Another study 
found increased risks for underweight, but not for overweight or obese women161. The results 
for early age at menarche were inconsistent134,159. Oestradiol levels are also higher in first 
pregnancies and twin pregnancies162,163, which were both repeatedly investigated for their 
association with hypospadias. Most studies showed that women having their first pregnancy5,6, 
10,15,16,18,23,24,134,155,164,165 or a twin or triplet pregnancy2,6,16,23-25,57,134,136,139 were at increased risk 
of having a son with hypospadias, but a few studies could not replicate the findings for 
primiparity or for multiple pregnancies5,10,18,165,166. The latter may be due to overadjustment for 
birth weight in some studies. As only early-onset intrauterine growth restriction (IUGR) could 
be a risk factor for hypospadias, it is more likely that low birth weight and hypospadias share 
an underlying cause rather than low birth weight being a risk factor for hypospadias.  
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Foetal hCG provision 
Placental hCG stimulates foetal testicular steroidogenesis before the foetus’s own pituitary-
gonadal axis is established. Placental insufficiency may result in inadequate foetal hCG 
provision and in IUGR, possibly explaining the association between hypospadias and low birth 
weight or being small for gestational age (SGA) that was consistently reported, although not 
always statistically significant2,5,6,8,10,18,23-25,57,134-136,139,154,159,164,166-171. However, because hCG 
levels were similar in maternal serum samples of hypospadias cases and controls, this is 
unlikely to be due to decreased maternal hCG production172. IUGR was also found more often 
in the affected twin of same-sex twin pairs discordant for hypospadias173,174. Direct proof of a 
link between placental insufficiency and hypospadias was provided by research showing an 
association between hypospadias and low placental weight60, an increased frequency of 
placental infarction among extremely low birth weight boys with hypospadias175, and a high 
rate of early-onset IUGR due to placental insufficiency among SGA newborns with hypospadias, 
with more posterior cases having more severe IUGR176. The association with low birth weight 
also seems to be stronger for more posterior forms of hypospadias18,57,166,177. 
  
Nausea in early pregnancy may be caused by the early surge of hCG178, suggesting that 
placental insufficiency may cause absence of nausea. Indeed, vomiting and nausea during early 
pregnancy were shown to decrease hypospadias risk16,135. Maternal hypertension during 
pregnancy25,57,134,135,179 and preeclampsia5,6,25,57,134,165,167 were consistently associated with 
hypospadias as well, and both factors may be associated with placental dysfunction, possibly 
by compromised uteroplacental perfusion179. Preterm delivery may be associated with late 
placental dysfunction, and several studies demonstrated an association with hypospadias8,15,23-
25,135,139,154,159, while others could not confirm this5,6,10,18,166,167, again maybe due to 
overadjustment for birth weight in some studies. 
 
Clinical factors 
Pregnancy complications 
In a few studies, associations were investigated between hypospadias and complications 
during pregnancy, such as maternal bleeding, which seemed to be more prevalent among 
cases5,24. The amount of weight gain was not associated with hypospadias15,134. Complications 
during labour, such as labour induction and Caesarean section, occurred more frequently 
among mothers of hypospadias cases5,15, indicating that hypospadias-affected pregnancies are 
associated with other difficulties that make them prone to these complications. Diabetes has 
been another focus of research, but most studies were too small to draw conclusions25,57,134,164, 
165. One study found maternal gestational and pre-existing diabetes not to be associated with 
occurrence of hypospadias5, whereas others reported an increased risk for pre-existing but not 
for gestational diabetes17,180. Results were inconsistent for thyroid disease5,181 and fever during 
pregnancy24,60. Women with gynaecological diseases (ovarian cysts or benign uterine 
tumours)168, hepatitis B antigen carriers25, and women experiencing a viral infection or 
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influenza in the first trimester of pregnancy134,182 seem to be at increased risk of giving birth to 
a son with hypospadias, but evidence was derived from only one study. Urinary infections and 
anaemia do not seem to increase hypospadias risk5.  
 
Maternal drug use 
Most therapeutic drugs, such as corticosteroids, antibiotics, antipsychotics, antifungal, and 
anti-asthmatic drugs do not seem to be associated with hypospadias, although some studies 
may suffer from under reporting57,136,183-187. Based on data from the Swedish Medical Birth 
Register 1995-2001, Källén et al. reported 15 hypospadias cases in 2780 infants born after 
maternal use of loratadine, an antihistamine, during pregnancy188, but in 2001-2004, only two 
cases were identified among 1911 loratadine-exposed infants, indicating that the primary 
finding occurred by chance189. Other studies also failed to find an association between 
loratadine and hypospadias190,191. Results for progestogens/progestins used for threatened 
abortion vary59,192. Use of loperamide193, antiretroviral therapy194, antihypertensive drugs57,179, 
nystatin195, or paroxetine196 during early pregnancy may increase hypospadias risk, while 
codeine182 may decrease the risk, but most of these associations were reported only once. In 
contrast, use of anti-epileptic drugs was linked to hypospadias several times197-201. Most studies 
showed no effects of folate57,202,203 or iron supplementation57,134 on hypospadias risk, although 
one study showed a reduced risk of folate204 and two others an increased risk of iron 
supplementation136,182.  
 
Maternal intra-uterine DES exposure 
In 2002, Klip et al. reported a 21 times increased hypospadias risk among sons of women 
exposed to diethylstilbestrol (DES) in utero in a cohort of women with fertility problems205. 
Thereafter, other studies were consistent in showing an increased risk for sons of DES-
daughters, although less strong57,206-208. This transgenerational effect may have been due to 
genetic or epigenetic changes in primordial oocytes, which were transmitted to the next 
generation, or in somatic cells of the DES-daughter, resulting in disturbed hormonal balance in 
adult life205. Another explanation would be that pathology of the DES-daughter’s reproductive 
structures interferes with normal foetal development206.  
 
Behavioural factors 
Parental age 
Women get pregnant at different ages, but overall, maternal and paternal age at time of 
conception did not seem to increase the risk of having a son with hypospadias5,6,10,15,23,25,27,57,134-
136,155,164-166,209. However, some studies reported higher maternal age8,16-18,28,164,210,211 or lower or 
higher paternal age209,212 to increase hypospadias risk.  
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Maternal diet 
In 2000, North and Golding reported a five times increased risk of a hypospadias-affected son 
for women with a vegetarian diet182, a finding that was confirmed in one study135, but not in 
others57,136,204. All of these results were based on case-control studies with relatively few 
exposed cases and controls (<15) however, except for a study in England reporting no 
association in more than 75 vegetarian cases and controls204. The suggestion that an increased 
risk might be due to intake of phytooestrogens was refuted by a small study involving 
phytooestrogen-specific questionnaires that did not find an association154. Another dietary 
factor found to be associated with hypospadias in two small studies is frequent consumption of 
fish, possibly due to bioaccumulation of contaminants in fish159,168. However, a larger case-
control study found a decreased hypospadias risk for frequent fish consumption135.  
 
Other lifestyle factors 
Alcohol consumption during pregnancy was consistently found not to be associated with 
hypospadias15,136,164, whereas for maternal smoking, most studies showed no association6,15,57, 
134-136,155,164,213. One small study found maternal cocaine use to be associated with hypo-
spadias214. 
 
Occupational factors 
Exposure to pesticides 
Occupational exposures have been a major focus in hypospadias research, especially exposure 
to pesticides, with contradicting results. Paternal exposure to pesticides before pregnancy does 
not seem to be associated with hypospadias23,57,136,215, although one small study reported a 
possibly increased  risk168. In addition, an increased risk was found among farmers who were 
indicated as exposed to pesticides in a register-based study216. Most studies showed no 
associations with maternal occupational exposure to pesticides either23,57,136,215,217,218, but being 
involved in agricultural activities25 or using insect repellents219 seemed to increase hypospadias 
risk in two studies. Maternal serum levels of dichlorodiphenyltrichloroethane (DDT) and 
dichlorodiphenyldichloroethane (DDE) during pregnancy were not associated with hypo-
spadias220,221, but maternal serum hexachlorobenzene (HCB) concentrations approximately one 
year after birth were more often above the median of all subjects among hypospadias cases 
than among controls159.  
 
Other occupational exposures 
Boys conceived to mothers employed in the leather industry222 and post-war to mothers who 
served in the Gulf war223 seemed to have a higher prevalence of hypospadias. Most other 
maternal occupational exposures were not associated with hypospadias, although results for 
EDCs, heavy metals, and phthalates vary, while exposure to hairspray increased the risk in one 
study23,57,136,159,204,217,218. For fathers, being a vehicle mechanic or manufacturer224,225, police 
officer or fire fighter224, and occupational exposure to dusts from grinding metals57 seemed to 
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increase the risk of having a son with hypospadias. Results on heavy metals vary23,217, but most 
other paternal occupational exposures were not associated with hypospadias23,57,136,217.  
 
Living environment 
Results on living in rural or (sub)urban areas are contradictory23,25, whereas living close to a 
landfill site seemed to be associated with an increased hypospadias risk226. Maternal serum 
levels of polychlorinated biphenyls (PCBs) were elevated during hypospadias-affected 
pregnancies in two small studies, but these results were not statistically significant159,227. 
Another study found marginally increased PCB levels in serum samples of women pregnant 
with a hypospadias-affected son, but the study samples were collected in the 1960s, when PCB 
exposure was substantially higher than nowadays228. Maternal exposure to water disinfection 
by-products was also suggested to increase hypospadias risk, but most studies provided little 
evidence for this association229-231. 
 
Hypospadias prevalence seemed to be higher in areas of intensive pesticide use or in 
agricultural areas in one study134. Another study showed an increased risk of hypospadias for 
living in an area where diclofopmethyl was applied, but a decreased risk for alachlor and 
permethrin or for pesticide application in aggregate15.  
 
In some older studies, a seasonal trend for hypospadias was identified232-234, which was 
attributed to factors such as hours of daylight, climate, or temperature, whereas more recent 
studies did not find seasonal variation24,134,235. 
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Table III.  Clinical, behavioural, occupational, and environmental factors investigated for 
their association with hypospadias in more than one study. 
 
 
FACTORS FREQUENTLY INVESTIGATED 
 
 
Factors with consistent results in all studies 
 
Factors consistently associated with hypospadias 
 Low birth weight / being small for gestational age  
 Placental insufficiency 
 Maternal hypertension 
 Preeclampsia 
 Maternal intrauterine DES exposure 
Factors consistently not associated with 
hypospadias 
 Gestational diabetes 
 Maternal alcohol consumption  
 
 
Factors with consistent results in most studies 
 
Factors associated with hypospadias in most studies  
 Use of intracytoplasmic sperm injection (ICSI)  
 Prolonged time to pregnancy (TTP)  
 High maternal body mass index (BMI)  
 Primiparity  
 Multiple pregnancy  
 Pre-existing maternal diabetes 
 Maternal medication use:  
  Anti-epileptic drugs 
Factors not associated with hypospadias in most 
studies 
 Use of oral contraceptives during pregnancy  
 Use of in vitro fertilisation (IVF)  
 Use of hormonal stimulation to induce pregnancy
 Maternal medication use:  
  Loratadine 
 Maternal folate supplementation  
 Paternal age  
 Maternal smoking  
 Maternal exposure to water disinfection by-
  products 
 
Factors showing inconsistent results 
 
 Preterm delivery 
 Maternal iron supplementation 
 Maternal age 
 Maternal vegetarian diet 
 Maternal fish consumption 
 Maternal and paternal exposure to pesticides 
 Maternal occupational exposure to: 
  Endocrine disruptors 
  Heavy metals 
  Phthalates 
 Maternal serum levels of polychlorinated 
  biphenyls (PCBs) 
 Seasonal trend 
 
FACTORS NOT FREQUENTLY INVESTIGATED 
 
Factors that seem to be associated with 
hypospadias 
 Paternal subfertility 
 Absence of nausea / vomiting in early pregnancy  
 Bleeding during pregnancy 
 Complications during labour 
 Maternal medication use: 
  Antihypertensive drugs 
 Father being a vehicle mechanic or manufacturer 
Factors that do not seem to be associated with 
hypospadias 
 Amount of weight gain during pregnancy 
 Maternal medication use: 
  Corticosteroids  
  Antibiotics 
 Most maternal and paternal occupational 
  exposures  
 
Factors showing inconsistent results 
 
 Early age at menarche  
 Maternal thyroid disease 
 Fever during first trimester of pregnancy  
 Use of progestogens / progestins for threatened 
  abortion 
 Paternal occupational exposure to heavy metals 
 Living in rural or urban areas 
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Conclusion 
 
Most hypospadias cases have an unknown aetiology, which is likely to be a mix of monogenic 
and multifactorial forms, implicating both genes and environmental factors.  
 
Several mutations have been found that might cause hypospadias, but most investigators are 
convinced that single mutations are not likely to be the cause for the majority of isolated 
hypospadias cases. Neverteheless, studies screening hypospadias patients for single gene-
defects found mutations in the genes WT1, SF1, BMP4, BMP7, HOXA4, HOXB6, FGF8, FGFR2, 
AR, HSD3B2, SRD5A2, ATF3, MAMLD1, MID1, and BNC2. Association studies found 
polymorphisms in FGF8, FGFR2, AR, HSD17B3, SRD5A2, ESR1, ESR2, ATF3, MAMLD1, DGKK, 
MID1, CYP1A1, GSTM1, and GSTT1 to be risk factors for hypospadias. In addition, gene 
expression studies indentified CTGF, CYR61, and EGF as candidate genes. 
 
Additional candidate genes for hypospadias aetiology include genes that were found to be 
mutated in case-reports, such as CYP11A1236, CYP17A1237, and HSD17B3238, and genes involved 
in syndromes commonly associated with hypospadias, not reviewed in this article. An example 
is the hand-foot-genital syndrome, which is caused by mutations in HOXA13239,240. Hoxa13 
mutant mice also exhibited hypospadias37, and expansion of a polyalanine tract in HOXD13 
found in synpolydactyly families also seems to be associated with hypospadias241,242. Mutations 
in zinc finger E-box binding homeobox 2 (ZEB2) cause Mowat-Wilson syndrome, which is 
associated with hypospadias in more than 50% of affected males243-247.  
 
Animal studies also provide some additional candidate genes, such as the genes encoding the 
cell-surface molecules ephrins and their receptors, EPH receptor B2 (EphB2) and Ephrin-B2 
(Efnb2)248,249. EFNB2 has been suggested as the gene underlying genital malformations in 
patients with a 13q33-34 deletion250-252.  
 
In conclusion, many candidate genes have been suggested for hypospadias. Although some 
associations with hypospadias were found, none of these associations were replicated 
consistently, with the possible exception of DGKK. Therefore, we suggest that a genome-wide 
association study using individual genotyping of a large group of cases and controls is the way 
forward to generate more knowledge about the genetic factors underlying isolated 
hypospadias. In addition, the novel exome or even whole-genome sequencing techniques 
generate new opportunities. Currently, the high costs make these techniques only suitable for 
identification of causes of monogenic forms of hypospadias, but with falling prices, the 
techniques may also be applied to large cohorts of isolated hypospadias patients in the future.  
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As for environmental factors, development of the male external genitalia is dependent on the 
balance between androgens and oestrogens. The fact that maternal exposure to synthetic 
oestrogens can induce hypospadias in murine models253 and that antiandrogens acting as 
inhibitors of steroid hormone synthesis or AR antagonists can induce male reproductive 
abnormalities in animal models254 suggests that EDCs have the potential to induce 
hypospadias. However, because of considerable species differences and markedly different 
oestrogen levels in humans compared to rodent pregnancy, it is debatable whether EDCs also 
induce hypospadias in humans. Phthalates inhibit steroidogenesis in the foetal rat testis, but 
this does not occur in vitro with human foetal Leydig cells255. The question remains whether 
exposure levels in humans are high enough to exert an effect on the occurrence of 
hypospadias. Given that even strong hormonal exposures, such as from hormonal stimulation 
to induce pregnancy and use of oral contraceptives while pregnant, do not show consistent 
associations with hypospadias, we think that exogenous hormones and EDCs may not be as 
important in the aetiology of hypospadias as has previously been assumed.  
 
The consistent association of hypospadias with low birth weight, maternal hypertension, and 
preeclampsia suggests that placental insufficiency may be a major risk factor for hypospadias, 
possibly through inadequate provision of hCG to the foetus. A role for endogenous hormones is 
suggested by free oestradiol levels linked to high maternal BMI, primiparity, and multiple 
pregnancies that appear to contribute to hypospadias susceptibility.  
 
In addition, maternal intrauterine DES exposure, use of anti-epileptic drugs, pre-existing 
diabetes, prolonged time to pregnancy, and ICSI-induced pregnancies have been associated 
with hypospadias in most studies. Other potential environmental risk other factors were not or 
not consistently associated with hypospadias, or studied too infrequently to draw conclusions.   
 
In our opinion, the lack of replication for both genetic and environmental factors associated 
with hypospadias may be due to subtle isolated effects of factors that may have larger 
influences in combination with other factors (e.g. gene-gene or gene-environment 
interactions). While a different genetic background of a population may affect its vulnerability 
to an environmental exposure, different environmental exposures may influence the effect of a 
genotype. Therefore, we think that the challenges for future research in disentangling the 
pathogenesis of hypospadias mainly lie in studies focussing on gene-gene or gene-environment 
interactions. 
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Abstract 
 
Context 
Hypospadias is a common congenital malformation of the male external genitalia with a 
multifactorial etiology. Little is known about the genes involved in hypospadias. A few genetic 
associations have been reported but mainly in studies of small sample size. Most of these 
associations have not been replicated. 
 
Objective 
The aim of this study was to investigate whether previously reported associations for four 
single-nucleotide polymorphisms (SNPs) in genes involved in hormonal pathways could be 
replicated in a large Dutch hypospadias sample. The SNPs investigated are rs523349 in steroid-
5α-reductase (SRD5A2), rs6932902 in estrogen receptor 1 (ESR1), rs2987983 in ESR2, and 
rs11119982 in activating transcription factor 3 (ATF3). 
 
Design, participants, and Methods 
We genotyped 620 Caucasian hypospadias cases and 596 controls for these SNPs using 
TaqMan-based genotyping. 
 
Results  
We did not replicate the associations of the SNPs in SRD5A2 and ESR1 with hypospadias. The 
SNPs in ESR2 and ATF3 were borderline associated with hypospadias [odds ratios 0.9 (95% 
confidence interval 0.7-1.0) and 1.2 (95% confidence interval 1.0-1.4), respectively] but in the 
opposite direction compared with earlier publications. Stratification according to localization of 
the urethral opening produced comparable results in the subgroups. 
 
Conclusions 
The lack of consistency between our and previously performed studies might represent 
spurious results or chance findings in our or the earlier studies, differences in criteria used to 
select the study populations, or a real difference between populations, i.e. different genes 
contributing to disease risk. These results once again confirm the importance of replication in 
genetic association approaches. 
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Introduction 
 
Hypospadias, a hypoplasia of the penis with proximal displacement of the urethral meatus on 
the ventral aspect of the penis, results from developmental arrest of the urethral fusion. The 
appearance of hypospadias is diverse, with the opening being located glanular, penile, scrotal, 
or even in the perineal region in different individuals. Although hypospadias is a common 
congenital disorder affecting approximately 21 in 10000 live births in The Netherlands in 20061, 
its etiology is incompletely understood. The development of the male external genitalia is a 
complex process influenced by multiple genes2, of which those coding for sex hormones have 
been the focus of interest in most previous studies. Originally studies trying to elucidate the 
etiology of hypospadias mainly focused on male hormones, but more recently focus has 
broadened to include female hormones as well. Estrogen receptors are expressed in the 
human fetal male external genitalia3, and exposure to estrogens seems to increase the risk of 
hypospadias4,5. Furthermore, estrogen-responsive genes are up-regulated in hypospadias6,7. 
 
Hypospadias clusters within families; 7% of hypospadias cases have a first-, second- or third-
degree relative with hypospadias, whereas the expected rate of familial cases among the 
general population is 3%8. This familial aggregation is believed to be caused by genetic rather 
than intrauterine environmental factors9. Rare mutations in genes have been found in only a 
few hypospadias patients, for example in the genes encoding the androgen receptor (AR)10-13, 
steroid-5α-reductase (SRD5A2)14, hydroxy-δ-5-steroid dehydrogenase (HSD3B2)15, mastermind-
like domain containing 1 [MALMD1, previously named chromosome X open reading frame 6 
(CXorf6)]16, and bone morphogenetic proteins 4 and 7 (BMP4 and BMP7)17 as well as in the 
genes coding for homeobox A4 and B6 (HOXA4 and HOXB6)17. However, most investigators are 
convinced that single mutations are not likely to be the cause of the majority of nonsyndromal 
hypospadias cases10-13,15,18. Segregation analysis suggests that the majority of cases have a 
multifactorial etiology19. 
 
According to the common gene, common disorder hypothesis20, multiple frequently occurring 
genetic variants (polymorphisms), each with a relatively small effect, contribute to 
multifactorial disorders. Although not many studies investigated polymorphisms in relation to 
hypospadias, some associations with hypospadias have been reported, mainly of 
polymorphisms in endocrine-related genes, namely in AR21,22, SRD5A223,24, the genes encoding 
estrogen receptors 1 (ESR1)25,26 and 2 (ESR2)26-28, and activating transcription factor 3 (ATF3)29. 
Furthermore, polymorphisms in the genes encoding fibroblast growth factor 8 (FGF8)18 and FGF 
receptor 2 (FGFR2)18 have been associated with hypospadias. Overall, however, the numbers of 
samples analyzed in these studies were relatively small, with only 43-380 cases plus controls 
included. Only three of the above associations (rs523349 in SRD5A2, the GGN repeat in AR, and 
the CA repeat in ESR2) have been reported in more than one study. Replication of results is a 
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major issue in research into genetic causes of multifactorial disorders because first studies 
often appear to overestimate the effect of the genetic variant (so-called winner’s curse)30, and 
studies reporting positive results are more likely to be published than those reporting negative 
results (publication bias)31. Therefore, the aim of this study was to investigate whether the 
previously reported associations of single-nucleotide polymorphisms (SNPs) in genes involved 
in hormonal pathways could be replicated in a large Dutch sample of 620 hypospadias cases 
and 596 controls.  
 
SNPs in four genes were studied; SRD5A2, ESR1, ESR2, and ATF3. SRD5A2 encodes an enzyme 
that converts circulating testosterone in the genital tubercle to the more potent androgen 
dihydrotestosterone, which stimulates normal differentiation and development of the genital 
tubercle into the external genitalia2. ESR1 and ESR2 encode estrogen receptors, and ATF3 is an 
estrogen-responsive gene, showing strong up-regulation in hypospadias6,7. Furthermore, we 
investigated whether localization of the meatus influenced our findings because hypospadias 
with different localizations of the urethral opening arise at distinct embryologic stages with 
different genes likely to be involved in the process. 
 
 
Subjects and Methods 
 
Cases and controls 
The Aetiologic Research into Genetic and Occupational/Environmental Risk Factors for 
Anomalies in Children (AGORA) project of the Radboud University Nijmegen Medical Centre 
aims at building a data bank and biobank with questionnaire data and DNA samples from 
patients with a congenital disorder and their parents. For the current study, DNA collected 
prospectively and retrospectively was available from 679 hypospadias cases. The majority of 
the cases were of European Caucasian descent (92%), whereas descent was not Caucasian (5%) 
or unknown (3%) for the remaining cases. Only Caucasian cases were included in the analyses. 
The retrospectively collected cases (n = 478) have been described before in studies on 
environmental risk factors for hypospadias32,33. Routine data collection since 2005 provided the 
prospective cases. Medical records of all cases were reviewed to identify syndromal cases of 
hypospadias and clinical characteristics of patients and determine the anatomical location of 
the urethral opening. The location was determined by experienced pediatric urologists during 
physical examination before surgery. For the current study, anatomical location was subdivided 
into three categories: anterior hypospadias (glanular and subcoronal), middle hypospadias 
(penile), and posterior hypospadias (penoscrotal, scrotal, and perineal).  
 
Controls were obtained from the Nijmegen Biomedical Study, a population-based survey 
conducted by the Department of Epidemiology, Biostatistics, and Health Technology 
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Assessment and the Department of Clinical Chemistry of the Radboud University Nijmegen 
Medical Centre in 2003. Age- and sex-stratified randomly selected inhabitants of the 
municipality of Nijmegen (n = 22500) received an invitation to fill out a postal questionnaire, 
e.g. on lifestyle and medical history, and to donate blood samples. The response to the 
questionnaire was 42% (n = 9373), whereas 72% (n = 6747) of the responders also donated 
blood samples34. The 596 youngest males of Dutch descent were selected for the current study. 
None of them had reported penile surgery in the self-report questionnaires administered by 
the Nijmegen Biomedical Study. 
 
The regional Committee on Research Involving Human Subjects approved both studies. All 
participants gave written informed consent for participation in the study.  
 
Genotyping 
Blood was collected in EDTA containing tubes for the largest part of the study population (n = 
980), whereas saliva was collected using Oragene containers (n = 295; DNA Genotek Inc., 
Ottawa, Ontario, Canada). DNA was extracted from blood or saliva using standard methods. 
Samples were genotyped for rs523349 in SRD5A223,24, rs6932902 in ESR125, rs2987983 in ESR227 
and rs11119982 in ATF329 using 5’-nuclease TaqMan SNP genotyping assays (SRD5A2: 
C_2362601_10, ESR1: C_2823640_10, ESR2: C_1436929_20, ATF3: C_27262262_10; Applied 
Biosystems, Foster City, CA). PCRs were carried out in 96-well plates in a 10-μl volume 
containing 10 ng genomic DNA, 5 μl Taqman universal PCR master mix, 0.125 μl assay mix, and 
milli-Q. The PCR consisted of an initial denaturation step at 95°C for 10 min followed by 40 
cycles of denaturation at 92°C for 15 sec and annealing and extension at 60°C for 60 sec. After 
PCR, allele-specific fluorescence was measured on an ABI 7500 FAST (Applied Biosystems). In 
each plate, five wells were loaded with randomly selected duplicate DNA samples from the 
same and other plates for quality control purposes. In addition, four blanks were included in 
each plate. Genotyping was carried out in a laboratory recognized and granted accreditation 
for quality control by the coordinating committee for improvement of quality control of 
laboratory research in health care.  
 
Statistical analysis 
Statistical analyses were performed using SPSS 16.0 (SPSS, Chicago, IL). Genotype frequencies 
in controls were tested for accordance with Hardy-Weinberg equilibrium. For the four SNPs, 
the most frequent homozygous genotypes in controls were used as reference values. Odds 
ratios (OR) for hypospadias risk and corresponding 95% confidence intervals (CI) were 
calculated at genotype and allelic level. Furthermore, χ2 tests were performed. P < 0.05 was 
considered statistically significant in the primary analyses. Applying the Bonferroni correction 
for multiple comparisons decreased the significance threshold to 0.004 for the 12 comparisons 
made.  
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In a second step, cases were subdivided into anterior, middle, and posterior categories, and the 
statistical analyses were repeated. Furthermore, to exclude bias due to the different sources of 
DNA (i.e. blood and saliva), the analyses were repeated separately for cases of whom DNA was 
obtained from either blood or saliva. 
 
To enable a better comparison between the results of our study and the previously published 
results, we recalculated the risk estimates of these studies according to the procedures 
described above. Exact 95% CI around the ORs were calculated using the Fisher exact method, 
whenever expected cell numbers were below five. 
 
 
Figure 1.  Flow chart of the selection of case samples for inclusion in the current study. 
 
 
 
AGORA, Aetiologic Research into Genetic and Occupational/Environmental Risk 
Factors for Anomalies in Children.  
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Results 
 
Figure 1 shows a flow chart of the collection and selection of cases for this study. In the 
analysis of the complete sample, 620 cases were included, whereas in the second step of the 
analysis, 579 case samples could be included for whom the hypospadias location had been 
determined. Table 1 shows the clinical characteristics of the patients. More than half of the 
posterior cases underwent the onlay island flap procedure. Other techniques used were the 
tubular graft (Duckett’s procedure) and tubularized incised plate urethroplasty. One third of 
these posterior hypospadias cases needed a two-stage repair. 
 
 
Table 1.  Clinical characteristics of the hypospadias patients. 
 
 
Anterior n=365 (59%) 
 
Middle n=133 (21%) 
 
 
HsH 
 
 
Glanular 
 
(Sub) 
coronal 
 
 
Distal 
penile 
 
Midshaft 
 
Proximal 
penile 
Total  39 100  226    71   55     7 
       
  Chordee  23   (59%)   38   (38%)  136  (60%)    49  (69%)   45  (82%)                       6 (86%) 
  Cryptorchidisma    5   (13%)     2      (2%)    11    (5%)      3     (4%)     2     (4%)     0 
  Micropenis    0     0      4     (2%)      1     (1%)     1     (2%)     0 
  DSD    0     0      0      0     0     0 
  Other deformitiesb 
 
 
   5   (13%)   14   (14%)    12    (5%)      4     (6%)     0      0  
 Posterior n=81 (13%) 
 
Unknown n=41 (7%) 
 
 
 
 
Penoscrotal 
 
Scrotal 
 
Perineal  
Total  69    5    7   41   
       
  Chordee  68   (99%)    5 (100%)    6  (86%)   17  (41%)   
  Cryptorchidisma  13   (19%)    3   (60%)    2  (29%)     3     (7%)   
  Micropenis    5      (7%)    2   (40%)     0     0   
  DSD    3      (4%)    2   (40%)    3  (43%)     0   
  Other deformitiesb 
 
 11   (16%)    0    2  (29%)     2     (5%)   
HsH, Hypospadias sine hypospadias; 
a
including only cases that underwent orchidopexy or 
orchidectomy; DSD, Disorders of sex development; 
b
including heart-, renal- and gastro-intestinal 
deformities, neural tube defects, cleft lip and/or palate and deformities of the lower extremities. 
 
 
Genotyping of the four SNPs was completed with a success rate of more than 99%. All 
genotype frequencies in controls were in Hardy Weinberg equilibrium (SRD5A2: P = 0.63, ESR1: 
P = 0.98, ESR2: P = 0.22, ATF3: P = 0.31). 
 
Table 2 presents the results of the primary genotype and allele association analyses of the four 
SNPs. For the SNP in SRD5A2, there was no indication of an association with hypospadias in our 
sample, neither at the genotypic nor at the allelic level. For the SNPs in ESR1 and ATF3, odds 
ratios for the risk of hypospadias were statistically significantly increased for both variant 
genotypes (ATF3) and the variant allele (ESR1, ATF3). For the SNP in ESR2, both variant 
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genotypes and the variant allele appeared to be negatively associated with hypospadias, 
although not statistically significant. After correction for multiple testing, none of the results 
remained statistically significant. Separate analyses for the anterior, middle, and posterior 
categories of hypospadias and for DNA obtained from blood and saliva showed comparable 
results in the subgroups (data not shown). 
 
 
Table 2.  Association analyses for single nucleotide polymorphisms in SRD5A2, ESR1, ESR2 
and ATF3 with hypospadias. 
  Controls 
   n=596  
    n  (%) 
   Cases 
   n=620  
    n  (%) 
 
 
 OR   (95% CI) 
 
 
χ2 P 
  Controls  
  n=1192  
      n  (%) 
     Cases 
   n=1240  
      n  (%) 
 
 
 OR   (95% CI) 
 
 
χ2 P 
 
Genotype frequencies 
 
 
Allele frequencies 
 
 
rs523349 in SRD5A2  
CC 290  (49) 291  (48) 1.00  (ref) ref  
CG 255  (43) 263  (43) 1.03  (0.81-1.30) 0.820 C   835  (70)   845  (69) 1.00  (ref) ref 
GG   51     (9)   55     (9) 1.07  (0.71-1.63) 0.733 G   357  (30)   373  (31) 1.03  (0.87-1.23) 0.719 
 
rs6932902 in ESR1  
GG 459  (77) 448  (73) 1.00  (ref) ref  
AG 128  (21) 153  (25) 1.22  (0.94-1.60) 0.139 G 1046  (88) 1049  (85) 1.00  (ref) ref 
AA     9     (2)   16     (3) 1.82  (0.80-4.16) 0.150 A   146  (12)   185  (15) 1.26  (1.00-1.60) 0.049 
 
rs2987983 in ESR2  
AA 265  (45) 308  (50) 1.00  (ref) ref  
AG 274  (46) 249  (41) 0.78  (0.62-0.99) 0.042 A   804  (67)   865  (71) 1.00  (ref) ref 
GG   56     (9)   54     (9) 0.83  (0.55-1.25) 0.370 G   386  (32)   357  (29) 0.86  (0.72-1.02) 0.087 
 
rs11119982 in ATF3  
CC 162  (27) 132  (22) 1.00  (ref) ref  
CT 285  (48) 310  (51) 1.33  (1.01-1.77) 0.043 C   609  (51)   574  (47) 1.00  (ref) ref 
TT 148  (25) 170  (28) 1.41  (1.03-1.94) 0.035 T   581  (49)   650  (53) 1.19  (1.01-1.39) 0.036 
The first shaded column presents the odds ratios and 95% confidence intervals comparing the two 
other genotypes to the most frequent homozygous genotype in controls as well as the statistical 
significance of the differences in genotype distributions between cases and controls. The second 
shaded column has the same structure, but for alleles. 
 
 
In Table 3 our results are compared with the results of previously reported studies. We were 
unable to replicate the results of Wang et al. and Thai et al. reporting an association of 
rs523349 in SRD5A2 with hypospadias in 90 Chinese cases and 87 controls24 and in 158 
Swedish, Turkish, and Middle Eastern cases and 96 Swedish controls23, respectively. We did not 
replicate the association of rs6932902 in ESR1 with hypospadias either, as reported earlier by 
Watanabe et al.25 in 43 Japanese cases and 135 controls. These authors investigated eight SNPs 
covering a linkage disequilibrium block in ESR1 and found the strongest association with 
hypospadias for rs6932902, which was nonsignificant in our sample, although showing a trend 
in the same direction. Our findings for rs2987983 in ESR2 and rs11119982 in ATF3 showed 
trends in the opposite direction compared with the earlier publications by Beleza-Meireles et 
al.27, who genotyped four haplotype-tagging SNPs in ESR2 in a Swedish cohort of 348 cases and  
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Table 3.  Association analyses for single nucleotide polymorphisms in SRD5A2, ESR1, ESR2 
and ATF3 with hypospadias in our study and in previously published studies. 
  Controls   
    n   (%) 
    Cases 
    n   (%) 
 
  OR  (95% CI) 
 
χ2 p 
  Controls   
     n   (%) 
     Cases 
     n   (%) 
 
OR (95% CI) 
 
χ2 p 
 
Genotype frequencies 
 
 
Allele frequencies 
 
rs523349 in SRD5A2 
 
 
 
Thai et al.23 (mixed ethnicity) (158 cases, 96 controls)  
 CC   59  (62)   44  (28)   1.0  (ref) ref  
 CG   18  (19)   64  (41)   4.8  (2.5-9.2) <0.001 C   136 (71)   152 (48) 1.0 (ref) ref 
 GG   19  (20)   50  (32)   3.5  (1.8-6.8) <0.001 G     56 (29)   164 (52) 2.6 (1.8-3.8) <0.001 
 
Wang et al.24 (Chinese) (90 cases, 87 controls)  
 CC   31  (36)   16  (18)   1.0  (ref) ref  
 CG   44  (51)   52  (58)   2.3  (1.1-4.7) 0.024 C   106 (61)     84 (47) 1.0 (ref) ref 
 GG   12  (14)   22  (24)   3.6  (1.4-9.0) 0.007 G     68 (39)     96 (53) 1.8 (1.2-2.7) 0.007 
 
Our results (609 cases, 596 controls)      
 CC 290  (49) 291  (48)   1.0  (ref) ref      
 CG 255  (43) 263  (43)   1.0  (0.8-1.3) 0.820 C   835 (70)   845 (69) 1.0 (ref) ref 
 GG 
 
  51     (9)   55     (9)   1.1  (0.7-1.6) 0.733 G   357 (30)   373 (31) 1.0 (0.9-1.2) 0.719 
 
rs6932902 in ESR1 
 
 
 
Watanabe et al.25 (Japanese) (43 cases, 135 controls)  
 GG   80  (59)   18  (42)   1.0  (ref) ref  
 AG   51  (38)   14  (33)   1.2  (0.6-2.7) 0.619 G   211 (78)     50 (58) 1.0 (ref) ref 
 AA     4     (3)   11  (26) 12.2  (3.1-57.0)a <0.001 A     59 (22)     36 (42) 2.6 (1.5-4.3) <0.001 
 
Our results (617 cases, 596 controls)  
 GG 459  (77) 448  (73)   1.0  (ref) ref      
 AG 128  (22) 153  (25)   1.2  (0.9-1.6) 0.139 G 1046 (88) 1049 (85) 1.0 (ref) ref 
 AA 
 
    9     (2)   16     (3)   1.8  (0.8-4.2) 0.150 A   146 (12)   185 (15) 1.3 (1.0-1.6) 0.049 
 
rs2987983 in ESR2 
 
 
 
Beleza-Meireles et al.27(Swedish)(348 cases, 377 controls)  
 AA 182  (48) 142  (41)   1.0  (ref) ref  
 AG 162  (43) 151  (43)   1.2  (0.9-1.6) 0.264 A   526 (70)   435 (63) 1.0 (ref) ref 
 GG   33     (9)   55  (16)   2.1  (1.3-3.5) 0.002 G   228 (30)   261 (38) 1.4 (1.1-1.7) 0.004 
 
Our results (611 cases, 595 controls)  
 AA 265  (45) 308  (50)   1.0  (ref) ref      
 AG 274  (46) 249  (41)   0.8  (0.6-1.0) 0.042 A   804 (68)   865 (71) 1.0 (ref) ref 
 GG 
 
  56     (9)   54     (9)   0.8  (0.6-1.3) 0.370 G   386 (32)   357 (29) 0.9 (0.7-1.0) 0.087 
 
rs11119982 in ATF3 
 
 
 
Beleza-Meireles et al.29(Swedish)(330 cases, 374 controls)  
 CC   60  (16)   82  (25)   1.0  (ref) ref  
 CT 168  (45) 160  (48)   0.7  (0.5-1.0) 0.074 C   288 (39)   324 (49) 1.0 (ref) ref 
 TT 146  (39)   88  (27)   0.4  (0.3-0.7) <0.001 T   460 (61)   336 (51) 0.6 (0.5-0.8) <0.001 
 
Our results (612 cases, 595 controls)  
 CC 162  (27) 132  (22)   1.0  (ref) ref      
 CT 285  (48) 310  (51)   1.3  (1.0-1.8) 0.043 C   609 (51)   574 (47) 1.0 (ref) ref 
 TT 
 
148  (25) 170  (28)   1.4  (1.0-1.9) 0.035 T   581 (49)   650 (53) 1.2 (1.0-1.4) 0.036 
The left half of the table presents genotype data and the right half allelic data. For each SNP, both 
our results and those from previously published studies are displayed. The first three columns of this 
table present the genotype distribution of the four SNPs investigated among hypospadias cases and 
controls. The shaded column presents the ORs and 95% CIs comparing the two other genotypes to 
the most frequent homozygous genotype in controls as well as the statistical significance of the 
differences in genotype distributions between cases and controls. The right half of the table has the 
same structure, but shows allele frequencies. 
a
Exact 95% CI calculated using the Fisher exact method. 
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377 controls and reported a statistically significant association with hypospadias for rs2987983. 
They also genotyped 330 cases and 374 controls for eight haplotype-tagging SNPs in ATF3 and 
concluded that rs11119982 was negatively associated with hypospadias29, whereas a positive 
association was observed in our study.  
 
 
Discussion 
 
It is a well-known fact that most associations reported in genetic studies do not replicate 
across subsequent studies35. This is true even for studies investigating very plausible candidate 
genes for a phenotype or disorder, as is the case in the current study, in which, among others, 
a gene implicated in monogenic forms of hypospadias (SRD5A2) was investigated. To our 
knowledge, the current study investigated the largest sample of hypospadias cases and 
controls for associated SNPs thus far reported. We were unable to replicate the results of three 
earlier studies in Caucasian populations. As for the results of the two earlier studies in non-
Caucasian populations, these findings did not generalize to our Caucasian population. The lack 
of consistency between our study and previously performed studies might be caused by 
spurious results or chance findings found in our or the earlier studies, especially in those with 
very small sample sizes, differences in the criteria used to select cases and/or controls, or a real 
difference between the populations36.  
  
Population stratification, which occurs when cases and controls are drawn from different 
subgroups that differ in disease prevalence and frequency of the genetic variant, may lead to 
spurious results. We selected only Caucasian cases and controls living in the same area in The 
Netherlands to minimize the chance of population stratification. Thai et al.23 included cases 
from Sweden, Turkey, and the Middle East, whereas all controls were Swedish, but when they 
restricted the analyses to only Swedish cases, the association was still observed, making 
population stratification in their study unlikely as well. We do not expect spurious results due 
to the different sources of the DNA used in our study because results were comparable in the 
stratified analyses. Small sample sizes may result in insufficient power to detect an association 
and may lead to genotype frequencies that are not representative of the frequencies in the 
population from which the sample was drawn due to chance. Therefore, we collected a large 
study sample of approximately 600 cases and 600 controls, providing a power of 82-94%, given 
an alpha of 0.05, to detect associations between hypospadias and SNPs with allele frequencies 
between 0.1 and 0.5 and a dominant genetic effect increasing the risk of disease 1.5-fold (a 
conservative estimate based on the previous studies shown in Table 3).  
 
Differences in results between our and other studies may also be caused by disease 
heterogeneity due to differences in the criteria used to select the cases. Indeed, more than 
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25% of the cases used in the Chinese and Japanese studies had micropenis24,25, which were 
nearly absent in our study population. Furthermore, the study by Thai et al.23 included a high 
proportion of familial cases. However, a subanalysis in their publication restricted to sporadic 
cases only still showed the association23, suggesting that familiality did not explain the 
observed association. All three studies mentioned above included more hypospadias cases 
with a posterior localization of the meatus than we did23-25. We tried to tackle this 
inconsistency between the studies by analyzing our data separately for the different categories 
of hypospadias, but comparable results were found in the different subgroups. In addition, we 
excluded patients with disorders of sex development or micropenis in an attempt to increase 
the homogeneity of our sample. This did not change the results either (data not shown). These 
findings suggest that localization of the meatus and familiality are no adequate explanation for 
the differences in results. 
 
Because the populations analyzed in the other studies are indeed dissimilar to the Dutch 
population and some of the populations even differ in ethnicity, a real difference between the 
populations studied might exist. There may be a difference in the etiology of hypospadias, 
manifested as other underlying trait loci or their alleles, or a difference in environmental 
exposures between populations. One can speculate that specific SNPs lead to an increased 
susceptibility of hypospadias only in the presence of an environmental exposure. Factors 
suspected to be of relevance in the etiology of hypospadias and potentially differing between 
populations include maternal age, assisted reproductive techniques, and iron 
supplementation5,32,37,38. Furthermore, there might be a difference in genetic backgrounds, 
affecting the associations if these are dependent on interactions with other SNPs that are 
present in one population but not in another or on linkage disequilibrium with a causal allele. 
Because the SNPs in ESR1, ESR2, and ATF3 are haplotype-tagging SNPs and haplotype block 
patterns may differ between populations, these SNPs might be in linkage disequilibrium with 
the causal SNPs in some populations but not in others. The SNP in SRD5A2, which causes a 
valine to leucine (V89L) substitution resulting in an approximately 30% decrease in enzyme 
activity39,40, is likely to be a causal SNP but not in our population. 
 
Our failure to replicate the previous findings in a large, well-powered study should not be 
taken as evidence that the tested genes do not contribute to disease risk. For the reasons 
explained above, we cannot exclude the possibility that the SNPs investigated in this study are 
associated with hypospadias in some populations. In addition, one should keep in mind that we 
examined only one SNP per gene. Other SNPs, SNP-haplotypes, or other types of 
polymorphisms, such as variable number tandem repeats, e.g. those reported in ESR228 and 
potentially also copy number polymorphisms, may be of relevance for hypospadias risk as well. 
 
Our study once again confirms the importance of replication studies for the validation of the 
results of genetic association approaches. These studies can provide information about the 
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generalizability of the findings and contribute to the determination of realistic estimates of 
effect sizes. In addition, in the specific case of hypospadias, in which clear evidence regarding 
the molecular pathways leading to disease is lacking, methods such as genome-wide 
association studies may be called for rather than candidate gene approaches to generate 
hypotheses regarding the pathways and genes involved in the etiology of hypospadias. 
 
 
Acknowledgements 
 
We are grateful to all patients, their parents, and controls for their participation in the study 
and to Karen Kwak, Jacqueline Knoll, Robert de Gier, Barbara Kortmann, Astrid Paauwen, Hing 
Gwan Kho, Jacques Driessen, the other anesthesiologists of operation room 18, and all others 
involved in the collection of the case samples. The control samples were derived from the 
Nijmegen Biomedical Study. Principal investigators of the Nijmegen Biomedical Study are 
L.A.L.M.K., M. den Heijer, A.L.M. Verbeek, D.W. Swinkels and B. F. S.H.H.M.V. and L.A.L.M.K. 
participated as representatives of the Nijmegen Biomedical Study. This work was performed 
within a PhD project supported by the Radboud University Nijmegen Medical Centre.  
 
 
References 
 
 1.  International Clearinghouse for Birth Defects Surveillance and Research 2009 Annual report 
2008, with data for 2006. Available at: http://www.icbdsr.org/page.asp?p=%2010065&l=1. 
Accessed December 3, 2009 
 2.  Yamada G, Satoh Y, Baskin LS, Cunha GR. Cellular and molecular mechanisms of development 
of the external genitalia. Differentiation 2003:71;445-460. 
 3.  Crescioli C, Maggi M, Vannelli GB, Ferruzzi P, Granchi S, Mancina R, Muratori M, Forti G, Serio 
M, Luconi M. Expression of functional estrogen receptors in human fetal male external 
genitalia. J Clin Endocrinol Metab 2003:88;1815-1824. 
 4.  Kim KS, Torres CR, Jr., Yucel S, Raimondo K, Cunha GR, Baskin LS. Induction of hypospadias in 
a murine model by maternal exposure to synthetic estrogens. Environ Res 2004:94;267-275. 
 5.  North K, Golding J. A maternal vegetarian diet in pregnancy is associated with hypospadias. 
BJU Int 2000:85;107-113. 
 6.  Liu B, Wang Z, Lin G, Agras K, Ebbers M, Willingham E, Baskin LS. Activating transcription 
factor 3 is up-regulated in patients with hypospadias. Pediatr Res 2005:58;1280-1283. 
 7.  Wang Z, Liu BC, Lin GT, Lin CS, Lue TF, Willingham E, Baskin LS. Up-regulation of estrogen 
responsive genes in hypospadias: microarray analysis. J Urol 2007:177;1939-1946. 
 8.  Fredell L, Kockum I, Hansson E, Holmner S, Lundquist L, Läckgren G, Pedersen J, Stenberg A, 
Westbacke G, Nordenskjöld A. Heredity of hypospadias and the significance of low birth 
weight. J Urol 2002:167;1423-1427. 
Polymorphisms in hypospadias 
 
79 
 9.  Schnack TH, Zdravkovic S, Myrup C, Westergaard T, Christensen K, Wohlfahrt J, Melbye M. 
Familial aggregation of hypospadias: a cohort study. Am J Epidemiol 2007:167;251-256. 
 10.  Alléra A, Herbst MA, Griffin JE, Wilson JD, Schweikert HU, McPhaul MJ. Mutations of the 
androgen receptor coding sequence are infrequent in patients with isolated hypospadias. J 
Clin Endocrinol Metab 1995:80;2697-2699. 
 11.  Hiort O, Klauber G, Cendron M, Sinnecker GHG, Keim L, Schwinger E, Wolfe HJ, Yandell DW. 
Molecular characterization of the androgen receptor gene in boys with hypospadias. Eur J 
Pediatr 1994:153;317-321. 
 12.  Nordenskjöld A, Friedman E, Tapper-Persson M, Söderhäll C, Leviav A, Svensson J, Anvret M. 
Screening for mutations in candidate genes for hypospadias. Urol Res 1999:27;49-55. 
 13.  Sutherland RW, Wiener JS, Hicks JP, Marcelli M, Gonzales ET, Jr., Roth DR, Lamb DJ. 
Androgen receptor gene mutations are rarely associated with isolated penile hypospadias. J 
Urol 1996:156;828-831. 
 14.  Silver RI, Russell DW. 5α-reductase type 2 mutations are present in some boys with isolated 
hypospadias. J Urol 1999:162;1142-1145. 
 15.  Codner E, Okuma C, Iñiguez G, Boric MA, Avila A, Johnson MC, Cassorla FG. Molecular study 
of the 3β-hydroxysteroid dehydrogenase gene type II in patients with hypospadias. J Clin 
Endocrinol Metab 2004:89;957-964. 
 16.  Fukami M, Wada Y, Miyabayashi K, Nishino I, Hasegawa T, Nordenskjöld A, Camerino G, Kretz 
C, Buj-Bello A, Laporte J et al. CXorf6 is a causative gene for hypospadias. Nat Genet 
2006:38;1369-1371. 
 17.  Chen T, Li Q, Xu J, Ding K, Wang Y, Wang W, Li S, Shen Y. Mutation screening of BMP4, BMP7, 
HOXA4 and HOXB6 genes in Chinese patients with hypospadias. Eur J Hum Genet 2007:15;23-
28. 
 18.  Beleza-Meireles A, Lundberg F, Lagerstedt K, Zhou X, Omrani D, Frisén L, Nordenskjöld A. 
FGFR2, FGF8, FGF10 and BMP7 as candidate genes for hypospadias. Eur J Hum Genet 
2007:15;405-410. 
 19.  Fredell L, Iselius L, Collins A, Hansson E, Holmner S, Lundquist L, Läckgren G, Pedersen J, 
Stenberg A, Westbacke G et al. Complex segregation analysis of hypospadias. Hum Genet 
2002:111;231-234. 
 20.  Peng B, Kimmel M. Simulations provide support for the common disease-common variant 
hypothesis. Genetics 2007:175;763-776. 
 21.  Radpour R, Rezaee M, Tavasoly A, Solati S, Saleki A. Association of long polyglycine tracts 
(GGN repeats) in exon 1 of the androgen receptor gene with cryptorchidism and penile 
hypospadias in iranian patients. J Androl 2007:28;164-169. 
 22.  Aschim EL, Nordenskjöld A, Giwercman A, Lundin KB, Ruhayel Y, Haugen TB, Grotmol T, 
Giwercman YL. Linkage between cryptorchidism, hypospadias, and GGN repeat length in the 
androgen receptor gene. J Clin Endocrinol Metab 2004:89;5105-5109. 
 23.  Thai HTT, Kalbasi M, Lagerstedt K, Frisén L, Kockum I, Nordenskjöld A. The valine allele of the 
V89L polymorphism in the 5-α-reductase gene confers a reduced risk for hypospadias. J Clin 
Endocrinol Metab 2005:90;6695-6698. 
 24.  Wang Y, Li Q, Xu J, Liu Q, Wang W, Lin Y, Ma F, Chen T, Li S, Shen Y. Mutation analysis of five 
candidate genes in Chinese patients with hypospadias. Eur J Hum Genet 2004:12;706-712. 
Chapter 2.1 
 
 
80 
 25.  Watanabe M, Yoshida R, Ueoka K, Aoki K, Sasagawa I, Hasegawa T, Sueoka K, Kamatani N, 
Yoshimura Y, Ogata T. Haplotype analysis of the estrogen receptor 1 gene in male genital and 
reproductive abnormalities. Hum Reprod 2007:22;1279-1284. 
 26.  Ban S, Sata F, Kurahashi N, Kasai S, Moriya K, Kakizaki H, Nonomura K, Kishi R. Genetic 
polymorphisms of ESR1 and ESR2 that may influence estrogen activity and the risk of 
hypospadias. Hum Reprod 2008:23;1466-1471. 
 27.  Beleza-Meireles A, Kockum I, Lundberg F, Söderhäll C, Nordenskjöld A. Risk factors for 
hypospadias in the estrogen receptor 2 gene. J Clin Endocrinol Metab 2007:92;3712-3718. 
 28.  Beleza-Meireles A, Omrani D, Kockum I, Frisén L, Lagerstedt K, Nordenskjöld A. 
Polymorphisms of estrogen receptor β gene are associated with hypospadias. J Endocrinol 
Invest 2006:28;5-10. 
 29.  Beleza-Meireles A, Töhönen V, Söderhäll C, Schwentner C, Radmayr C, Kockum I, 
Nordenskjöld A. Activating transcription factor 3: a hormone responsive gene in the etiology 
of hypospadias. Eur J Endocrinol 2008:158;729-739. 
 30.  Ioannidis JPA, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of 
genetic association studies. Nat Genet 2001:29;306-309. 
 31.  Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with 
complex outcomes. Lancet 2003:361;865-872. 
 32.  Brouwers MM, Feitz WFJ, Roelofs LAJ, Kiemeney LALM, de Gier RPE, Roeleveld N. Risk factors 
for hypospadias. Eur J Pediatr 2007:166;671-678. 
 33.  Brouwers MM, van der Zanden LFM, de Gier RPE, Barten EJ, Zielhuis GA, Feitz WFJ, Roeleveld 
N. Hypospadias: risk factor patterns and different phenotypes. BJU Int 2010:105;254-262. 
 34.  Hoogendoorn EH, Hermus AR, de Vegt F, Ross HA, Verbeek ALM, Kiemeney LALM, Swinkels 
DW, Sweep FCGJ, den Heijer M. Thyroid function and prevalence of anti-thyroperoxidase 
antibodies in a population with borderline sufficient iodine intake: influences of age and sex. 
Clin Chem 2006:52;104-111. 
 35.  Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic 
association studies. Genet Med 2002:4;45-61. 
 36.  Sillanpää MJ, Auranen K. Replication in genetic studies of complex traits. Ann Hum Genet 
2004:68;646-657. 
 37.  Källén B, Finnström O, Nygren KG, Olausson PO. In vitro fertilization (IVF) in Sweden: risk for 
congenital malformations after different IVF methods. Birth Defects Res A Clin Mol Teratol 
2005:73;162-169. 
 38.  Porter MP, Faizan MK, Grady RW, Mueller BA. Hypospadias in Washington State: maternal 
risk factors and prevalence trends. Pediatrics 2005:115;e495-e499. 
 39.  Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, Shi CY, Yu MC, Henderson 
BE, Reichardt JKV. A prevalent missense substitution that modulates activity of prostatic 
steroid 5α-reductase. Cancer Res 1997:57;1020-1022. 
 40.  Makridakis NM, di Salle E, Reichardt JKV. Biochemical and pharmacogenetic dissection of 
human steroid 5α-reductase type II. Pharmacogenetics 2000:10;407-413. 
 
Polymorphisms in hypospadias 
 
81 
 
  
 
  
 
Chapter 2.2 
 
Exploration of gene-environment interactions,  
maternal effects, and parent-of-origin effects  
in the etiology of hypospadias 
 
Loes FM van der Zanden, Tessel E Galesloot,  
Wout FJ Feitz, Marijn M Brouwers, Min Shi,  
Nine VAM Knoers, Barbara Franke,  
Nel Roeleveld, Iris ALM van Rooij 
 
Submitted for publication 
Chapter 2.2 
 
 
84 
Abstract 
 
Context 
Hypospadias is a common congenital malformation of the male external genitalia. Association 
studies for single nucleotide polymorphisms (SNPs) in genes encoding steroid-5-alpha-
reductase (SRD5A2), estrogen receptors 1 (ESR1) and 2 (ESR2), and activating transcription 
factor 3 (ATF3) have been equivocal.  
 
Objective 
The aim of this study was to examine whether non-replication of findings for four SNPs in these 
genes could be due to interaction with environmental exposures.  
 
Design, Participants, and Methods 
We genotyped 712 Dutch hypospadias case-parent triads for the four SNPs, used composite 
measures from questionnaire information to determine exposures, and performed association 
tests using the log-linear approach. We studied gene-environment interactions for the four 
SNPs with exogenous estrogen exposure, increased maternal estradiol levels during pregnancy, 
reduced human chorionic gonadotropin (hCG) provision to the fetus, and fetal exposure to 
cytokines or cigarette smoke. In addition, the presence of maternal genetic and parent-of-
origin effects was tested. 
 
Results 
Gene-environment interactions were identified for rs523349 in SRD5A2 and exogenous 
estrogen exposure, as well as for rs11119982 in ATF3 and exposure to cytokines, although the 
latter was only suggestive. Both SNPs only seemed to influence hypospadias risk in exposed 
cases. For rs6932902 in ESR1, only maternally derived alleles appeared to increase hypospadias 
risk in offspring.  
 
Conclusions 
This study shows that interactions between genetic and environmental factors may help to 
explain non-replication in genetic studies of hypospadias. 
Gene-environment interactions in hypospadias 
 
85 
Introduction 
 
Hypospadias is a congenital hypoplasia of the penis, resulting from developmental arrest of 
urethral fusion. This leads to displacement of the urethral opening along the ventral side of the 
penis. The displacement can be small, with the opening located in the glandular region, or 
more substantial, with penile, scrotal or perineal openings. Hypospadias is one of the most 
common birth defects among boys, affecting approximately 0.3 to 0.7% of newborn boys in 
Europe1,2. Despite surgery in the first two years after birth, patients may suffer from severe 
medical, social, and sexual problems later in life3,4. 
 
Hypospadias shows familial clustering, and segregation analyses suggest that the majority of 
cases have a multifactorial etiology5, involving both genes and environmental factors. 
Originally, studies trying to elucidate the etiology of hypospadias mainly focused on male 
hormones. More recently, focus has broadened to include female hormones as well, because 
estrogen receptors are expressed in the human fetal male external genitalia6, and exposure to 
estrogens can induce hypospadias in mice7. Some genetic associations with hypospadias have 
been reported, mainly for polymorphisms in endocrine-related genes, such as those encoding 
estrogen receptors 1 (ESR1)8,9 and 2 (ESR2)9,10, activating transcription factor 3 (ATF3)11, and 
steroid-5-alpha-reductase (SRD5A2)12,13. ATF3 is an estrogen-responsive gene showing strong 
upregulation in hypospadias14, while SRD5A2 encodes an enzyme that converts circulating 
testosterone in the genital tubercle to the more potent androgen dihydrotestosterone.  
 
The numbers of samples analyzed in these genetic studies were relatively small, with only 43 - 
350 cases included, and most associations could not be replicated in a much larger study by our 
group including 620 cases and 596 controls15. While the association between hypospadias and 
rs6932902 in ESR1 originally reported by Watanabe et al.8 was confirmed (albeit with smaller 
effect sizes), we did not observe the association with rs523349 in SRD5A2 described by several 
groups12,13, and found indications of opposite effects for rs2987983 in ESR2 and rs11119982 in 
ATF3 compared to the original reports10,11. The variant in SRD5A2 causes a valine to leucine 
substitution (V89L)  resulting in an approximately 30% decrease in enzyme activity16 and thus in 
less dihydrotestosterone. The other SNPs examined were intronic haplotype-tagging SNPs, not 
likely to be causal themselves, but rather a marker for an unknown, linked variant.  
 
A lack of consistency between studies might be caused by spurious results, chance findings, or 
differences in the criteria used to select cases or controls, or it may reflect real differences 
between populations, for example, differences in genetic background or environmental 
exposure15. Several reviews have called for studies simultaneously examining genes and 
environment in relation to hypospadias17, but so far, such studies have rarely been performed. 
Therefore, we set out to examine whether the lack of replication between our findings and 
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those of earlier studies could be due to gene-environment interactions between the four single 
nucleotide polymorphisms (SNPs) described above and exogenous exposure to estrogens, 
increased maternal estradiol levels during pregnancy, or reduced provision of human chorionic 
gonadotropin (hCG) to the fetus. All information was derived from questionnaires, and for the 
latter two exposures, we used composite parameters derived from a combination of several 
known risk factors for hypospadias, such as high maternal BMI, primiparity, multiple 
pregnancy, hypertension, preeclampsia, or children being born small for gestational age18-21. 
For ATF3, we also studied fetal exposure to cytokines and cigarette smoke. 
 
In addition to gene-environment interactions, other (epi)genetic mechanisms may be involved 
in the etiology of hypospadias. Maternal genotype may affect the intra-uterine environment, 
thus modulating hypospadias risk, and gene imprinting may cause the copy derived from one 
parent to be more fully expressed than the copy derived from the other parent. Therefore, we 
also examined whether maternal genotype influences hypospadias risk and whether the risk of 
hypospadias differs with the risk allele being inherited from father or mother. 
 
 
Material and Methods 
 
Cases and parents 
AGORA (Aetiologic research into Genetic and Occupational/environmental Risk factors for 
Anomalies in children) is a large data- and biobank in the Radboud University Nijmegen 
Medical Centre, Nijmegen, the Netherlands, in which questionnaire data and DNA samples are 
collected from patients with congenital malformations or childhood cancer and their parents. 
For the current study, DNA was available from 796 hypospadias cases born between 1980 and 
2008 and 1,422 parents, collected until 2009. Medical records of all cases were reviewed to 
identify syndromic hypospadias cases, to collect clinical characteristics of the patients, and to 
obtain information about the anatomical location of the urethral opening, which was 
determined by experienced pediatric urologists before or during surgery. The regional 
Committee on Research Involving Human Subjects approved the study protocol. All parents as 
well as children of 12 years of age or older gave written informed consent for participation in 
the study.  
 
Environmental risk factor data 
Questionnaires were sent to the parents of all patients, containing questions about 
demographics, family, and pregnancy history, as well as about health, life style, nutrition, 
medication use, and occupation in the three months before and during pregnancy. Because 
SRD5A2, ESR1, and ESR2 are involved in endocrine processes and ATF3 is an estrogen-
responsive gene, we studied interactions with exogenous exposure to estrogens, increased 
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maternal estradiol levels during pregnancy, and reduced provision of hCG to the fetus. 
Exogenous exposure to estrogens was defined as continued use of oral contraceptives during 
early pregnancy or consumption of soy or linseed products, which contain high amounts of 
phytoestrogens22, at least once a week in the first 14 weeks after conception. Women who 
became pregnant while they had a hormonal coil implanted were excluded because of the 
weak estrogen exposure. Women exposed to pesticides at work were excluded as well because 
pesticides can have either estrogenic or anti-estrogenic effects, information that we could not 
derive from the questionnaires.  
 
Estradiol levels are thought to be higher in twin pregnancies23 and in first pregnancies24. In 
addition, maternal serum estradiol levels increase with increasing body mass index (BMI)25. 
Therefore, we used dizygotic twin and trizygotic triplet pregnancies, first pregnancies, and 
women with a BMI > 25 kg/m2 as proxies for increased estradiol levels during pregnancy.  
 
Placental hCG controls fetal Leydig cell growth and stimulates fetal testicular steroidogenesis 
before the fetus’ own pituitary-gonadal axis is established26, thereby influencing the 
production of testosterone and dihydrotestosterone, two hormones that are important in the 
development of the male genitalia. Placental insufficiency may result in inadequate provision 
of hCG to the fetus. In addition, it may cause maternal hypertension and preeclampsia as well 
as intrauterine growth retardation, resulting in the child being born small for gestational age 
(SGA). Mothers delivering an SGA newborn were shown to have reduced serum beta-hCG 
levels around the 10th week of gestation27. In this study, we used self-reported maternal 
hypertension and preeclampsia, as well as SGA offspring as proxies for reduced fetal hCG 
provision. These factors have all been strongly associated with hypospadias in previous 
studies18,19,21. SGA was defined as a birth weight < 10th percentile for that gestational age, using 
Dutch reference curves for birth weight by gestational age28. 
 
In most tissues, ATF3 mRNA can be induced by various stress signals, such as cytokines and 
chemicals from cigarette smoke29,30. Therefore, we also included these exposures in the gene-
environment interaction analyses for ATF3. Because the placental barrier is permeable to 
cytokines31 and chemicals from cigarette smoke32, we categorized cases whose mothers 
smoked at least one cigarette per day during some time in the first 14 weeks after conception 
as exposed to cigarette smoke, and cases whose mothers reported the presence of an infection 
and/or inflammation in the first 14 weeks after conception as exposed to cytokines. Women 
with an infection and/or inflammation were defined as those who reported a severe cold, 
infection of the bladder or renal pelvis, flu, mononucleosis, chickenpox, sinusitis, or other viral, 
bacterial or fungal infections, as well as those with chronic inflammatory diseases such as 
asthma, bronchitis, rheumatoid arthritis, psoriasis, and Crohn’s disease. 
 
Chapter 2.2 
 
 
88 
Genotyping 
Blood was collected in EDTA containing tubes for more than two thirds of the participants and 
their parents (n=1,405), and saliva was collected using Oragene containers for the others 
(n=687; DNA Genotek Inc., Ottawa, Ontario, Canada). DNA was extracted from blood or saliva 
using standard methods. Samples were genotyped using 5’-nuclease TaqMan SNP genotyping 
assays (rs523349 in SRD5A2: C_2362601_10; rs6932902 in ESR1: C_2823640_10; rs2987983 in 
ESR2: C_1436929_20; rs11119982 in ATF3: C_27262262_10; Applied Biosystems, Foster City, 
CA, USA). PCR reactions were carried out in 96-well plates in a 5 μl reaction volume containing 
10 ng genomic DNA, 2.5 μl Taqman Universal PCR master mix, 0.0625 μl assay mix and milli-Q. 
The PCR reaction consisted of an initial denaturation step at 95°C for 12 minutes followed by 
40 cycles of denaturation at 92°C for 15 seconds and annealing and extension at 60°C for 60 
seconds. After PCR, allele-specific fluorescence was measured on an ABI 7500 FAST (Applied 
Biosystems). In each plate, 5 wells were loaded with randomly selected duplicate DNA samples 
from the same and other plates for quality control purposes. In addition, 3 blank controls were 
included in each plate.  
 
Statistical analyses 
We used the case-parent triad design. The most frequent homozygous genotypes in parents 
served as the reference genotypes. The log-linear approach33 was applied to assess genetic 
associations, providing relative risks associated with having one or two copies of the variant 
allele relative to the reference genotype, for both the maternal and offspring genotypes. Log-
linear models were fitted without assumption of Hardy-Weinberg equilibrium and information 
on families with one missing parental genotype were included in the analyses by using the 
expectation-maximization algorithm34. The likelihood ratio test (LRT), comparing a full model 
including both maternal and offspring genotypes to a reduced model including either maternal 
or offspring genotype only, was computed to determine the relevance of the maternal and 
offspring genotypes for hypospadias risk. We also conducted the aforementioned analyses 
separately for the groups of either anterior (hypospadias sine hypospadias, glandular and   
(sub-) coronal), middle (penile), or posterior (penoscrotal, scrotal and perineal) hypospadias 
cases, because different risk factors may be responsible for the different phenotypes21,35. 
 
Parent-of-origin analyses were conducted in two steps. As an initial screening, we used the 
transmission asymmetry test (TAT), which is similar to the transmission disequilibrium test but 
with stratified analyses in fathers and mothers while excluding families with both parents being 
heterozygotes33. This approach provides insights into the data, but is invalid when maternal 
effects exist. The parent-of-origin LRT (PO-LRT), which is less intuitive but valid even in the 
presence of maternal effects, was used to confirm the results36.  
 
Interactions between environmental exposures and offspring genotypes were tested using  log-
linear models with the LRT comparing a full model including gene-environment interactions to 
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a reduced model including only the offspring genotype37. If the LRT indicated the presence of 
an interaction (PLRT < 0.10), relative risks (RR) and 95% confidence intervals (95% CI) were 
calculated separately for the different strata of the exposure variable using the variance 
calculated with the LEM program, which takes into account missing genotypes38. All other 
analyses were performed using the SAS System for Windows, release 8.02 (SAS Institute, Cary, 
North Carolina). 
 
 
Results 
 
Of the 796 available hypospadias cases, 38 patients were excluded because DNA of both 
parents was not available. To ensure independence, we excluded the youngest brother from 
the 22 sib-pairs present in the dataset, and from the three twin-pairs, one brother was 
excluded at random. We excluded 19 patients because of syndromic hypospadias, 
chromosome abnormalities, or a known cause of hypospadias (e.g. androgen receptor defect). 
Finally, two triads were excluded because of Mendelian errors. The final data set consisted of 
712 cases. For 668 cases, DNA of both parents was available, and for 44 cases, we only had 
DNA from one parent. Environmental data were missing for 70 families. The majority of the 
cases were of European Caucasian descent (91%), and the remaining were of non-European 
(5%) or unknown descent (4%).  
 
Almost 60% of the cases had an anterior hypospadias, while 20% and 13% had middle and 
posterior openings, respectively. Almost all posterior cases presented with additional 
anomalies such as chordee, cryptorchidism, and micropenis (97%, 19%, and 11%, respectively), 
percentages that were much lower for the middle (74%, 4%, and 1%, respectively) and anterior 
cases (51%, 5%, and 2%, respectively). Table 1 shows the distribution of the environmental risk 
factors studied. Exogenous exposure to estrogens during early pregnancy and fetal exposure to 
cytokines were relatively rare (<10%), whereas increased maternal estradiol levels during 
pregnancy (63%), reduced fetal hCG provision (29%), and fetal exposure to cigarette smoke 
(16%) were more common. 
 
Genotyping of the SNPs was completed with a success rate of more than 98.5%. All genotype 
frequencies in parents were in Hardy Weinberg Equilibrium (rs523349 in SRD5A2: P = 0.28; 
rs6932902 in ESR1: P = 0.61; rs2987983 in ESR2: P = 0.52; rs11119982 in ATF3: P = 0.77). Table 
2 shows the genetic association results for offspring and maternal genotypes from the log-
linear models. The offspring genotype of the variant in ESR1 was associated with hypospadias, 
as reported earlier in a partly overlapping sample15, whereas the results for the variant in ATF3 
were suggestive of an association. Maternal genotypes of the four SNPs were not associated 
with hypospadias in offspring. Repeating the analyses separately for subgroups of anterior, 
middle, and posterior hypospadias cases showed comparable results (data not shown).  
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Table 1.  Distribution of environmental risk factors for hypospadias patients. 
Exposure 
 
       yes 
    n      (%)  
 
       no 
    n      (%)  
 
   unknowna 
    n      (%) 
 
 
Exogenous exposure to estrogens    29     (4%) 580   (81%) 103   (14%) 
 
 Use of oral contraceptives during pregnancy      8     (1%) 626   (88%)   78   (11%) 
 
 Consumption of soy products during pregnancy   16     (2%)  620   (87%)   76   (11%) 
 
 Consumption of linseed products during pregnancy     7     (1%) 626   (88%)   79   (11%) 
 
Increased maternal estradiol levels  449   (63%) 174   (24%)   89   (13%) 
 
 Dizygotic twin or trizygotic triplet pregnancy   34     (5%) 597   (84%)   81   (11%) 
 
 First pregnancy 361   (51%) 277   (39%)   74   (10%) 
 
 BMI > 25 kg/m2 158   (22%) 450   (63%) 104   (15%) 
 
Reduced fetal hCG provision  203   (29%) 419   (59%)   90   (13%) 
 
 Hypertension or preeclampsia 107   (15%) 533   (75%)   72   (10%) 
 
 Small for gestational age 125   (18%) 505   (71%)   82   (12%) 
 
Fetal exposure to cytokines   67     (9%) 499   (70%) 146   (21%) 
 
 From a severe cold    15     (2%) 574   (81%) 123   (17%) 
 
 From other viral, bacterial or fungal infections    28     (4%) 563   (79%) 121   (17%) 
 
 From chronic inflammatory diseases    29     (4%) 605   (85%)   78   (11%) 
 
Fetal exposure to cigarette smoke 117   (16%) 505   (71%)   90   (13%) 
Percentages do not add up to 100% due to rounding; n, number; 
a
for 70 patients, environmental 
data was completely missing because parents did not fill out the questionnaires. 
 
 
 
 
Table 2.  Genetic association results for offspring and maternal genotypes of single 
nucleotide polymorphisms in SRD5A2, ESR1, ESR2, and ATF3 with hypospadias. 
  
 
Offspring genotype 
 
 
 
Maternal genotype 
 
SNP 
 
Geno-      
 type 
 
Cases 
n      (%)  
 
RR 
 
95% CI 
 
P 
 
 
PLRT
a 
 
 
      
  Mothers 
    n      (%)  
 
RR 
 
95% CI 
 
 P 
 
PLRT
b 
 
 
rs523349  
in SRD5A2 
 
CC 
CG 
GG 
333  (48%) 
298  (43%) 
  70   10%) 
ref 
1.1 
1.0 
 
0.9-1.3 
0.7-1.5 
 
0.60 
0.83 0.87 
326  (47%) 
313  (45%) 
  57    (8%) 
ref 
1.0 
0.9 
 
0.8-1.3 
0.6-1.3 
 
0.69 
0.46 0.64 
 
rs6932902 
in ESR1 
 
GG 
AG 
AA 
513  (72%)  
177  (25%) 
  18    (3%) 
ref 
1.5 
2.0 
 
1.2-2.0 
1.1-3.8 
 
1×10-3 
0.03 3×10-3 
523  (75%)  
159  (23%) 
  16    (2%) 
ref 
1.1 
1.7 
 
0.8-1.4 
0.7-3.7 
 
0.61 
0.21 0.42 
 
rs2987983 
in ESR2 
 
AA 
AG 
GG 
345  (49%) 
293  (42%) 
  67  (10%) 
ref 
0.8 
0.8 
 
0.7-1.0 
0.5-1.1 
 
0.06 
0.12 0.13 
328  (47%) 
297  (43%) 
  72  (10%) 
ref 
1.0 
1.0 
 
0.8-1.3 
0.7-1.4 
 
0.97 
0.86 0.98 
 
rs11119982 
in ATF3 
 
CC 
CT 
TT 
163  (23%) 
354  (50%) 
188  (27%) 
ref 
1.2 
1.4 
1.0-1.6 
1.0-1.9 
 
0.07 
0.02 0.07 
180  (26%) 
332  (48%) 
187  (27%) 
ref 
0.9 
1.1 
 
0.7-1.1 
0.8-1.6 
 
0.23 
0.37 0.09 
Percentages do not add up to 100% due to rounding; CI, confidence interval; LRT, likelihood ratio 
test; n, number; RR, relative risk; 
a
P-value of the likelihood ratio test comparing a full model including 
maternal and offspring genotypes to a reduced model including only maternal genotypes; 
b
P-value of 
the likelihood ratio test comparing a full model including maternal and offspring genotypes to a 
reduced model including only offspring genotypes. 
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Table 3 shows the results of the likelihood ratio tests comparing full models including gene-
environment interactions to reduced models including only the offspring genotype, while 
Figure 1 presents the corresponding relative risks for SRD5A2 and ATF3. The results pointed 
towards evidence for an interaction between the offspring genotype of rs523349 in SRD5A2 
and exogenous estrogen exposure. Although the risk estimates had wide confidence intervals, 
offspring carrying the variant allele seemed to be at increased risk of hypospadias only when 
there was exogenous estrogen exposure during pregnancy. Furthermore, an indication for an 
interaction was observed between rs11119982 in ATF3 and exposure to cytokines, with 
increased risk of hypospadias for offspring carrying the variant allele only when the mother 
reported an infection and/or inflammation during pregnancy. Due to the small number of cases 
with estrogen exposure we also considered a reduced model assuming the same mating type 
parameters for exposed and unexposed cases. This model handles small sample size situations 
better, but it loses the robustness to population stratification. The risk estimates from this 
model show the same direction of gene by exposure interaction, albeit much less strong and 
more difficult to interpret for the homozygous variant (Figure 2). 
 
 
Table 3.  Results of the tests for gene-environment interactions for single nucleotide 
polymorphisms in SRD5A2, ESR1, ESR2 and ATF3.  
SNP 
 
 Environmental risk factor 
 
 
PLRT
a
 
 
 
rs523349 in SRD5A2 
 
 
 
Exogenous exposure to estrogens 
Increased maternal estradiol levels 
Reduced fetal hCG provision 
 
2×10-3* 
0.45 
0.64 
 
 
rs6932902 in ESR1 
 
 
 
Exogenous exposure to estrogens 
Increased maternal estradiol levels 
Reduced fetal hCG provision 
 
0.30 
0.12 
0.25 
 
 
rs2987983 in ESR2 
 
 
 
Exogenous exposure to estrogens 
Increased maternal estradiol levels 
Reduced fetal hCG provision 
 
0.28 
0.67 
0.71 
 
 
rs11119982 in ATF3 
 
 
 
 
 
Exogenous exposure to estrogens 
Increased maternal estradiol levels 
Reduced fetal hCG provision 
Fetal exposure to cytokines 
Fetal exposure to cigarette smoke 
 
0.55 
0.92 
0.12 
0.07* 
0.80 
LRT, likelihood ratio test; 
a
P-value of the likelihood ratio test comparing a full model 
including gene-environment interactions to a reduced model including only offspring 
genotypes; 
*
indication of gene-environment interaction. 
 
 
The results of the parent-of-origin effects analyses are shown in Table 4. For rs6932902 in 
ESR1, the estimated PO-LRT relative risk for an imprinting effect was 1.61 (95% CI = 1.02 - 
2.53), indicating that a maternally derived copy seemed to be associated with a greater risk of 
hypospadias than a paternally derived copy. The TAT showed that only the maternally derived 
copy increased the risk of the disorder (RR = 1.8, 95% CI = 1.3 - 2.7), whereas the paternally 
derived copy did not.   
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Table 4.  Results of the parent-of-origin analyses.  
 
 
Transmission asymmetry test (TAT) 
 
  
 
PO-LRT 
 
 
 
Mothers 
 
 
 
Fathers 
 
 
     
SNP (minor allelea) 
 
 
 
T 
 
 
NT 
 
 
RR 
 
 
95% CI   
 
P  
 
 
 T 
 
 
NT 
 
 
RR 
 
 
95% CI 
 
 
P 
 
 
PTAT 
 
 
RR 
 
 
P 
 
 
 
 
rs523349 in SRD5A2 (G) 
 
81 
 
80 
 
1.0 
 
0.7-1.4  
 
0.94 
 
66 
 
81 
 
0.8 
 
0.6-1.1 
 
0.22 
 
0.34 
 
1.2 
 
0.27 
 
rs6932902 in ESR1 (A) 79 43 1.8 1.3-2.7 1×10-3 58 53 1.1 0.8-1.6 0.64 0.05 1.6 0.07 
 
rs2987983 in ESR2 (G) 59 95 0.6 0.5-0.9 4×10-3 64 82 0.8 0.6-1.1 0.14 0.33 0.8 0.27 
 
rs11119982 in ATF3 (T) 83 71 1.2 0.9-1.6 0.33 111 70 1.6 1.2-2.1 3×10-3 0.17 0.8 0.25 
CI, confidence interval; NT, minor allele not transmitted; PO-LRT, parent-of-origin likelihood ratio 
test; RR, relative risk; T, minor allele transmitted; TAT, transmission asymmetry test; 
a
the least 
frequent allele in the parents. 
 
 
 
 
Figure 1.  Relative risks of hypospadias with 95% confidence intervals for genotypes of (a) 
rs523349 in SRD5A2 within strata of exogenous estrogen exposure and (b) 
rs11119982 in ATF3 within strata of fetal exposure to cytokines. 
 
A 
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Figure 2.  Relative risks of hypospadias with 95% confidence intervals for genotypes of 
rs523349 in SRD5A2 within strata of exogenous estrogen exposure using a 
reduced model assuming the same mating type parameters for the exposed and 
unexposed individuals. 
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Discussion 
 
This study is a follow-up to our earlier association study of genetic variants in SRD5A2, ESR1, 
ESR2, and ATF3 and hypospadias risk with a case-control design. In that study, 620 cases were 
included. For the current study, we excluded 37 cases because DNA of both parents was not 
available or an older brother was present in the dataset. The sample was extended with 129 
cases not included in the earlier study because of non-Caucasian or unknown ethnicity or 
because they were collected after 2007. We included gene-environment interactions as well as 
maternal and parent-of-origin effects in an attempt to reconcile our findings with those of 
others. We found no associations for rs523349 in SRD5A2 and rs2987983 in ESR2, whereas 
rs6932902 in ESR1 was associated with hypospadias, and the results for rs11119982 in ATF3 
were suggestive of an association. These results are comparable to the results we reported 
previously15, although the association with the variant in ESR1 was stronger in the current 
study. For this SNP, we also identified a parent-of-origin effect suggesting that the association 
is brought about by maternally derived alleles only. For the variants in SRD5A2 and ATF3, we 
found indications for an interaction between offspring genotype and exogenous estrogen 
exposure during pregnancy or fetal exposure to cytokines, respectively.  
 
The interaction between offspring genotype of the SNP in SRD5A2 and exogenous estrogen 
exposure during early pregnancy showed that heterozygous offspring had a more than nine 
fold increased risk of hypospadias only in case of exogenous estrogen exposure in the full log-
linear model. In the reduced model, we observed a more than two times increased risk in case 
of exogenous estrogen exposure. The clearly increased risk was absent for offspring 
homozygous for the variant allele, but this was most likely due to insufficient power, with only 
one case being both exposed and homozygous for the variant allele. The interaction between 
this variant and exogenous estrogen exposure seems biologically plausible, because the SNP 
results in less production of dihydrotestosterone. Additional estrogen exposure might cause an 
androgen-estrogen imbalance in carriers of this variant, resulting in hypospadias. The gene-
environment interaction observed could help to explain differences in association findings for 
this SNP between our study and studies from Sweden and China12,13,15. The latter two observed 
associations with the malformation, not taking environmental parameters into account, while 
we did not. However, phytoestrogen exposure is known to be higher in Chinese and Swedish 
populations compared to the Dutch. Chinese people consume more soy products, while in 
Nordic countries more rye bread and berries are consumed. These food products contain large 
amounts of isoflavonoids and lignans, respectively, whereas in a typical Western diet, both 
lignans and isoflavonoids are almost completely lacking because of the low content of fiber-
rich food39.  
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The SNP in ATF3 seemed to be associated with an increased hypospadias risk only when the 
mother reported an infection and/or inflammation during pregnancy. ATF3 shows strong 
upregulation in hypospadias patients14 and is upregulated in response to cytokines29. While the 
rs11119982 variant is functionally uncharacterized, a working hypothesis could be that the 
variant underlying the association between the SNP and hypospadias causes an increased 
expression of ATF3 in response to cytokines. However, this finding does not reconcile our 
results with those reported by Beleza-Meireles et al.11, who reported a decreased hypospadias 
risk in the presence of the ATF3 variant.  
 
The parent-of-origin analyses indicated that only a maternally derived copy of the variant in 
ESR1 seems to be associated with an increased hypospadias risk. This suggests that the 
maternally derived allele of ESR1 is more fully expressed than the paternally derived allele. 
Although ESR1 is not one of the currently known imprinted genes (www.geneimprint.com), the 
experimental identification of imprinted genes is challenging, because monoallelic expression 
of imprinted genes may occur only in particular tissues, at particular stages of development, or 
in one of the isoforms40. Therefore, it is unlikely that all human imprinted genes are already 
known.  
 
We did not identify gene-environment interactions with reduced fetal hCG provision, increased 
maternal estradiol levels, or fetal exposure to cigarette smoke. While this may reflect true non-
existence of such effects, we also have to acknowledge some limitations of our study design. 
For fetal hCG provision and maternal estradiol levels, we had to rely on composite exposure 
parameters as these were not measured directly. Although the proxies used were shown to be 
associated with hypospadias in most studies18-21, a certain degree of misclassification is highly 
likely. In addition, we cannot rule out misclassification due to recall problems, since the 
average time between birth of the affected child and filling out the questionnaires was 10.2 
years, ranging from 0 to 27 years. Although this misclassification does not depend on genotype 
and probably resulted in attenuation of the results rather than in bias, it may have obscured 
some effects. To our knowledge, we investigated the largest sample of hypospadias cases thus 
far reported in genetic studies, while the power of our study was further increased by including 
information on families with one missing parental genotype using the expectation-
maximization algorithm. However, numbers of cases having a specific genotype or being 
exposed to a particular environmental risk factor were still small, resulting in large confidence 
intervals for the effect estimates. Our definition of exogenous estrogen exposure, for example, 
assured a selective group of women experiencing high levels of exposure, but resulted in low 
numbers of exposed women. This indicates that very large samples are needed to study gene-
estrogen-exposure interaction. 
 
We showed that parent-of-origin effects and gene-environment interactions contribute to the 
etiology of hypospadias, and that environmental factors can explain genetic non-replication 
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between studies. Our results warrant further research directed at elucidating the combined 
effects of genetic and environmental factors for this important urological birth defect. 
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Abstract 
 
Hypospadias is a common congenital malformation of the male external genitalia. We 
performed a genome-wide association study using pooled DNA from 436 individuals with 
hypospadias (cases) and 494 controls of European descent and selected the highest ranked 
SNPs for individual genotyping in the discovery sample, an additional Dutch sample of 133 
cases and their parents, and a Swedish series of 266 cases and 402 controls. Individual 
genotyping of two SNPs (rs1934179 and rs7063116) in DGKK, encoding diacylglycerol kinase κ, 
produced compelling evidence for association with hypospadias in the discovery sample (allele-
specific odds ratio (OR) = 2.5, P = 2.5 × 10-11 and OR = 2.3, P = 2.9 × 10-9, respectively) and in the 
Dutch (OR = 3.9, P = 2.4 × 10-5 and OR = 3.8, P = 3.4 × 10-5) and Swedish (OR = 2.5, P = 2.6 × 10-8 
and OR = 2.2, P = 2.7 × 10-6) replication samples. Expression studies showed expression of 
DGKK in preputial tissue of cases and controls, which was lower in carriers of the risk allele of 
rs1934179 (P = 0.047). We propose DGKK as a major risk gene for hypospadias. 
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Article 
 
Hypospadias is a common congenital hypoplasia of the penis, affecting approximately 1 in 750 
births in Europe (see URLs). Due to developmental arrest of urethral fusion, the urethral 
opening is displaced along the ventral side of the penis. The opening can be located glandular, 
penile or even more posterior in the scrotum or perineum. Although most children with this 
condition undergo surgery in their second year of life, serious medical, social and sexual 
problems may still exist later in life. Hypospadias shows familial clustering1, pointing toward 
genetic factors being important in its etiology2. Hypotheses about the multifactorial etiology of 
hypospadias mainly focus on hormonal disturbances. Polymorphisms in endocrine-related 
genes have been associated with hypospadias3-11. However, most of these associations have 
been found in small studies and were not replicated in the series used in the present study12. 
Therefore, our understanding of the molecular pathways leading to hypospadias is incomplete.  
 
With the availability of SNP microarrays, genome-wide association studies (GWASs) have 
become feasible in elucidating the genetic basis of common complex disorders. Large sample 
sizes are needed in GWASs to detect genetic factors with modest effects on disease risk, having 
substantial implications in terms of costs. A useful solution is offered by DNA pooling, which 
has been proven to be feasible and accurate13-15. 
 
To identify genetic variants contributing to hypospadias susceptibility, we performed the first 
GWAS for this malformation using pooled DNA samples. We included 436 cases of European 
descent with isolated anterior or middle hypospadias from the AGORA (Aetiologic research into 
Genetic and Occupational/environmental Risk factors for Anomalies in children) project 
(Supplementary Fig. 1 and Supplementary Table 1) and 494 unaffected male controls of 
European descent from the Nijmegen Biomedical Study. In this discovery sample, we 
allelotyped 906,600 SNPs in duplicate using Affymetrix GeneChip 6.0 microarrays and 
calculated allele frequencies using k-corrected signal intensities (see Supplementary Note). The 
worst performing 5% of measurements, indicated by the biggest differences between the allele 
frequency estimates from the duplicate measurements, were excluded. Furthermore, we 
excluded SNPs based on several quality control criteria, such as high variance in case or control 
pools and minor allele frequencies (MAF) below 5%. A total of 574,400 SNPs passed quality 
control steps and were included in the analyses. We selected the 50 highest ranked SNPs based 
on the standard χ2 statistic and a modified χ2 statistic16 applied to the raw and k-corrected 
allele frequency estimates. Of these 50 SNPs, we chose 20 based on several criteria, such as 
location near a gene and MAF (Supplementary Table 2). Seven of these 20 SNPs were located in 
the X-chromosomal gene DGKK, encoding diacylglycerol kinase κ. As most SNPs in this gene are 
in strong linkage disequilibrium (LD) with each other (Supplementary Fig. 2), we selected the 
intronic SNP that tagged the most other SNPs (rs1934179) for individual genotyping in the 
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discovery sample, as well as a potentially regulatory SNP in the 5’ upstream region (rs7063116). 
Furthermore, nine SNPs in other genes were individually genotyped (Supplementary Table 3).  
 
 
Table 1.  Association of hypospadias with SNPs in DGKK in the discovery sample, the 
Dutch replication sample and the Swedish replication sample. 
Study population 
 
 
rs1934179 in DGKK 
 
 
 
rs7063116 near DGKK 
 
OR   (95% CI) 
 
χ2 P 
 
 
 
OR    (95% CI) 
 
 
χ2 P 
 
 
Dutch discovery sample 2.46  (1.88-3.21) 2.5×10-11  2.25  (1.72-2.96) 2.9×10-9 
 
Dutch replication sample 3.92  (2.08-7.38) 2.4×10-5  3.83   (2.03-7.24) 3.4×10-5 
 
Swedish replication sample 2.48 (1.80-3.42) 2.6×10-8  2.16   (1.56-2.99) 2.7×10-6 
OR, odds ratio; CI, confidence interval. 
 
 
Individual genotyping was completed with a success rate of ≥99%. All genotype frequencies in 
the controls were in Hardy-Weinberg equilibrium (P > 0.05). Both SNPs in DGKK showed 
genome-wide significant association in the discovery sample (OR for the A (risk) allele of these 
X-chromosomal SNPs in our male sample = 2.5, P = 2.5 × 10-11 for rs1934179 and OR = 2.3, P = 
2.9 × 10-9 for rs7063116) (Table 1). These results were validated by genotyping the parents of 
the cases using the transmission disequilibrium test, a method robust to population 
stratification (Table 2). Eight of the other nine SNPs showed suggestive association with 
hypospadias (P < 0.05) (Supplementary Table 4). 
 
 
Table 2.  Association of hypospadias with SNPs in DGKK in cases in the discovery sample 
and their parents. 
 
SNP 
 
 
Minor allelea 
 
 
T 
 
 
NT 
 
 
OR  (95% CI) 
 
 
χ2 P 
 
 
rs1934179 in DGKK A 147 58 2.53 (1.87-3.43) 2.0×10-9 
 
rs7063116 near DGKK A 134 65 2.06 (1.53-2.77) 1.7×10-6 
a
The least frequent allele in the controls of the discovery sample; NT, minor allele not transmitted; T, 
minor allele transmitted; OR, odds ratio; CI, confidence interval. 
 
 
For the ten associated SNPs, we subsequently attempted replication in an additional Dutch 
sample of 133 anterior or middle hypospadias cases of European descent and their parents. 
Seven SNPs showed similar ORs in this sample compared to the discovery sample, although 
most of these SNPs did not reach statistical significance, probably due to the small number of 
heterozygous parents. The only exceptions to this were the SNPs in DGKK, in which the same A 
alleles were again strongly associated with hypospadias (OR = 3.9, P = 2.4 × 10-5 for rs1934179 
and OR = 3.8, P = 3.4 × 10-5 for rs7063116) (Table 1 and Supplementary Table 5). A second 
replication in a Swedish cohort of 266 anterior or middle hypospadias cases and 402 male 
controls convincingly confirmed the associations with the A alleles of the SNPs in DGKK (OR = 
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2.5, P = 2.6 × 10-8 for rs1934179 and OR = 2.2, P = 2.7 × 10-6 for rs7063116), whereas 
associations with the other eight SNPs did not reach statistical significance (Table 1 and 
Supplementary Table 6). We then performed a meta-analysis with both the discovery sample 
and the two replication samples (Supplementary Table 7). In addition to the SNPs in DGKK, 
SNPs in PPARGC1B (rs4705372) and GRID1 (rs1880386) reached statistical significance in this 
analysis after correcting the critical P value for multiple testing (critical Bonferroni P < 0.005).  
 
The pathogenesis of hypospadias probably includes many causal factors. We calculated the 
population attributable fraction (PAF) for hypospadias of rs1934179 in DGKK to be 32% in the 
Dutch population and 31% in the Swedish population, meaning that the variant underlying the 
association between rs1934179 in DGKK and hypospadias is one of the causal factors in nearly 
one third of hypospadias cases. As a comparison, the PAF for APOE in Alzheimer’s disease is 
26% (ref. 17), and that association is one of the strongest and best known genetic associations 
reported for a multifactorial disorder. However, the PAF calculated for hypospadias is based on 
data from our study only, and independent population-based studies should be performed to 
verify the validity of the estimate. 
 
DGKK encodes a human type II diacylglycerol kinase18. Diacylglycerol kinases modulate the 
balance between diacylglycerol and phosphatidic acid, two signaling lipids, thereby playing an 
important role in signal transduction. DGKK mRNA is most abundant in testis and placenta18. 
Although DGKK has not previously been associated with hypospadias and there are other genes 
in close proximity to it, we suggest DGKK as the hypospadias susceptibility gene in the 
identified X-chromosomal locus as the LD block in which the gene is located encompasses only 
DGKK (Supplementary Fig. 2). Because the LD block also covers likely regulatory regions, 
variants regulating DGKK expression may underlie the association of DGKK with hypospadias. 
We performed real-time quantitative PCR analyses showing that DGKK is expressed in preputial 
skin of all investigated healthy boys (n = 10) and of hypospadias cases (n = 14) (Supplementary 
Fig. 3). Expression was lower in individuals with the A (risk) allele (n = 15) of rs1934179 (P = 
0.047) (Fig. 1). These results suggest that variants regulating DGKK mRNA expression underlie 
the association of rs1934179 with hypospadias. A search for potential functional variants 
identified one SNP in a FOXL1 transcription factor binding site, rs1934176, which is in high LD 
(r2 = 0.99) with rs1934179; however, the significance of this SNP requires further study. 
 
SNPs in GRID1, PPARGC1B and KIAA2022 showed associations in the same direction in the 
discovery sample and in both replication samples, resulting in outcomes with a higher level of 
statistical significance in the meta-analysis. This suggests that nonsignificance of results may be 
due to lack of power. Indeed, the power of our study to detect associations with OR < 1.5 was 
limited and was even further reduced by the fact that we used DNA pooling. Using DNA pools 
instead of individual DNA samples results in less accurate allele frequency estimates, possibly 
producing more false-positive and false-negative findings. Validating our results by individual 
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genotyping enabled us to identify false-positive findings arising from such inaccurate estimates. 
False-negative results cannot be identified, however, and we may have missed additional 
associations that we would have detected with a GWAS based on individual genotyping. In 
addition, we may have missed associations with rare variants by excluding SNPs with MAF 
below 5%, that is, SNPs for which we had insufficient power. Therefore, individual GWAS 
(preferentially in larger samples) may identify additional hypospadias loci. 
 
 
Figure 1.  Quantification of DGKK mRNA expression (± s.e.m.) in preputial skin of 
hypospadias cases and controls relative to GAPDH mRNA expression. 
 
 
 
Previously performed studies showed familial occurrence of hypospadias for anterior and 
middle forms of hypospadias but not for posterior types1,19. Because of this apparent etiologic 
heterogeneity, we included only anterior and middle cases in the current analyses. As 
expected, an additional analysis of the SNPs in DGKK in cases with posterior hypospadias 
showed weaker associations (Table 3), although the small number of cases used may have 
hampered a fair comparison. Nevertheless, these data are compatible with anterior and middle 
forms of hypospadias having an oligogenic or polygenic multifactorial etiology, including a 
crucial role for DGKK, and with posterior forms having a different etiology. These results 
warrant stratification by hypospadias phenotype based on location of the urethral opening in 
future genetic studies, which may reduce genetic heterogeneity and improve the 
reproducibility of the results. 
 
In summary, we have identified a new X-chromosomal risk locus for hypospadias. We showed 
expression of DGKK in preputial skin, which was lower in boys with the risk allele. We propose 
DGKK as a major risk gene for anterior and middle forms of hypospadias. Because hypospadias 
is a fusion defect, DGKK might be important for other congenital closure defects as well. 
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Table 3.  Association of different forms of hypospadias with SNPs in DGKK. 
 
Study population 
(ncontrols/ncases) 
 
 
Minor allele (A) frequency (%) 
 
  
 
Controls 
 
Cases 
 
OR   (95% CI) 
 
χ2 P 
 
 
rs1934179 in DGKK 
  
   
 
Dutch sample    
 
 
Anterior and middle cases (494/436)  
(cases used in the discovery sample) 32.9 54.6 2.46  (1.88-3.21)  2.5×10-11 
 
Posterior cases (494/87) 32.9 38.1 1.26  (0.78-2.03)    0.348 
 
Swedish sample    
 
Anterior and middle cases (402/266) 
(cases used in the replication sample) 31.0 52.7 2.48 (1.80-3.42)  2.6×10-8 
 
Posterior cases (402/62) 31.0 45.9 1.89  (1.09-3.26)    0.021 
 
rs7063116 near DGKK 
 
 
Dutch sample     
 
 
Anterior and middle cases (494/436) 
(cases used in the discovery sample) 29.3 48.3 2.25  (1.72-2.96)  2.9×10-9 
 
Posterior cases (494/87) 29.3 26.2 0.86  (0.51-1.45)    0.565 
 
Swedish sample     
 
Anterior and middle cases (402/266) 
(cases used in the replication sample) 29.4 47.3 2.16  (1.56-2.99)  2.7×10-6 
 
Posterior cases (402/62) 
 
29.4 
 
41.0 
 
1.67  (0.96-2.91) 
 
   0.067 
 
OR, odds ratio; CI, confidence interval. 
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Online methods 
 
Pool construction 
The AGORA (Aetiologic research into Genetic and Occupational/environmental Risk factors for 
Anomalies in children) project of the Radboud University Nijmegen Medical Centre (RUNMC), 
Nijmegen, The Netherlands, is building a data bank and bio bank with questionnaire data and 
DNA samples from individuals with a congenital malformation or childhood cancer, as well as 
their parents. DNA was available for 679 hypospadias cases from the AGORA project 
(Supplementary Fig. 1 and Supplementary Table 1) and 596 unaffected male controls of 
European descent from the Nijmegen Biomedical Study20. The Arnhem-Nijmegen Regional 
Committee on Research Involving Human Subjects approved both studies. All participants 
and/or their parents gave written informed consent for participation in the studies. A detailed 
description of the study populations and pooling process can be found in the Supplementary 
Note. Finally, DNA samples of 436 cases of European descent with isolated anterior or middle 
hypospadias and 494 unaffected male controls of European descent were pooled in eight case 
pools and eight control pools. 
 
Genome-wide analysis  
We allelotyped each pool in duplicate using Affymetrix GeneChip 6.0 microarrays containing 
906,600 polymorphic SNPs. Array experiments were performed according to protocols 
provided by the manufacturer. We used the SNPMaP package21 in the statistical software 
program R (see URLs) to calculate relative allele signal (RAS) scores and k-corrected raw allele 
frequency (RAFk) estimates for each SNP, as is described in the Supplementary Note.   
 
A total of 574,400 SNPs passed quality control steps (described in the Supplementary Note) 
and were included in the association analyses. We averaged data across case pools and control 
pools separately to obtain RAFk and RAS estimates for cases and controls. We subsequently 
calculated the modified χ2 statistic16, which is expressed as: 
                        Pcases - Pcontrols 
Z =  
                           Pp × (1 - Pp) × (1 / 2Ncases + 1 / 2Ncontrols) + σ
2
pool × (1 / npcases + 1 / npcontrols) 
 
Where Pcases is the allele frequency estimate (RAFk) in the case pools, Pcontrols is the RAFk in the 
control pools and Pp is an estimate of the allele frequency in the population, for which we used 
the allele frequency in 603 individually genotyped in-house controls of European descent22. 
Ncases is the number of individuals in the case pools and Ncontrols is the number of individuals in 
the control pools, taking into account the loss of cases and controls after the quality control. A 
SNP-specific variance calculated across the two measurements for each DNA pool was 
averaged across the pools to obtain σ2pool. Finally, npcases and npcontrols are the number of 
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measurements (pools) for the case and control pools. We selected the 5,000 SNPs with the 
highest Z scores, and calculated two additional statistics for these SNPs: the standard χ2 
statistic using the expected numbers of alleles in the cases and controls calculated from the 
RAFk estimates and the adjusted χ
2 statistic using the RAS values. Combining the results from all 
three statistics enabled us to select the most promising SNPs. 
 
We used several criteria to select SNPs from the pooled GWAS as eligible for individual 
genotyping in the discovery sample to validate the results as is described in the Supplementary 
Note. Ultimately, 20 SNPs were eligible. As seven of these 20 SNPs were SNPs in high LD within 
DGKK (Supplementary Fig. 2), we genotyped  the SNP that tagged most of the other SNPs 
(rs1934179, an intronic SNP). In addition, we genotyped a potentially regulatory SNP in the 5’ 
upstream region (rs7063116).  
 
Validation of the results from the pooled GWAS 
Taqman SNP genotyping assays could not be designed for four of the 15 SNPs that were 
selected for individual genotyping in the discovery sample. We excluded these SNPs from 
further analysis. The other 11 SNPs (Supplementary Table 3) were individually genotyped using 
5’ nuclease TaqMan SNP genotyping assays (Supplementary Table 8). In each 96-well plate, we 
loaded five wells with randomly selected duplicate DNA samples from the same and other 
plates for quality control purposes. In addition, we included four blanks in each plate. 
Genotyping was completed with a success rate of at least 99%.  
 
All genotype frequencies in controls were in Hardy-Weinberg equilibrium, with P values 
ranging from 0.34 to 0.94. For the genotyped SNPs, we calculated ORs for hypospadias risk and 
the corresponding 95% confidence intervals (CIs) at a genotypic and an allelic level using the 
most frequent homozygous genotypes in controls as reference values. Furthermore, we 
performed χ2 tests. When the expected cell numbers were below five, exact 95% CIs around 
the ORs were calculated using the Fisher exact method. Ten of the associations were 
statistically significant (P < 0.05), but only the association with the two SNPs in the X-
chromosomal DGKK gene reached genome-wide significance (P < 5.0 × 10-8) (Supplementary 
Table 4). These results were validated by genotyping the parents of the cases. For these case-
parent triads, we used the transmission disequilibrium test (TDT)23 for statistical analysis of the 
data with the software program Haploview 4.1 (ref.24). Furthermore, we calculated the ORs for 
hypospadias risk and corresponding 95% CIs at the allelic level25 (Table 2). 
 
Replication studies 
A detailed description of the study populations can be found in the Supplementary Note. The 
Arnhem-Nijmegen Regional Committee on Research Involving Human Subjects and the Ethics 
Committee at Karolinska Institutet approved the studies and all participants and/or their 
parents gave written informed consent for participation in the studies. 
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For the Dutch replication sample, we genotyped 133 cases of European descent with isolated 
anterior or middle hypospadias and their parents for the SNPs that were associated with 
hypospadias in the individually genotyped discovery sample (P < 0.05). Genotyping was 
completed with a success rate of at least 95%. All genotype frequencies in the parents were in 
Hardy-Weinberg equilibrium (with P values ranging from 0.16 to 0.99). For these case-parent 
triads, we again used the TDT23 for statistical analysis of the data with the software program 
Haploview 4.1 (ref.24), and we calculated the ORs for hypospadias risk and the corresponding 
95% CIs at the allelic level25 (Supplementary Table 5).  
 
For the Swedish replication sample, we genotyped 266 Swedish cases with anterior or middle 
hypospadias and 402 male Swedish controls for the SNPs that were associated with 
hypospadias in the individually genotyped discovery sample (P < 0.05). Genotyping was 
completed with a success rate of at least 98%. All genotype frequencies in the controls were in 
Hardy-Weinberg equilibrium (with P values ranging from 0.13 to 0.99), except for rs1022357 in 
SLCO3A1 (P = 0.01). However, after correcting the critical P value for multiple testing, this 
result did not reach statistical significance (critical Bonferroni P < 0.005). We calculated ORs for 
hypospadias risk and the corresponding 95% CIs at genotypic and allelic level, performed χ2 
tests and calculated exact 95% CIs around the ORs using the Fisher exact method when 
expected cell numbers were below five (Supplementary Table 6).  
 
Meta-analysis 
We combined the results of both the discovery sample and the two replication samples in a 
meta-analysis in Review Manager 5 (see URLs) using the inverse-variance method and random 
effects models (Supplementary Table 7). 
 
Expression of DGKK 
We isolated RNA from preputial skin samples from 14 hypospadias cases and ten age-matched 
controls. The origin of the samples and the methods used are described in the Supplementary 
Note. We performed RT-PCR according to the standard protocol as described in the 
Supplementary Note. Expression levels of DGKK were reported relative to GAPDH. We also 
genotyped DNA samples for the two SNPs in DGKK and compared relative gene expression 
levels between boys with the G allele (45.9% of GAPDH, n = 9) and the A (risk) allele (40.1% of 
GAPDH, n = 15) of the X-chromosomal SNP rs1934179 in DGKK using the independent samples 
t test. 
 
Search for potential functional variants 
We searched different databases, such as dbSNP and HapMap, for nonsynonymous SNPs that 
might be causative variants, taking validation of the SNPs, conservation of amino acids, and 
Grantham scores of amino acid replacements into account. Concerning non-coding areas, we 
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used the UCSC genome browser to check for microRNA binding sites, enrichments of histone 
marks associated with enhancers or promoters, and for transcription factor binding sites. 
 
Calculation of Population Attributable Fraction 
We calculated the population attributable fraction (PAF) as26: 
 
    q (OR - 1)  
PAF =  
  q (OR - 1) + 1 
 
where OR is the odds ratio and q is the proportion of exposed individuals (proportion of 
individuals with the risk allele) in the control group, which is the A allele of rs1934179 in DGKK.  
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Supplementary figures 
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Suppl. figure 3.  Quantification of DGKK mRNA expression (± s.e.m.) in preputial skin of 
hypospadias cases and controls relative to GAPDH mRNA expression. 
Relative gene expression levels were compared between cases (43.1% of 
GAPDH, n = 14) and controls (41.2% of GAPDH, n = 10) using the 
independent samples t-test. 
 
 
 
 
Supplementary tables 
 
Suppl. table 1.  Clinical characteristics of the hypospadias patients in the discovery sample. 
 
 
Anatomical location of urethral opening 
 
 
 
Anterior n=318 (73%) 
 
 
 
Middle n=118 (27%) 
 
 
HsH 
 
 
Glandular 
 
(Sub)-
coronal 
 
 
 
Distal 
penile 
 
 
Midshaft 
 
 
Proximal 
penile 
 
 
Total 33 88 197  63 48   7 
 
 Chordee 21 (64%) 30 (34%) 115 (58%)  41 (65%) 38 (79%)                       6 (86%) 
 Cryptorchidisma   4 (12%)   2    (2%)   11    (6%)    3    (5%)   1    (2%)   0 
 Other deformitiesb   4 (12%) 10 (11%)     8    (4%)    4    (6%)   0    0  
HsH, Hypospadias sine hypospadias; 
a
including only cases that underwent orchidopexy or 
orchidectomy; 
b
including cases with heart-, renal- and gastro-intestinal deformities, neural tube 
defects, cleft lip and/or palate and deformities of the lower extremities. 
 
 
Suppl. table 2.  SNPs appearing in the top 200 ranks for all three statistical tests used. The 
grey-shaded SNPs are the SNPs that were selected based on the criteria 
used. As seven of these 20 SNPs were SNPs in high LD within the DGKK gene, 
we selected the SNP that tagged most of the other SNPs (rs1934179) for 
individual genotyping in the discovery sample. In addition, we genotyped a 
potentially regulatory SNP in the 5’-upstream region (rs7063116). Taqman 
SNP genotyping assays could not be designed for four of the fifteen SNPs 
that were thus selected for individual genotyping in the discovery sample. 
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Suppl. table 2. 
SNP 
 
Chr 
 
 
Rank 
adj  
χ2-test  
using 
RAS 
 
 
Rank 
adj  
χ2-test  
using 
RAFk 
 
 
Rank  
χ2-test 
using 
RAFk 
 
Nearest gene 
 
Location 
 
 
MAF in  
 in-
house 
control 
samples 
 
 
Sup-
porting 
evidence 
from 
SNPs in 
LDa 
 
 
Reason 
exclusion 
from 
individual 
geno-
typing 
 
 
rs1934179 X       46   21      4 DGKK intron 0.337 yes  
rs16985967 22       26     4    12 TTC28 intron 0.080 yes  
rs7085066 10       35    19    31 SLC16A12 intron 0.105 yes  
rs1022357 15     199 176    79 SLCO3A1 intron 0.166 yes  
rs10184015 2       32   17    83 SOS1 intron 0.066 yes  
rs6607499 X       38   33  133 KIAA2022 12 kb up 0.065 yes  
rs4705372 5     165 119  168 PPARGC1B intron 0.123 yes  
rs3755071 2       31   81    16 SRBD1 intron 0.226 -  
rs1880386 10     180   42    35 GRID1 intron 0.152 -  
rs12660161 6       30   11    56 MTHFD1L 39 kb down 0.085 -  
rs7896487 10       19 144    55 CDH23 intron 0.123 - assay 
rs9735061 11       73 186  139 FAM86A 43 kb up 0.122 - assay 
rs7321040 13       21   13    75 DIAPH3 31 kb down 0.055 - assay 
rs10997978 10       28     2    26 MYPN intron 0.056 yes assay 
rs1934171 X         3     1      1 DGKK intron 0.336 yes other SNP 
rs1934188 X       52     5      2 DGKK intron 0.314 yes other SNP 
rs1934176 X         8     3      3 DGKK intron 0.337 yes other SNP 
rs4826629 X       99   79      5 DGKK intron 0.316 yes other SNP 
rs1934175 X       77   57      8 DGKK intron 0.336 yes other SNP 
rs17281440 X     182 169    34 DGKK intron 0.240 yes other SNP 
rs17051831 13       85   95  118 NBEA intron 0.096 - LD/MAF 
rs7229296 18     126 103  137 RAB31 9 kb down 0.092 - LD/MAF 
rs4869674 5       13   27    32 SPEF2 intron 0.091 - LD/MAF 
rs17126762 1       34   14    80 CACHD1 intron 0.072 - LD/MAF 
rs17021660 4       16     9    22 POU4F2 17 kb up 0.062 - LD/MAF 
rs527834 15     193   18    13 CHRM /AVEN intron 0.053 - LD/MAF 
rs16841107 1     196   88    69 RGS7 intron 0.050 - LD/MAF 
rs12465925 2     191 151    72 TMEFF2 intron 0.132 no LD 
rs17236770 15     135 106    21 TMEM85 intron 0.123 no LD 
rs3771698 2         9   32    17 BAZ2B intron 0.088 no LD 
rs16842909 2       83   50    97 MAP2 intron 0.072 no LD 
rs764125 3       78   40  146 CMTM8 intron 0.057 no LD 
rs9308056 4         6   93  172 TKTL2 54 kb down 0.083 yes distance 
rs2114929 5       48 102    62 TARS 63 kb up 0.141 yes distance 
rs1560398 18       10     8    40 MC4R 123 kb up 0.063 - distance 
rs1397151 16       79    39    76 CES7 130 kb up 0.057 yes distance 
rs16888346 4       63   38    18 HSP90AB2P 135 kb up 0.113 - distance 
rs6847625 4         5   10    52 GPRIN3 197 kb up 0.069 - distance 
rs10497759 2       81   72      6 SLC39A10 244 kb up 0.297 - distance 
rs2174232 10       53   37    67 ZWINT 816 kb up 0.070 - distance 
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 Suppl. table 2. (continued) 
SNP 
 
Chr 
 
 
Rank 
adj  
χ2-test  
using 
RAS 
 
 
Rank 
adj  
χ2-test  
using 
RAFk 
 
 
Rank  
χ2-test 
using 
RAFk 
 
Nearest gene 
 
Location 
 
 
MAF in  
 in-
house 
control 
samples 
 
 
Sup-
porting 
evidence 
from 
SNPs in 
LDa 
 
 
Reason 
exclusion 
from 
individual 
geno-
typing 
 
 
rs6127262 20     101 185  100 DOK5 62 kb down 0.010 - distance 
rs4850833 2       98   69    64 PLCL1 73 kb down 0.114 yes distance 
rs12544855 8       86   45    70 LOC100129963 87 kb down 0.100 - distance 
rs16864680 2         4   23  164 LOC400940 91 kb down 0.080 - distance 
rs10733948 10     176 107  142 ZWINT 131 kb down 0.095 no distance 
rs2468265 12     177 110      7 SUDS3 199 kb down 0.477 - distance 
rs10024666 4       57   35  175 TRAM1L1 314 kb down 0.078 - distance 
rs12265647 10       17   16  182 YWHAZ 321 kb down 0.070 - distance 
rs11046765 12         1     6    33 ETNK1 356 kb down 0.061 yes distance 
rs5942497 X     120 104  157 CPXCR1 574 kb down 0.063 no distance 
Chr, chromosome; adj, adjusted; RAS, relative allele signal; RAFk, k-corrected raw allele frequency 
estimate; MAF, minor allele frequency; LD, linkage disequilibrium; kb, kilobases; up, upstream; down, 
downstream; assay, assay unavailable; other SNP, other SNP in gene; LD/MAF, LD and MAF < 0.10; 
distance, gene distance;  
a
yes = supporting evidence defined as at least half of the SNPs in high LD (r
2
 
> 0.8) having a low average P-value (< 0.22, the 10
th
 percentile of the average P-values of all 574,400 
SNPs), no = reduced evidence defined as at least half of the SNPs in high LD having a high average P-
value, - = no SNPs in high LD. 
 
 
Suppl. table 3. Single nucleotide polymorphisms individually genotyped in the discovery 
sample. 
 
SNP  
 
 
Chr 
 
 
Nearest gene 
 
 
Location 
 
 
rs1934179 X DGKK intron 
 
rs7063116 X DGKK 21 kb upstream 
 
rs1880386 10 GRID1 intron 
 
rs6607499 X KIAA2022 12 kb upstream 
 
rs12660161 6 MTHFD1L 39 kb downstream 
 
rs4705372 5 PPARGC1B intron 
 
rs7085066 10 SLC16A12 intron 
 
rs1022357 15 SLCO3A1 intron 
 
rs10184015 2 SOS1 intron 
 
rs3755071 2 SRBD1 intron 
 
rs16985967 22 TTC28 intron 
Chr, chromosome. 
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Suppl. table 4.  Association analyses with hypospadias for single nucleotide polymorphisms 
in selected genes in the discovery sample. 
 
 
Controls 
n=494 
     n (%) 
 
Cases 
n=436 
    n (%) 
 
 
  OR (95% CI) 
 
 
χ2 P 
 
Controls 
n=494 
    n (%) 
Cases 
n=436 
    n (%) 
 
 
  OR (95% CI) 
 
 
χ2 P 
 
Allele frequencies 
 
 
Genotype frequencies 
 
 
rs1934179 in DGKK       
G  331 (67) 196 (45) 1.00 (ref) ref Not applicable, X-chromosomal SNP 
A  162 (33) 236 (55) 2.46 (1.88-3.21) 2.5×10-11      
 
rs7063116 near DGKK       
G  348 (71) 224 (52) 1.00 (ref) ref Not applicable, X-chromosomal SNP 
A  144 (29) 209 (48) 2.25 (1.72-2.96) 2.9×10-9      
 
rs1880386 in GRID1      
C  844 (86) 698 (81) 1.00 (ref) ref CC 360 (73) 285 (66) 1.00 (ref) ref 
T  140 (14) 162 (19) 1.40 (1.09-1.79) 0.008 CT 124 (25) 128 (30) 1.30 (0.97-1.75) 0.075 
     TT     8   (2)   17   (4) 2.68 (1.14-6.31) 0.019 
 
rs6607499 near KIAA2022      
G  474 (96) 402 (93) 1.00 (ref) ref Not applicable, X-chromosomal SNP 
A    18  (4)   31   (7) 2.03 (1.12-3.68) 0.018      
 
rs12660161 near MTHFD1L      
G  909 (92) 766 (88) 1.00 (ref) ref GG 419 (85) 343 (79) 1.00 (ref) ref 
A    79   (8) 100 (12) 1.50 (1.10-2.05) 0.010 AG   71 (14)   80 (18) 1.38 (0.97-1.95) 0.073 
     AA     4   (1)   10   (2) 3.05 (0.95-9.82) 0.049 
 
rs4705372 in PPARGC1B      
G  856 (87) 714 (82) 1.00 (ref) ref GG 371 (75) 298 (69) 1.00 (ref) ref 
A  132 (13) 154 (18) 1.40 (1.09-1.80) 0.009 AG 114 (23) 118 (27) 1.29 (0.96-1.74) 0.096 
     AA     9   (2)   18   (4) 2.49 (1.10-5.62) 0.024 
 
rs7085066 in SLC16A12      
G  898 (91) 769 (89) 1.00 (ref) ref GG 409 (83) 338 (78) 1.00 (ref) ref 
C    90   (9)   95 (11) 1.23 (0.91-1.67) 0.177 CG   80 (16)   93 (22) 1.41 (1.01-1.96) 0.043 
     CC     5   (1)     1   (0) 0.24 (0.01-2.18)a 0.325 
 
rs1022357 in SLCO3A1      
A  824 (84) 689 (79) 1.00 (ref) ref AA 344 (70) 277 (64) 1.00 (ref) ref 
G  162 (16) 179 (21) 1.32 (1.04-1.67) 0.020 AG 136 (28) 135 (31) 1.23 (0.93-1.64) 0.151 
     GG   13   (3)   22   (5) 2.10 (1.04-4.25) 0.035 
 
rs10184015 in SOS1      
G  923 (93) 781 (90) 1.00 (ref) ref GG 430 (87) 353 (81) 1.00 (ref) ref 
A    65   (7)   87 (10) 1.58 (1.13-2.21) 0.007 AG   63 (13)   75 (17) 1.45 (1.01-2.09) 0.044 
     AA     1   (0)     6   (1) 7.31 (0.88-337)a 0.074 
 
rs3755071 in SRBD1      
A  690 (70) 652 (75) 1.00 (ref) ref AA 238 (48) 242 (56) 1.00 (ref) ref 
G  292 (30) 214 (25) 0.78 (0.63-0.95) 0.016 AG 214 (44) 168 (39) 0.77 (0.59-1.01) 0.060 
     GG   39   (8)   23   (5) 0.58 (0.34-1.00) 0.049 
 
rs16985967 in TTC28      
C  924 (94) 771 (89) 1.00 (ref) ref CC 432 (88) 339 (78) 1.00 (ref) ref 
T    62   (6)   97 (11) 1.88 (1.34-2.62) 0.0002 CT   60 (12)   93 (21) 1.98 (1.39-2.82) 0.0001 
     TT     1   (0)     2   (0) 2.55 (0.13-151)a 0.822 
OR, odds ratio; CI, confidence interval; ref, used as reference; 
a
exact 95% CI calculated using the 
Fisher exact method. 
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Suppl. table 5. Association analyses with hypospadias for single nucleotide polymorphisms 
in selected genes in the Dutch replication sample. 
 
SNP  
 
 
Minor allelea 
 
 
NT 
 
 
T 
 
 
OR     (95%CI) 
 
 
χ2 P 
 
 
rs1934179 in DGKK A 12 47 3.92   (2.08-7.38) 2.4×10-5 
 
rs7063116 near DGKK A 12 46 3.83   (2.03-7.24) 3.4×10-5 
 
rs1880386 in GRID1  T 24 33 1.38   (0.81-2.33)   0.233 
 
rs6607499 near KIAA2022 A   6   7 1.17   (0.39-3.47)   0.782 
 
rs12660161 near MTHFD1L A 17 28 1.65   (0.90-3.01)   0.101 
 
rs4705372 in PPARGC1B A 21  31 1.48   (0.85-2.57)   0.166 
 
rs1022357 in SLCO3A1 G 28 37 1.32   (0.81-2.16)   0.264 
 
rs10184015 in SOS1 A 19 18 0.95   (0.50-1.81)   0.869 
 
rs3755071 in SRBD1 G 35 40 1.14   (0.73-1.80)   0.564 
 
rs16985967 in TTC28 T   7 14 2.00   (0.81-4.96)   0.127 
OR, odds ratio; CI, confidence interval; NT, minor allele not transmitted; T, minor 
allele transmitted; 
a
the least frequent allele in the controls of the discovery 
sample. 
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Suppl. table 6. Association analyses with hypospadias for single nucleotide polymorphisms 
in selected genes in the Swedish replication sample. 
 
 
Controls 
n=402  
     n (%) 
 
Cases 
n=266 
    n (%) 
 
 
   OR (95% CI) 
 
 
χ2 P 
 
 
Controls 
n=402  
     n (%) 
 
Cases 
n=266 
    n (%) 
 
 
   OR (95% CI) 
 
 
χ2 P 
 
Allele frequencies 
 
 
Genotype frequencies 
 
 
rs1934179 in DGKK       
G 276 (69) 123 (47) 1.00 (ref) ref Not applicable, X-chromosomal SNP 
A 124 (31) 137 (53) 2.48 (1.80-3.42) 2.6×10-8      
 
rs7063116 near DGKK       
G 284 (71) 137 (53) 1.00 (ref) ref Not applicable, X-chromosomal SNP 
A 118 (29) 123 (47) 2.16 (1.56-2.99) 2.7×10-6      
 
rs1880386 in GRID1      
C 676 (85) 428 (82) 1.00 (ref) ref CC 288 (72) 179 (69) 1.00 (ref) ref 
T 124 (16)   92 (18) 1.17 (0.87-1.57) 0.293 CT 100 (25)   70 (27) 1.13 (0.79-1.61) 0.515 
     TT   12   (3)   11   (4) 1.47 (0.64-3.41) 0.362 
 
rs6607499 near KIAA2022      
G 372 (93) 235 (90) 1.00 (ref) ref Not applicable, X-chromosomal SNP 
A   29    (7)   27 (10) 1.47 (0.85-2.55) 0.165      
 
rs12660161 near MTHFD1L      
G 714 (89) 473 (91) 1.00 (ref) ref GG 320 (80) 213 (82) 1.00 (ref) ref 
A   84 (11)   49   (9) 0.88 (0.61-1.28) 0.502 AG   74 (19)   47 (18) 0.95 (0.64-1.43) 0.820 
     AA     5   (1)     1   (0) 0.30 (0.01-2.72)a 0.473 
 
rs4705372 in PPARGC1B      
G 709 (89) 453 (86) 1.00 (ref) ref GG 313 (78) 199 (76) 1.00 (ref) ref 
A   89 (11)   73 (14) 1.28 (0.92-1.79) 0.139 AG   83 (21)   55 (21) 1.04 (0.71-1.53) 0.833 
     AA     3   (1)     9   (3) 4.72 (1.16-27.3)a 0.027 
 
rs1022357 in SLCO3A1      
A 649 (81) 414 (81) 1.00 (ref) ref AA 271 (68) 163 (63) 1.00 (ref) ref 
G 151 (19) 100 (19) 1.04 (0.78-1.38) 0.794 AG 107 (27)   88 (34) 1.37 (0.97-1.93) 0.073 
     GG   22   (6)     6   (2) 0.45 (0.18-1.14) 0.086 
 
rs10184015 in SOS1      
G 738 (92) 477 (91) 1.00 (ref) ref GG 341 (85) 220 (84) 1.00 (ref) ref 
A   66   (8)   49   (9) 1.15 (0.78-1.69) 0.483 AG   56 (14)   37 (14) 1.02 (0.65-1.60) 0.917 
     AA     5   (1)     6   (2) 1.86 (0.47-7.79)a 0.468 
 
rs3755071 in SRBD1      
A 627 (78) 382 (75) 1.00 (ref) ref AA 241 (60) 143 (56) 1.00 (ref) ref 
G 173 (22) 130 (25) 1.23 (0.95-1.60) 0.115 AG 145 (36)   96 (38) 1.12 (0.80-1.55) 0.516 
     GG   14   (4)   17   (7) 2.05 (0.98-4.28) 0.053 
 
rs16985967 in TTC28      
C 720 (90) 467 (90) 1.00 (ref) ref CC 324 (81) 208 (80) 1.00 (ref) ref 
T   80 (10)   53 (10) 1.02 (0.71-1.47) 0.910 CT   72 (18)   51 (20) 1.10 (0.74-1.64) 0.629 
     TT     4   (1)     1   (0) 0.39 (0.01-3.98)a 0.710 
OR, odds ratio; CI, confidence interval; ref, used as reference; 
a
exact 95% CI calculated using the 
Fisher exact method. 
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Suppl. table 7. Association analyses with hypospadias for single nucleotide polymorphisms 
in selected genes in the discovery sample, the Dutch replication sample and 
the Swedish replication sample, and results of the meta-analysis. 
  
 
Discovery sample 
  
Dutch replication sample 
 
 
MAF (%) 
 
 
 
 
  TDT 
 
 
 
SNP (minor allelea) 
 
 
Con-
trols 
n= 
494 
 
Cases 
n= 
436 
 
 
OR  (95%CI) 
 
 
χ2 P 
 
NT 
 
T 
 
 
OR  (95%CI) 
 
 
χ2 P 
 
 
rs1934179 in DGKK (A) 32.9 54.6 2.5 (1.9-3.2) 2.5×10-11 12 47 3.9 (2.1-7.4) 2.4×10-5 
 
rs7063116 near DGKK (A) 29.3 48.3 2.3 (1.7-3.0) 2.9×10-9 12 46 3.8 (2.0-7.2) 3.4×10-5 
 
rs1880386 in GRID1 (T) 14.2 18.8 1.4 (1.1-1.8)   0.008 24 33 1.4 (0.8-2.3)   0.233 
 
rs6607499 near KIAA2022 (A)   3.7   7.2 2.0 (1.1-3.7)   0.018   6   7 1.2 (0.4-3.5)   0.782 
 
rs12660161 near MTHFD1L (A)   8.0 11.5 1.5 (1.1-2.1)   0.010 17 28 1.7 (0.9-3.0)   0.101 
 
rs4705372 in PPARGC1B (A) 13.4 17.7 1.4 (1.1-1.8)   0.009 21  31 1.5 (0.9-2.6)   0.166 
 
rs7085066 in SLC16A12 (C)   9.1 11.0 1.2 (0.9-1.7)   0.177     
 
rs1022357 in SLCO3A1 (G) 16.4 20.6 1.3 (1.0-1.7)   0.020 28 37 1.3 (0.8-2.2)   0.264 
 
rs10184015 in SOS1 (A)   6.6 10.0 1.6 (1.1-2.2)   0.007 19 18 1.0 (0.5-1.8)   0.869 
 
rs3755071 in SRBD1 (G) 29.7 24.7 0.8 (0.6-1.0)   0.016 35 40 1.1 (0.7-1.8)   0.564 
 
rs16985967 in TTC28 (T)   6.3 11.2 1.9 (1.3-2.6)   0.0002   7 14 2.0 (0.8-5.0)   0.127 
  
 
 
Swedish replication sample 
 
 
 
Meta-analysis results 
 
  
 
MAF (%) 
 
  
 
 
SNP (minor allelea) 
 
 
Con-
trols 
n= 
402 
 
Cases 
n= 
266 
 
 
 OR (95%CI) 
 
 
χ2 P 
 
  
 
 OR (95%CI) 
 
 
χ2 P 
 
 
rs1934179 in DGKK (A) 31.0   52.7 2.5 (1.8-3.4) 2.6×10-8   2.6 (2.1-3.1) 2.8×10-21 
 
rs7063116 near DGKK (A) 29.4   47.3 2.2 (1.6-3.0) 2.7×10-6   2.4 (1.9-3.0) 1.2×10-12 
 
rs1880386 in GRID1 (T) 15.5   17.7 1.2 (0.9-1.6)   0.293   1.3 (1.1-1.6)   0.003 
 
rs6607499 near KIAA2022 (A)   7.2   10.3 1.5 (0.9-2.6)   0.165   1.6 (1.1-2.4)   0.011 
 
rs12660161 near MTHFD1L (A) 10.5     9.4 0.9 (0.6-1.3)   0.502   1.3 (0.9-1.9)   0.242 
 
rs4705372 in PPARGC1B (A) 11.2   13.9 1.3 (0.9-1.8)   0.139   1.4 (1.1-1.7)   0.001 
 
rs7085066 in SLC16A12 (C)         
 
rs1022357 in SLCO3A1 (G) 18.9   19.5 1.0 (0.8-1.4)   0.794   1.2 (1.0-1.4)   0.027 
 
rs10184015 in SOS1 (A)   8.2     9.3 1.2 (0.8-1.7)   0.483   1.3 (1.0-1.7)   0.075 
 
rs3755071 in SRBD1 (G) 21.6   25.4 1.2 (1.0-1.6)   0.115   1.0 (0.7-1.4)   0.952 
 
rs16985967 in TTC28 (T) 10.0   10.2 1.0 (0.7-1.5)   0.910   1.5 (0.9-2.4)   0.103 
MAF, minor allele frequency; OR, odds ratio; CI, confidence interval; TDT, transmission disequilibrium 
test; NT, minor allele not transmitted; T, minor allele transmitted; 
a
the least frequent allele in the 
controls of the discovery sample. 
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Suppl. table 8.  Primer and reporter sequences for the custom designed Taqman assays, ID 
numbers of the Taqman SNP genotyping assays, and oligonucleotide primers 
for the real-time PCR reactions. 
 
SNP / Gene 
 
 
Sequence / Taqman SNP genotyping assay ID 
 
 
rs6607499 upstream of KIAA2022 
 
 
 Forward primer GAGTGGAATTTCTGGGTCATATGGA 
 Reverse primer TGGTGCAGCTTCTATGGAAAACA 
 Reporter 1 CATTTGGAGTAACTATCAGAC 
 Reporter 2 ATTTGGAGTAACTGTCAGAC 
 
rs7085066 in SLC16A12 
 
 
 Forward primer CCAGAGACCAAAATGGAACTGAAGT 
 Reverse primer AAGAGTAAGGGCGTGAAATAACCT 
 Reporter 1 CACCAACAAGAGCACC 
 Reporter 2 CACCAACAACAGCACC 
 
rs7063116 upstream of DGKK  
 
 
 Assay ID C_196656_10 
 
rs1934179 in DGKK  
 
 
 Assay ID C_12116498_10 
 
rs1880386 in GRID1 
 
 
 Assay ID C_12127943_10 
 
rs12660161 downstream of MTHFD1L  
 
 
 Assay ID C_11414015_20 
 
rs4705372 in PPARGC1B  
 
 
 Assay ID C_27948404_10 
 
rs1022357 in SLCO3A1 
 
 
 Assay ID C_8719491_10 
 
rs10184015 in SOS1 
 
 
 Assay ID C_30456791_10 
 
rs3755071 in SRBD1 
 
 
 Assay ID C_2773842_10 
 
rs16985967 in TTC28 
 
 
 Assay ID C_34310741_10 
 
GAPDH (PCR product size: 160bp) 
 
 
 Forward primer CATGTTCGTCATGGGTGTGAACCA 
 Reverse primer AGTGATGGCATGGACTGTGGTCAT 
 
DGKK (PCR product size: 160bp) 
 
 
 Forward primer AGAAGAGATGAACACCCAGGGCAA 
 Reverse primer GCAGGTTTGGCAAGGAGATGGTTT 
bp, basepairs. 
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Supplementary note 
 
Dutch discovery sample 
AGORA project 
The AGORA (Aetiologic research into Genetic and Occupational/environmental Risk factors for 
Anomalies in children) project of the Radboud University Nijmegen Medical Centre (RUNMC), 
Nijmegen, The Netherlands, is building a data- and biobank with questionnaire data and DNA 
samples from patients with a congenital malformation or childhood cancer and their parents. 
For the current study, DNA was available of 679 hypospadias cases born between 1980 and 
2007, collected within the AGORA biobank until 2007. All cases were living in the catchment 
area of this hospital, which is Nijmegen and surrounding area. The majority of the cases were 
of European descent (83%), whereas descent was not European (3%) or unknown (14%) for the 
remaining cases. We excluded non-European cases from the analyses. Medical records of all 
cases were reviewed to identify information on syndromal hypospadias cases, to collect clinical 
characteristics of patients, and to determine anatomical location of the urethral opening. The 
location of the urethral opening was determined by experienced pediatric urologists before or 
during surgery. For the current study, anatomical location was subdivided into two categories: 
anterior and middle hypospadias (anterior cases with hypospadias sine hypospadias, glandular 
and (sub)coronal urethral openings and middle cases with penile urethral openings) and 
posterior hypospadias (cases with penoscrotal, scrotal, and perineal urethral openings). The 
Arnhem-Nijmegen Regional Committee on Research Involving Human Subjects approved the 
AGORA project. All participants and/or their parents gave written informed consent for 
participation in the study.  
 
Nijmegen Biomedical Study 
We obtained controls from the Nijmegen Biomedical Study, a population-based survey 
conducted by the Department of Epidemiology, Biostatistics and HTA and the Department of 
Clinical Chemistry of the RUNMC in 2003. Age and sex stratified randomly selected inhabitants 
of the municipality of Nijmegen (n = 22,500) received an invitation to fill out a postal 
questionnaire on lifestyle and medical history, and to donate blood samples. The response to 
the questionnaire was 42% (n = 9,373), whereas 72% (n = 6,747) of the respondents also 
donated blood samples2. We selected the 596 youngest males of Dutch descent for the current 
study. None of them reported hypospadias or penile surgery in the questionnaires. The 
Arnhem-Nijmegen Regional Committee on Research Involving Human Subjects approved the 
Nijmegen Biomedical Study. All participants gave written informed consent for participation in 
the study.  
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Dutch replication sample 
Of the 515 cases that were assigned to one of the eight pools, only 436 could be pooled. The 
remaining 79 cases served as a replication sample, supplemented with 54 cases of European 
descent with isolated anterior or middle hypospadias collected in the AGORA project in 2008 
and 2009. 
 
Swedish replication sample 
Swedish nonsyndromic hypospadias patients from the Karolinska University Hospital, 
Stockholm, Sweden, selected through medical records, served as a second replication sample. 
In total, DNA samples were collected from 356 patients for the replication study, of which we 
selected 266 samples from patients with anterior or middle hypospadias. DNA from 222 
ethnically comparable anonymous healthy male voluntary blood donors at Karolinska 
University Hospital, Sweden, served as a control group, as well as 180 DNA samples from 
placentas taken after birth of a child without a visible malformation. The Ethics Committee at 
Karolinska Institutet approved the study protocol and all participants or parents gave written 
informed consent for participation in the study.  
 
DNA Pooling 
DNA was extracted from blood (n = 980) or saliva (n = 295, Oragene, DNA Genotek Inc.) using 
standard methods. We created eight case pools, after exclusion of six syndromal cases, 22 
cases of non-European descent, 87 cases with posterior hypospadias, and 49 cases with 
unknown localization of the urethral opening. The remaining 515 cases were assigned to one of 
the eight pools based on the source of DNA (blood or saliva) and the localization of the urethral 
opening. Controls were randomly assigned to one of eight control pools.  
 
For each pool, we diluted DNA samples to approximately 100 ng μl-1 in one 96-wells plate. 
Sixteen case samples were excluded due to low concentration (< 50 ng μl-1). Before pooling, we 
verified DNA integrity of the samples by gel electrophoresis. Three case and nineteen control 
samples showed band smearing, which is evidence of DNA degradation, and were excluded. 
We tested DNA quality of the diluted samples using 5’-nuclease TaqMan SNP genotyping assays 
for two SNPs (rs6932902 in ESR1: C_2823640_10 and rs11119982 in ATF3: C_27262262_10, 
Applied Biosystems). One case sample failing both assays was excluded.  
 
Genomic DNA of each sample was quantified in triplicate using PicoGreen (Molecular Probes). 
We only included DNA samples from which reliable triplicate readings could be obtained, 
indicated by less than 10% difference between the readings, in the pools. This led to the 
exclusion of 59 case and 83 control samples. Finally, 436 case and 494 control samples could be 
pooled in eight case and eight control pools. We added equal quantities of DNA from each 
sample to the pools, with a minimum volume of 5 µl, which we considered the minimum 
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volume that could be pipetted sufficiently accurately. Supplementary Figure 1 shows a 
flowchart of the collection, selection, and exclusion of cases for this study. Clinical charac-
teristics of the pooled patients (discovery sample) are displayed in Supplementary Table 1. 
 
We tested accuracy of the pools by comparing the allele frequencies of the individually 
genotyped SNPs (rs6932902 in ESR1 and rs11119982 in ATF3) in the individuals contributing to 
a pool, with the allele frequencies of these SNPs determined in the respective pool. The pools 
and an individual heterozygote were allelotyped using the same allele-specific Taqman probes 
in a real-time PCR 20 times. PCR reactions were carried out in 96-wells plates in a 10 μl volume 
containing 10 ng genomic DNA, 5 μl Taqman Universal PCR master mix, 0.125 μl assay mix and 
MilliQ. The PCR reaction consisted of an initial denaturation step at 95°C for 10 min, followed 
by 40 cycles of denaturation at 92°C for 15 sec, and annealing and extension at 60°C for 60 sec. 
During PCR, allele-specific fluorescence was measured on an ABI 7500 FAST (Applied 
Biosystems). Ct values indicate the cycle time that an allele needs to produce a detectable 
amount of fluorescent signal. This is an indication of the initial quantity of the allele in the pool. 
The delta Ct value is the difference in cycle time that each of the alleles needs to produce a 
detectable amount of fluorescent signal, which is an indication of the proportion of both alleles 
in the pools3. We averaged delta Ct values in the pools across the 20 measurements and 
calculated allele frequencies after correcting for unequal detection of the two alleles based on 
the average delta Ct value in the heterozygote. The allele frequency determined in the 
individual samples differed on average only 1.2% from the allele frequency determined in the 
pools. Therefore, we concluded that the pools accurately reflected the allele distributions of 
the samples, meaning that the pools appear to be correctly constructed with equal amounts of 
DNA from all samples.  
 
Derivation of allele frequency estimates from microarray analysis 
We used the SNPMaP package4 in the statistical software program R (http://www.R-
project.org) to calculate Relative Allele Signal (RAS) scores for each SNP from the CEL files 
generated by the Affymetrix GeneChip Command Console. Using this package, RAS scores were 
calculated by dividing the signal intensity of allele A by the sum of the signal intensities of 
alleles A and B (RAS = A / (A + B)), the method most commonly used in the literature. The signal 
intensities of allele A and B should be the same in a heterozygous individual (equivalent to a 
pool with a 50% allele frequency), however, due to differential amplification and hybridization, 
this is rarely the case. Therefore, corrections need to be made to RAS scores to generate more 
reliable estimates of the allele frequency. The k-correction factor can be calculated for each 
SNP using the ratio of the average signal intensities across all known heterozygotes (k = A / B) 
to obtain a k-corrected raw allele frequency estimate for each SNP (RAFk = A / (A + k*B)). We 
used the SNPMaP package to calculate the RAS values for each SNP from 603 healthy in-house 
controls of European descent assayed individually on the same genotyping platform1. Using the 
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average RAS value from all individuals heterozygous for a SNP, we calculated the k-correction 
factor for each SNP. Using these k-correction factors, RAFk was calculated.  
 
Quality control 
We excluded the worst performing 5% of the measurements, indicated by the biggest 
difference between the RAFk estimates from the duplicate measurements (> 0.07). Thereafter, 
we averaged RAFk and RAS across the remaining duplicate measurements to obtain estimates 
for each SNP.   
 
A SNP-specific variance was calculated across the RAFk values of the case pools and of the 
control pools. Furthermore, we averaged RAFk values across case pools with DNA extracted 
from blood and case pools with DNA extracted from saliva to obtain a RAFk estimate for each of 
these two types of DNA origins. SNPs with a difference between these two estimates above the 
95th percentile (> 0.043) were excluded. In addition, we excluded SNPs with a variance in the 
case or control pools above the 95th percentile (> 0.0018 or > 0.0017, respectively) and SNPs 
with a minor allele frequency below 5% in the individually genotyped in-house controls. A total 
of 574,400 SNPs passed quality control steps and were included in the association analyses. 
 
Selection of SNPs eligible for individual genotyping in the discovery sample 
We used several criteria to select SNPs from the pooled GWAS eligible for individual 
genotyping in the discovery sample to validate the results. First of all, SNPs were required to 
appear in the top 200 ranks for all three statistical tests used, which resulted in 50 eligible SNPs 
(Supplementary Table 2). Secondly, SNPs had to map in or near a known gene (< 50 kb), as 
determined by the annotation data provided by Affymetrix, leaving 32 eligible SNPs. This 
criterion increases the biological interpretability of findings, although we are aware of the risk 
of overlooking associations with intergenic SNPs that may lie in regulatory sequences or yet 
unknown genes. Finally, for the remaining eligible SNPs, we examined whether they were in 
high linkage disequilibrium (LD) (r2 > 0.8) with other SNPs on the array using data from the in-
house controls. If so, the average P-values from the three statistical tests were calculated for 
the SNPs in high LD with an eligible SNP.  
 
We divided eligible SNPs into three groups; 1: A group with supporting evidence defined as at 
least half of the SNPs in high LD having a low average P-value (< 0.22, the 10th percentile of the 
average P-values of all 574,400 SNPs), 2: A group with reduced evidence defined as at least half 
of the SNPs in high LD having a high average P-value, and 3: A group with no supporting 
evidence because of no SNPs in high LD. For individual genotyping in the discovery sample, we 
selected the fourteen eligible SNPs with supporting evidence and the four eligible SNPs with no 
supporting evidence, but with a minor allele frequency above 10% in the individually 
genotyped in-house controls. Furthermore, we selected two additional SNPs with no 
supporting evidence, the SNPs near MTHFD1L and DIAPH3, because we considered these to be 
Chapter 2.3 
 
 
128 
promising functional candidate genes. DIAPH3 is an important factor in epithelial cell 
migration5, and a previous study suggested an association of hypospadias with intake of certain 
nutrients related to one-carbon metabolism6, in which the MTHFD1L gene plays a role. Thus, 
20 SNPs were eligible for individual genotyping in the discovery sample.  
 
Expression of DGKK 
Preputial skin samples 
Excess preputial skin was obtained from fourteen patients with hypospadias undergoing 
surgical repair and from ten age-matched controls undergoing elective circumcision between 
January 2004 and June 2004 at the Department of Urology of the University of California, San 
Francisco, CA, USA. Patients with undescended testis, intersex condition or known endocrine 
abnormalities were excluded from the study. No patients received preoperative testosterone 
treatment.  The institutional Committee on Human Research at the University of California, San 
Francisco approved this study and all parents gave written informed consent for participation 
in the study.  
 
RNA preparation, reverse transcription and real-time PCR 
We isolated RNA from the preputial skin samples using the QIAGEN RNeasy Midi Kit (QIAGEN 
Inc.). The manufacturer’s protocol was modified to eliminate any contaminating protein and 
DNA by adding Proteinase K (Roche Diagnostics GmbH) and incubation at 55 C for 20 min, and 
by adding RNase-free DNase I (QIAGEN Inc.), which was incubated at room temperature for 15 
min. RNA quantity and purity were measured using a Nanodrop spectrophotometer (Thermo 
Fisher Scientific Inc.) and RNA integrity was visualized in agarose gels by the 28s and 18s 
ribosomal RNA bands. We performed the reverse transcription (RT) polymerase chain reaction 
(PCR) according to the standard protocol. Briefly, 2.5 µg RNA was reverse transcribed in a 20 µl 
reaction volume and RT products were diluted 4-fold with TE buffer (10 mM Tris-HCI, pH 8, 1 
mM EDTA).  
 
We designed real-time PCR primers according to target gene sequences published in the NCBI 
nucleotide sequence database (Supplementary Table 8) and these were synthesized by 
Integrated DNA Technologies Inc. Real-time PCR was performed in a 20 μl reaction volume 
containing 20 ng template DNA, 1 × Power SYBR Green PCR master mix (Applied Biosystems) 
and 300 nM primers. Amplification was carried out in 96-wells plates in a 7300 Fast sequence 
detection system (Applied Biosystems) with the manufacturer's default thermal profile (50°C 
for 2 min, 95°C for 10 min, and 40 cycles of 95°C for 15 sec and 60°C for 1 min) followed by a 
dissociation stage (95°C for 15 sec, 60°C for 15 sec, followed by a slow ramp to 95°C). We 
performed primer titration and dissociation experiments to prevent primer dimers or false 
amplicons from interfering with the result. After the RT PCR experiment, Ct numbers were 
extracted for both the reference gene and the target gene with auto baseline and manual 
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threshold using standard 7300 Fast software. Expression levels of DGKK were reported relative 
to GAPDH. We repeated the PCR three times for each sample and averaged results across the 
three measurements when no exceptional outliers were seen. Consequently, two samples 
were averaged across two measurements. 
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Abstract 
 
Objective 
To obtain more insight into the origin of hypospadias by exploring a wide range of potential 
risk factors in a case-referent study in which a distinction was made between different 
phenotypes. 
 
Patients and methods  
Cases and referents were 305 boys with hypospadias and 629 boys with middle ear effusion 
whose parents completed postal questionnaires. Hypospadias phenotype was classified as 
distal (195 boys), middle (67), and proximal (43). Adjusted odds ratios (OR) with 95% 
confidence intervals (CI) were estimated using logistic regression.  
 
Results  
Low birth weight, being a twin or triplet, mother being a diethylstilbestrol-daughter, fertility 
treatments, paternal subfertility, obesity, prescriptive drug use, and familial occurrence of 
hypospadias or testicular cancer were associated with hypospadias in general. For familial 
occurrence of hypospadias, there were high risk estimates for the distal and middle 
phenotypes with an OR (95%CI) of 10.4 (4.5-24.1) and 9.0 (3.1-26.0), but not for the proximal 
type at 1.8 (0.2-14.9). By contrast, the association with low birth weight (a proxy for placental 
dysfunction) seemed much stronger for proximal hypospadias with an OR (95%CI) of 9.1 (3.4-
24.2) compared with distal and middle hypospadias at 2.6 (1.4-5.0) and 2.3 (0.8-6.5). There 
were similar estimates for pre-eclampsia.  
 
Conclusion  
These findings indicate aetiological heterogeneity of hypospadias and provide indications for 
the possible mechanisms through which specific risk factors may interfere with penile 
development.  
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Introduction 
 
Hypospadias is a common urogenital birth defect that originates from a disturbed penile 
development between gestational weeks 7 and 141. There is a large diversity in manifestations 
of hypospadias, in which the location of the urethral meatus can vary from the penile glans to 
the scrotum or perineum. Hypospadias affects about one in 150 boys2. Causal explanations are 
limited to only a few patients3, which stresses the need for further aetiological research.  
 
Previous studies have consistently reported familial clustering of hypospadias with ≈7% of the 
patients reporting hypospadias in first- or second-degree relatives4. Familial occurrence has 
been noticed to be more common for patients with glanular hypospadias, while patients with 
penoscrotal or perineal hypospadias are most often sporadic cases5. An increased occurrence 
of hypospadias in children with low birth weight has also been well established and this 
association appears to be stronger in more proximal manifestations of hypospadias6,7. Low 
birth weight may reflect placental insufficiency in providing the fetus with both nutrients and 
gonadotrophins, which is also a plausible explanation for increased occurrence of hypospadias 
in twins and triplets and for the association with pre-eclampsia8-10. Other factors that have 
been linked to hypospadias include increased maternal age6,11, maternal intrauterine exposure 
to diethylstilbestrol (DES)12-14, fertility treatment15-18, paternal subfertility19,20, smoking21, 
prescriptive drug use20, and maternal obesity22 and iron supplementation20,23.  
 
According to the Testicular Dysgenesis Syndrome (TDS) hypothesis, hypospadias partly shares 
its aetiology with undescended testes (UDT), testicular cancer, and reduced semen quality24. 
The hypothesis indicates prenatal exposure to endocrine disruptors and genetic predisposition 
as common causes for the four disorders. Endocrine disruptors include a growing list of 
industrial chemicals such as pesticides, dioxins, and phthalates, but also synthetic hormones 
and natural phytoestrogens. Examples of reproductive defects in wildlife after environmental 
pollution and findings from experimental animal and in vitro models with endocrine disruptors 
are cause for concern. However, there is little epidemiological evidence for a role of endocrine 
disruptors in the aetiology of hypospadias21,23,25,26.  
 
In summary, several potential risk factors for hypospadias have been reported, but these 
require confirmation. The role of other factors, and especially exposure to endocrine dis-
ruptors, remains largely unclear. In addition, some suggestions for aetiological heterogeneity of 
hypospadias have been described, although this had not extensively been studied. For these 
reasons, we conducted a case-referent study in which we explored a wide range of potential 
risk factors. We distinguished between distal, middle, and proximal hypospadias phenotypes, 
with the expectation that these more homogeneous subgroups could reveal novel associations 
and could give more insight into the pathological mechanisms involved.  
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Patients and methods 
 
Cases and referents were recruited at one university hospital and three general hospitals in the 
Netherlands. All subjects were born between 1996 and 2004. Cases were boys who had surgery 
for hypospadias at departments of Urology. Referents were recruited at the departments of 
Otorhinolaryngology and were boys who received ear ventilation tubes for persistent middle 
ear effusion. This is a very common surgical procedure, so we expected these referents to be a 
good representation of the general population. By including children who had early childhood 
surgery as referents, we also aimed to minimize recall bias. Most of the cases and some of the 
referents were treated at the Radboud University Nijmegen Medical Centre, which serves as a 
referral hospital for hypospadias for a large population in the eastern part of the Netherlands. 
To recruit additional referents from the same catchment area, three general hospitals located 
in this area were also involved.  
 
The total numbers of eligible cases and referents identified from the hospitals’ information 
systems were 494 and 2911, respectively. The cases were restricted to 465 boys who resided 
within the catchment areas of the participating hospitals. Seventy-four of these already 
participated in a case-referent study on hypospadias in 200220. Based on the distribution of the 
postal area codes among the cases, 1125 referents were randomly selected. The personal data 
of all subjects were screened to identify twins and triplets (from which one sibling was 
randomly selected), other siblings (from which the oldest sibling was selected), and double 
records, resulting in a final selection of 460 cases and 1091 referents.   
 
In February 2005, the parents of cases and referents were sent identical sets of questionnaires, 
followed by two reminders after 3 and 7 weeks to increase the response rate. The 
questionnaires included items on socioeconomic characteristics, familial history of birth defects 
and illnesses, and the medical history of their son. Referring to the time just before and during 
the index pregnancy, parents were asked about health status, pregnancy details, life style, 
various exposures at work or during leisure time activities, and diet. These items included 
questions about the use of personal care products and exposure to pesticides, solvents, or 
other chemicals at work and during home improvements or hobbies as potential sources of 
exposure to endocrine disruptors. For the dietary intake variables, we focused on soy 
replacements for meat or dairy (as rich sources of phytoestrogens) and seafood (as a rich 
source of persistent endocrine disrupting pollutants). We also included a question included 
about being a ‘DES-daughter’ or ‘DES-son’, and parents who suspected or were certain about 
prenatal DES exposure were asked to clarify this. 
 
To avoid selective non-response and information bias, parents were informed that the study 
was designed to investigate associations between life style, diet, illnesses, and complications 
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around pregnancy and children’s health in general, not focusing on urogenital birth defects. 
About 150 parents were contacted by phone to complete their questionnaire information. 
Clinical data of the cases were collected from medical files. The location of the urethral 
opening was classified in the nine levels that are presented in Fig. 1. Cases with a glanular or 
coronal urethral opening but with a poorly developed membrane-like penile urethra were 
classified as proximal penile hypospadias. The study was approved by the Regional Committee 
on Research Involving Human Subjects. 
 
 
Figure 1. Prevalence and classification of hypospadias phenotypes in the present study. 
 
 
0. ‘sine hypospadia’ (n=18) 
  1. glanular (n=63)        distal (n=195) 
  2. (sub)coronal (n=114) 
 
3. distal penile (n=38) 
  4. midshaft (n=22)       middle (n=67)  
5. proximal penile (n=7) 
 
6. penoscrotal (n=42) 
  7. scrotal (n=1)       proximal (n=43) 
8. perineal (n=0) 
 
 
 
Based on the questionnaire data, referents with a major birth defect as defined in the 
European Concerted Action on Congenital Anomalies and Twins (EUROCAT) registry protocol27 
were excluded from the study population. Referents with UDT, a minor abnormality according 
to EUROCAT, were excluded as well, because this disorder shares several risk factors with 
hypospadias. Only cases with syndromal hypospadias or chromosome abnormalities were 
excluded, but subanalyses were performed to see whether exclusion of cases with other major 
birth defects affected the main study results. The hypospadias phenotypes were divided in 
distal, middle, and proximal hypospadias, according to the location of the urethral opening as 
shown in Fig. 1. ‘Hypospadias sine hypospadia’, i.e. a ventral lack of prepuce but a normal 
location of the urethral opening, was classified as distal hypospadias in the primary analyses, 
but subanalyses were performed excluding this phenotype.  
 
For the risk factor data, adjustments were made to the input for specific occupational 
exposures, as the data indicated that occupational exposure was sometimes confused with 
private use of chemical products. For instance, only parents who were employed in the 
cosmetic industry (e.g. beauticians and hairdressers) or in health care (e.g. nurses and geriatric 
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helpers) were considered likely to work with cosmetics. For the private use of cosmetics, 
parents listed all products they had used daily at time of the index pregnancy. These products 
were classified into different product groups, e.g. ‘deodorant’, ‘hairstyling products’, and ‘body 
lotion’. Then, a summary variable was made with three categories based on the number of 
product groups used per day.  
 
In the case-referent comparisons, crude odds ratios (ORs) with 95%CIs were calculated for all 
potential risk factors.  Next, multivariable logistic regression analyses were performed for 
factors with crude ORs ≥ 1.5 and a lower bound of the 95%CI ≥ 0.7 and for less elevated ORs 
with more precision, in order to adjust for confounding. In these analyses, parental educational 
level, ethnic origin, and all other identified or previously reported risk factors for hypospadias 
(≈20 variables), were treated as potential confounders, except for those factors that shared 
their causal pathway with the risk factor of interest (e.g. low birth weight was not included as a 
confounder in the analysis of pre-eclampsia). Confounders that changed the crude ORs by at 
least 10% were included in the multivariable analyses simultaneously. All associations were 
adjusted for year of birth to account for potential trends in exposure levels or probabilities 
over time. To obtain an indication for the influence of misclassification in case of a long recall 
interval, subanalyses were performed to assess differences in ORs in cases of short (1-5 years) 
or long (6-9 years) periods between delivery and data collection.     
 
Effect estimates for the distal, middle, and proximal phenotypes were calculated with 
multinomial logistic regression analyses. These analyses included potential risk factors 
identified in the present data, previously reported risk factors, and factors reflecting endocrine 
disruptor exposure, but were restricted to variables with at least three exposed subjects in the 
referent group and in each of the three case subgroups. All ORs were adjusted for the same 
confounders as in the case-referent analyses described above. Additionally, we assessed 
confounding by other risk factors for which there were heterogeneous associations with distal, 
middle, and proximal hypospadias. 
 
 
Results 
 
Completed questionnaires were received from the parents of 328 cases and 741 referents, 
which correspond to response rates of 74% and 70%, respectively, taking into account 17 cases 
and 37 referents with unknown address changes. For two cases and seven referents essential 
questionnaire data were missing. An additional 105 referents were excluded, because of UDT 
(12 boys) or major birth defects (93), including 37 orofacial clefts and seven Down syndromes, 
which are associated with persistent middle ear effusion. We also excluded seven cases with 
syndromal hypospadias or chromosome abnormalities and 14 ‘cases’ who did not have 
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hypospadias, but were treated for epispadias (five boys), phimosis (eight), or complications of a 
previous circumcision (one). Thus, the data analysis included 629 referents and 305 cases, of 
whom 195 cases were classified as distal (64%), 67 as middle (22%), and 43 as proximal 
hypospadias (14%) (Fig. 1).   
 
Cases were ≈10 months younger than referents, their mean (SD) age at time of data collection 
was 4.7 (2.0) and 5.5 (2.1) years, respectively. Additionally, parents of cases more often 
reported a non-European ethnic origin, including Turkish, Moroccan, Surinamese, Antillean, 
Asian, and other origins (Table 1). A Turkish origin in particular was more common among 
parents of cases (nine mothers and nine fathers) compared with parents of referents (two 
mothers and two fathers). No substantial differences in parental education were identified. 
Due to the population recruitment strategy, the two populations had similar geographical 
distributions. 
 
 
Table 1.  Parental educational level and ethnic background of cases and referents. 
Variable 
 
 
Referents  
n=629  (%) 
\ 
 
  Cases  
n=305 (%) 
 
 
Educational level of parents    
 Mother Low   153 (24.6)   77 (25.7) 
Intermediate  306 (49.1) 154 (51.3) 
High  164 (26.3)   69 (23.0) 
 Father Low   164 (28.2)   94 (33.1) 
Intermediate  227 (39.1)   98 (34.5) 
High  190 (32.7)   92 (32.4) 
 
Ethnic background of parents    
 Mother European Caucasian  609 (97.9) 283 (93.7) 
Other    13   (2.1)   19   (6.3) 
 Father European Caucasian  568 (97.4) 270 (94.4) 
Other    15   (2.6)   16   (5.6) 
N.B. There were no questionnaire data available from two mothers and 19 fathers of 
cases and four mothers and 46 fathers of referents. Proportions of missing data were 
<1% per variable.   
 
 
Crude and adjusted ORs for potential risk factors for hypospadias are given in Tables 2 and 3, 
which show generally little influence of confounding. The highest risk estimate for hypospadias 
was associated with occurrence of the disorder in first- or second-degree relatives: OR (95%CI) 
8.8 (3.9-19.7) (Table 2). There was also an association with familial occurrence of testicular 
cancer: OR (95%CI) 5.0 (1.2-20.2), although cell counts were low. The data also reflected 
associations with low birth weight: OR (95%CI) 3.2 (1.8-5.7), twin and triplet pregnancies: 2.0 
(1.0-3.9), and pre-eclampsia: 3.2 (1.6-6.4). Correspondingly, there were associations with 
gestational hypertension and with antihypertensive drug use: OR (95%CI) 2.2 (0.9-5.1) (Table 
3). Other pregnancy complications (e.g. gestational diabetes or anaemia) and increased 
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maternal age were not  associated with hypospadias. However, there  appeared to be a slightly 
elevated risk of hypospadias when the mother thought or was certain that she was a DES-
daughter, because her mother had used DES or an unknown drug to prevent miscarriage: OR 
(95%CI) 1.6 (0.7-3.4). In addition, hypospadias occurred more often after a prolonged time to 
pregnancy: OR (95%CI) 1.6 (1.1-2.3), after in vitro fertilization (IVF) or intracytoplasmic sperm 
injection (ICSI) treatment: 2.3 (0.9-5.8), and when fathers reported subfertility: 2.9 (1.4-5.8).  
 
 
Table 2.  Associations between hypospadias and familial predisposition, gestational and 
obstetric risk factors, and factors associated with subfertility. 
 
Variable 
 
 
 Refe-   
 rents  
n=629  
 
 
 Cases  
n=305 
 
 
                   OR (95%CI) 
 
 
   Crude 
 
 
   Adjusteda 
 
 
Familial history (1st or 2nd degree) of hypospadias     
 Hypospadias       8     31 8.3 (3.8-18.3) 8.8 (3.9-19.7) 
 Cryptorchidism     45     26 1.1 (0.7-1.9) 1.1 (0.7-1.9) 
 Testicular cancer       3       6 4.1 (1.0-16.6) 5.0 (1.2-20.2) 
 
Gestational and obstetric characteristics     
 Low birthweight (<2500g)b     43     59 2.9 (1.6-5.0) 3.2 (1.8-5.7) 
 Twin or triplet     20     18 1.9 (1.0-3.7) 2.0 (1.0-3.9) 
 Pre-eclampsia during index pregnancy     15     22 3.2 (1.6-6.2) 3.2 (1.6-6.4) 
 Gestational hypertension during index pregnancy     77     51 1.4 (1.0-2.1) 1.4 (1.0-2.1) 
 Increased maternal age (≥35 years)     99     50 1.1 (0.7-1.5) 1.1 (0.7-1.6) 
 
Prenatal DES exposure     
 Mother is probably DES-daughter     16     12 1.6 (0.8-3.4) 1.6 (0.7-3.4) 
 Father is probably DES-son     14       8 1.1 (0.5-2.7) 1.2 (0.5-3.0) 
 
Factors associated with subfertility     
 TTP > 6 months, excluding fertility treatments     98     65 1.6 (1.1-2.3) 1.6 (1.1-2.3) 
 Subfertility of mother     61     25 0.8 (0.5-1.4) 0.8 (0.5-1.4) 
 Subfertility of father     17     22 2.8 (1.5-5.3) 2.9 (1.4-5.8)c  
 Index pregnancy achieved with fertility treatment (any)     42     32 1.6 (1.0-2.7) 1.2 (0.7-2.2)d  
 Index pregnancy achieved with IVF/ICSI     10     14 3.0 (1.3-6.8) 2.3 (0.9-5.8)d  
N.B. There were no questionnaire data available from two mothers and 19 fathers of cases and four 
mothers and 46 fathers of referents. Proportions of missing data were <5% per variable, except for 
familial history of hypospadias (8%) and cryptorchidism (15%) and prolonged TTP (10%); 
a
all risk 
estimates were adjusted for year of birth; 
b
adjusted for gestational age (in weeks); 
c
adjusted for year 
of birth, low birth weight, and gestational age (in weeks); 
d
adjusted for year of birth and familial 
occurrence of hypospadias. 
 
 
There was some indication for an association with obesity of the father (but not of the 
mother): OR (95%CI) 1.5 (0.8-2.9) (Table 3). Fathers of cases also slightly more often reported 
prescriptive drug use, particularly antipsychotic drugs, in the 3 months before the index 
pregnancy: OR 1.5 (95%CI 0.9-2.4). Mothers of cases less often reported the use of antibiotics 
just before or during pregnancy: OR (95%CI) 0.5 (0.3-0.8), but there were no associations with 
other prescription drugs or vitamin supplements (including folic acid). Also, hypospadias could 
not be associated with smoking or private use of cosmetics by either parent. Against expecta- 
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Table 3.  Associations between hypospadias and obesity, prescriptive drug use, vitamin 
supplements, smoking, cosmetics, occupational exposures, and diet.  
 
Variable 
 
 
refe-
rents 
n=629 
 
 
cases 
n=305 
 
 
                   OR (95%CI) 
 
 
      Crude 
 
 
    Adjusteda 
 
Obesity (body mass index > 30 kg/m2)b     
 Motherb      30     18 1.2 (0.7-2.3) 1.0 (0.5-1.9) 
 Fatherb      25     19 1.6 (0.8-2.9) 1.5 (0.8-2.9) 
Prescriptive drug use      
 Motherc Any drug    340   156 0.9 (0.7-1.2) 0.9 (0.7-1.2) 
  Iron supplements    238     95 0.7 (0.6-1.0) 0.8 (0.6-1.1) 
  Antibiotics      64     18 0.6 (0.3-1.0) 0.5 (0.3-0.8) 
  Antihypertensives      11     12 2.3 (1.0-5.3) 2.2 (0.9-5.1) 
  Antipsychotic drugs        7       4 1.2 (0.3-4.1) 1.1 (0.3-4.0) 
  Oral contraceptives: after conception        7       4 1.2 (0.3-4.1) 1.1 (0.3-4.0) 
 Fatherb Any drug      42     33 1.6 (1.0-2.7) 1.5 (0.9-2.4) 
  Antipsychotic drugs        2       6 6.1 (1.2-30.3) 3.1 (0.6-16.7)e 
Maternal intake of folic acid or other vitamin supplementsf     459   229 1.1 (0.8-1.5) 0.9 (0.6-1.2) 
Maternal smoking d    109     47 0.9 (0.6-1.2) 0.9 (0.6-1.3) 
Paternal smoking b    204     93 0.9 (0.7-1.2) 0.9 (0.7-1.3) 
Private use of cosmetics/day     
 Motherc Used 0-2 product groups      85     37 ref g ref g 
  Used 3-6 product groups     401     37 1.2 (0.8-1.9) 1.1 (0.7-1.7) 
  Used 7/8 product groups     131   213 0.9 (0.5-1.5) 0.8 (0.5-1.4) 
 Fatherb Used 0/1 product groups    162     74 refg refg 
  Used 2-4 product groups     389   202 1.1 (0.8-1.6) 1.1 (0.8-1.5) 
  Used 5 product groups       20       6 0.7 (0.3-1.7) 0.7 (0.3-1.8) 
Occupational exposures     
 Motherc Cosmetics      37       8 0.4 (0.2-0.9) 0.4 (0.2-1.0)h 
  Pesticides      12       4 0.7 (0.2-2.1) 0.8 (0.2-2.4) 
  Paints, ink, adhesives, or thinnersi        6       2 0.7 (0.1-3.4) 0.6 (0.1-3.2) 
  Industrial cleaning agents or solventsi        7       4 1.2 (0.3-4.0) 1.0 (0.3-3.5) 
  Dusts (any)        7       8 2.4 (0.9-6.6) 1.8 (0.6-5.2)j 
 Fatherb Pesticides      30     11 0.7 (0.4-1.5) 0.8 (0.4-1.6) 
  Paints, ink, adhesives, or thinnersi      27     13 1.0 (0.5-1.9) 1.1 (0.5-2.2) 
  Industrial cleaning agents or solventsi      12       7 1.2 (0.5-3.1) 1.2 (0.5-3.1) 
  Dusts (any)      52     35 1.4 (0.9-2.3) 1.5 (0.9-2.3) 
  Dusts from grinding metals        3       5 3.4 (0.8-14.5) 4.3 (1.0-18.4) 
  Gasoline fumes      15     14 2.0 (0.9-4.1) 1.9 (0.9-4.0) 
Diet     
 Motherd Vegetarian or vegan diet      12       6 1.0 (0.4-2.8) 1.0 (0.4-2.7) 
  Soy meat replacementsk      18       6 0.7 (0.3-1.7) 0.7 (0.3-1.7) 
  Seafoodk    293   132 0.9 (0.7-1.2) 0.9 (0.7-1.2) 
 Fatherb Vegetarian or vegan diet        4       0 - - 
  Soy meat replacementsk      17       7 0.8 (0.3-2.0) 0.7 (0.3-1.8) 
  Seafoodk    284   123 0.8 (0.6-1.1) 0.9 (0.6-1.1) 
N.B. There were no questionnaire data available from two mothers and 19 fathers of cases and four 
mothers and 46 fathers of referents; Proportions of missing data were <5% per variable, except for 
paternal obesity (6%), prescriptive drug use (15%), and intake of soy meat replacements (6%); 
a
all 
risk estimates were adjusted for year of birth; 
b
in the 3 months before pregnancy; 
c
in the 3 months 
before pregnancy and/or during pregnancy; 
d
during pregnancy; 
e
adjusted for year of birth and 
familial occurrence of hypospadias and testicular cancer; 
f
in the 3 months before pregnancy and/or 
in the first 4 months of pregnancy; 
g
reference category; 
h
adjusted for year of birth and familial 
occurrence of hypospadias; 
i
at least 8h/week;  
j
adjusted for year of birth, low birth weight, and 
gestational age (in weeks). 
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tions, mothers of cases less often reported occupational exposure to cosmetics at time of 
pregnancy: OR (95%CI) 0.4 (0.2-1.0). Both case-parents were more likely to respond positively 
to an open-ended question on occupational exposure to dusts, which was difficult to interpret 
because different types of dust were listed, such as dust from hay, grain, construction 
processes, and plastic manufacturing. Only fathers of cases more often reported exposure to 
dusts from grinding metals: OR (95%CI) 4.3 (1.0-18.4). Additionally, fathers more often 
described occupational exposure to gasoline fumes in the 3 months prior to pregnancy: OR 
(95%CI) 1.9 (0.9-4.0). There were no associations with other occupational exposures. A 
vegetarian or vegan diet, intake of soy replacements for meat or dairy, and intake of seafood 
could not be associated with hypospadias, either. 
 
In the stratified subanalyses, no clear differences were found in the ORs for dietary intake 
variables, occupational exposures, prescriptive drug use, and familial history between subjects 
aged 6-9 years and subjects aged 1-5 years at the time of data collection. However, the 
potentially increased risk of hypospadias in cases of paternal obesity and the inverse 
association with maternal use of antibiotics, seemed to be more pronounced in younger 
subjects compared with the older age group: OR (95%CI) 2.4 (1.0-5.3) vs 0.7 (0.2-2.4) and 0.3 
(0.1-0.5) vs 1.6 (0.7-3.7), respectively. In contrast, there were somewhat stronger associations 
with low birth weight and paternal subfertility in older vs. younger subjects: OR (95%CI) 4.9 
(0.9-1.1) vs 2.0 (0.9-4.5) and 5.1 (1.9-13.6) vs 1.5 (0.5-4.1), respectively. There was a similar but 
much larger difference in ORs for IVF/ICSI treatment: 7.2 (1.8-29.0) vs 0.5 (0.1-2.3). 
 
Figure 2 shows the adjusted ORs for the distal, middle, and proximal phenotypes. The analyses 
were restricted to relatively common factors as defined in the method section, except for 
familial occurrence of hypospadias because of its high effect estimate in the case-referent 
comparisons. There were associations of similar strength between familial occurrence and the 
distal and middle phenotypes: OR (95%CI) 10.5 (4.5-24.1) and 9.0 (3.1-26.0), whereas the OR 
for proximal hypospadias was much lower, albeit imprecise: 1.8 (0.2-14.9). In contrast, the 
association with low birth weight seemed much stronger for proximal hypospadias: OR (95%CI) 
9.1 (3.4-24.2) compared with distal and middle hypospadias: 2.6 (1.4-5.0) and 2.3 (0.8-6.5), 
respectively. A remarkably similar trend in ORs emerged for pre-eclampsia: distal 1.8 (0.7-4.3), 
middle 2.6 (0.8-8.3), and proximal 12.4 (5.1-30.0). Among the cases with proximal hypospadias 
(43 boys), 20 boys had low birth weight (47%) and 10 boys were born after gestational pre-
eclampsia (23%). 
 
The increased risks of hypospadias when the mother was a DES-daughter or the father was 
obese seemed to be restricted to the middle and proximal phenotypes. Fertility treatment as a 
group appeared to only increase the risk of middle hypospadias with an OR (95%CI) of 2.5 (1.1-
5.3). The associations with paternal subfertility and IVF/ICSI treatment also seemed to be 
strongest for middle hypospadias, although the prevalence of IVF/ICSI was too low to assess  
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Figure 2.  Associations between potential risk factors for hypospadias and the distal, 
middle, and proximal phenotypes. 
A 
 
B 
 
N.B. Potential risk factors with effect estimates ≈1 were omitted for parsimony (see text); all risk 
estimates were adjusted for year of birth; 
a
adjusted for year of birth and gestational age (in weeks); 
b
adjusted for year of birth and gestational pre-eclampsia; 
c
adjusted for year of birth, ethnic 
background and educational level of mother, low birth weight, and gestational age (in weeks); 
d
adjusted for year of birth and paternal obesity; 
e
adjusted for year of birth, ethnic background and 
educational level of the father, low birth weight, and gestational age (in weeks); 
f
adjusted for year of 
birth and familial occurrence of hypospadias; 
g
adjusted for year of birth, low birth weight and 
gestational age (in weeks); 
h
adjusted for year of birth and ethnic background and educational level 
of the father. 
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this in a multivariable model. The associations with self-reported paternal exposure to dusts 
and gasoline fumes were strongest for middle hypospadias: OR (95%CI) 3.0 (1.5-5.8) and distal 
hypospadias: 2.2 (1.0-4.8), respectively. There were no substantial differences in ORs between 
phenotypes for being a twin or triplet, prolonged time to pregnancy, paternal prescriptive drug 
use, maternal use of antibiotics (not shown), and maternal occupational exposure to cosmetics 
(not shown). Additionally, the multinomial analyses did not show associations between 
hypospadias phenotypes and other suggested risk factors or endocrine disruptor exposures, 
including increased maternal age, maternal obesity, maternal and paternal smoking, use of 
cosmetics, and intake of seafood, and paternal occupational exposure to pesticides or paint, 
ink, adhesives or thinners.  
 
Exclusion from the analyses of 31 cases with coexisting birth defects (including 15 cases with 
UDT) or 18 cases with hypospadias sine hypospadia did not substantially affect any of the 
reported effect estimates.  
 
 
Discussion 
  
The present study supports several previously reported associations and gives indications for 
some novel risk factors for hypospadias, including familial occurrence of testicular cancer and 
paternal obesity. Furthermore, there were indications for aetiological heterogeneity of hypo-
spadias. To correctly interpret these results, we will first reflect on some methodological 
issues. 
 
We selected boys who received ear ventilation tubes as the referent population, to obtain a 
comparable group of boys who had early childhood surgery and geographically represented 
the source population of the cases. To our knowledge, persistent middle ear effusion has not 
been associated with the risk factors that were investigated in the present study28. However, 
the same may not be true for the birth defects that were reported for referents, which led to 
exclusion of these referents from the analyses. The prevalence of birth defects among 
referents (14%) was much higher than the expected prevalence in the general population (2-
3%)29; this can partly be explained by the greater occurrence of middle ear effusion among 
children with cranial abnormalities (orofacial clefts, Down's syndrome). In addition, some 
referents may have had only minor malformations that were misclassified as major defects due 
to the self-reported nature of the data. Sub-analyses also excluding cases with co-occurring 
birth defects did not lead to different findings. Response rates among cases and referents were 
quite high. This resulted in a final study population with an 80% power to detect statistically 
significant elevated ORs of ≥2 for factors with an exposure prevalence of at least 5%. The 
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power to detect similar ORs in the analyses for the three subgroups of cases ranged from 30 to 
65%, with an 80% power to detect ORs of at least 2.3-4.0.  
 
The self-reported nature of the data, which were obtained at 2-9 years after delivery, is a 
potentially important limitation of the present study design and may raise concerns about 
exposure misclassification. Because both cases and referents were hospital populations and 
parents were not informed about their case/referent status, we expect that this 
misclassification was mostly non-differential. Although recall bias of some specific 
determinants cannot be excluded and requires caution, it is reassuring that many of the 
present findings correspond with published data. For a subset of items in the questionnaires, 
we assessed the reproducibility during a telephone interview with 72 mothers and 55 fathers in 
2006. For most of these items, moderate to good agreements were calculated between the 
questionnaires and interviews, except for specific questions on home improvement activities 
and occupational exposures at time of the pregnancy. Therefore, these items were probably 
subject to substantial random misclassification. In the stratified subanalyses, there was some 
indication that the effect estimates for paternal obesity and maternal use of antibiotics were 
underestimated due to the sometimes long recall intervals. However, for low birth weight, 
paternal subfertility, and IVF/ICSI treatment ORs were calculated if there were >5 years 
between the delivery and data collection. Because these factors are probably accurately 
remembered, even 6-9 years after delivery, it is unlikely that the differences in ORs result from 
over-reporting by parents of older cases. An alternative explanation would be the changes in 
fertility treatments over time.  
 
The strong association between hypospadias and occurrence of the disorder in first- and 
second-degree relatives corresponds with previous findings and most likely reflects 
transmission of genetic risk factors4,5,20,30. There was also an association with familial 
occurrence of testicular cancer, which to our knowledge has not been described before. 
Together with the association between hypospadias and paternal subfertility, these findings 
indicate familial clustering of TDS. However, the present findings do not support an association 
between hypospadias and familial occurrence of UDT, the fourth disorder that is referred to in 
the TDS hypothesis24. The present data seem to agree with findings from Fredell et al.5, who 
reported that familial cases less often present with penoscrotal and perineal hypospadias than 
sporadic cases. Due to power limitations, we could not assess if the same applies to familial 
occurrence of testicular cancer.  
 
Another explanation for the association with paternal subfertility is that fertility treatments 
increase the hypospadias risk in offspring, which corresponds with present and previous 
findings concerning IVF/ICSI treatment15-18. In addition to the underlying subfertility of the 
parents, different mechanisms have been proposed. Ovulation stimulants and progestins were 
suggested to increase the risk of hypospadias by interfering with the fetal endocrine 
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system31,32, whereas the in vitro procedures of IVF/ICSI have recently been reported to involve 
a risk of epigenetic defects33. Furthermore, in vitro chorion formation was hypothesized to 
affect placental development, which could be an explanation for the greater occurrence of low 
birth weight and pre-eclampsia after IVF/ICSI treatments34.  
 
Placental dysfunction in early pregnancy is also thought to partly explain the associations 
between hypospadias and low birth weight5, twin or triplet pregnancies8, pre-eclampsia or 
hypertension10, and maternal DES-exposure12,14, independent from IVF/ICSI. Especially the 
elevated ORs for proximal hypospadias associated with low birth weight and pre-eclampsia, 
suggest that early placental dysfunction may significantly affect penile development. There was 
a similar pattern for the associations with maternal DES exposure and fertility treatments, as 
the risks were highest for the middle and proximal phenotypes.  
 
The findings for maternal and paternal prescriptive drug use are more difficult to interpret. The 
increased risk of hypospadias after maternal iron supplementation that we previously 
reported20, was not reflected in the present data. The lack of biological plausibility of the 
associations with paternal prescriptive drug use and maternal use of antibiotics, however, casts 
doubts on the validity of the present data on prescriptive drugs in general. For the latter 
finding, we speculate that mothers of boys with persistent middle ear effusion may have used 
antibiotics more often because of an increased familial predisposition to infections.  
  
The case-referent comparisons and the phenotype-specific analyses provided little evidence for 
an increased risk of hypospadias from maternal and paternal endocrine disruptor exposure. 
There was an unexpected inverse association with maternal occupational exposure to 
cosmetics, a potential source of phthalates and parabens35. Private use of cosmetics was not 
associated with hypospadias. The present findings for occupational exposure to dusts and 
gasoline fumes were based on data collected with open-ended questions36, which raises 
further concern about recall bias36, especially because there were associations between 
hypospadias and other occupational or leisure time exposures to endocrine disruptors, such as 
pesticides, organic solvents, and industrial cleaning agents. However, these null-findings could 
be affected by severe random misclassification, as indicated by the reproducibility study 
described before. More extensive exposure assessment seems necessary to draw conclusions 
about occupational exposure.  
 
As it is also difficult to accurately quantify dietary intake by means of retrospective 
questionnaires, we may not have been able to detect an increased risk of hypospadias 
associated with maternal intake of phytoestrogens in soy as has been reported23. Similarly, we 
could not identify an association with intake of fish and seafood, as a rich source of dioxin-like 
substances37. However, increased dietary intake or storage capacity for such chemicals could 
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be an explanation for the association between obesity of the father and hypospadias, which 
seemed to be restricted to the middle and proximal phenotypes.  
 
Overall, the results indicated a role for genetic risk factors, factors associated with placental 
insufficiency, paternal subfertility and fertility treatment, and other risk factors in the aetiology 
of hypospadias. In addition, there were indications for substantial differences in effect 
estimates between the distal, middle, and proximal phenotypes for several risk factors. Due to 
power limitations, CIs for these estimates were broad and the analyses were restricted to 
relatively prevalent risk factors. Larger studies could further clarify the risk factor patterns for 
distal, middle, and proximal hypospadias and thereby provide insights into causal mechanisms, 
which may involve timing, frequency, and level of exposure, as well as diversity in pathogenic 
effects. Differences in risk factor patterns between phenotypes may also explain 
inconsistencies in effect estimates between populations. Therefore, aetiological heterogeneity 
of hypospadias should be considered in future research. 
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Abstract 
 
Purpose 
Hypospadias is a common urogenital birth defect in boys with a urethral opening displacement. 
Depending on the location of the opening, hypospadias is subdivided into different 
phenotypes. These may arise as a result of dissimilar embryonic processes in different time 
windows. The objective of this study was to identify specific risk factors for different 
phenotypes of hypospadias.   
 
Materials and Methods 
In this Dutch case-control study, we included 405 hypospadias cases and 627 male controls. 
Medical records of cases were reviewed to determine anatomical location of the urethral 
opening, and demographic, lifestyle, and pregnancy-related risk factor data were obtained 
from self-administered questionnaires. Multivariable and multinomial logistic regression 
analyses were used to calculate effect estimates for the total hypospadias group and the 
different phenotypes. 
 
Results 
Cases were subdivided into anterior (glandular and coronal) (59%), middle (penile) (29%) and 
posterior (penoscrotal, scrotal and perineal) (12%) hypospadias. Family history of hypospadias 
increased the risk of hypospadias (odds ratio: 9.9, 95% confidence interval: 4.5-21.7), an effect 
that was predominantly seen in anterior and middle forms. Being part of a twin/triplet, 
primiparity, preeclampsia, preterm delivery, and being small for gestational age were 
associated with hypospadias, particularly in posterior cases. Maternal obesity seemed to 
increase the risk of hypospadias in general, while hormone-containing contraceptive use during 
pregnancy especially increased the risk of middle and posterior hypospadias.  
 
Conclusions 
Our study provides strong indications for etiologic heterogeneity of hypospadias, with genetic 
predisposition being more pronounced for the anterior and middle phenotypes and posterior 
hypospadias being predominantly associated with pregnancy-related factors.   
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Introduction 
 
Hypospadias is the most common urogenital birth defect in boys, affecting one in 140 to 330 
newborn boys in Europe1,2. In hypospadias, the urethral opening is displaced along the ventral 
side of the penis, and different phenotypes are classified as anterior when the urethral opening 
is at the glans or corona, middle when it is located on the shaft of the penis, and posterior 
when the urethra ends in the penoscrotal region, scrotum, or perineum. The only treatment 
for hypospadias is surgical repair or expectant management if minimal abnormalities are 
present, but patients may still encounter functional and psychological difficulties early and 
later in life3,4. 
 
Hypospadias is believed to have a multifactorial etiology, in which several genes act in concert 
with environmental factors. Many researchers have investigated environmental risk factors 
and hypothesized that transgenerational effects of DES, fertility treatment, and some 
environmental endocrine disruptors may be important in the etiology of hypospadias5-7. 
Convincing evidence shows that low birth weight, maternal hypertension, and multiple 
pregnancies are associated with hypospadias, suggesting a role for placenta insufficiency8-10, 
but exact causes for hypospadias are as yet unknown.   
 
The various phenotypes of hypospadias may arise as a result of dissimilar embryonic processes 
in different time windows, suggesting etiological heterogeneity.  However, few studies investi-
gated risk factors for different hypospadias phenotypes and used clinical data from registries, 
did not include a representative control group, missed data on potential confounders, or the 
subgroups were too small to draw firm conclusions about etiologic heterogeneity. Therefore, 
the objective of this study was to identify specific risk factors for different phenotypes of 
hypospadias in a large group of well-defined hypospadias cases.    
 
 
Materials and Methods 
 
Study population 
Two groups of cases were included to avoid overlap with a similar previous study 11. One group 
consisted of 490 boys, born between 1987 and 1997, who were surgically treated for 
hypospadias at the department of Urology of the Radboud University Nijmegen Medical Centre 
(RUNMC)9. The second group originated from AGORA (Aetiologic research into Genetic and 
Occupational/Environmental Risk Factors for Anomalies in Children), a large biobank at the 
RUNMC with questionnaire and clinical data, and DNA from cases diagnosed with congenital 
disorders or childhood cancers, started in 2005. All children in AGORA who had surgery for 
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hypospadias and were not part of previous studies9,11 were included. Most children were born 
between 2003 and 2006. Medical records were reviewed to identify cases with syndromes, 
associations, or known causes, and to determine anatomical location of the urethral opening. 
The latter was assessed by experienced pediatric urologists during physical examination before 
or during surgery. 
 
The control group was derived from a previous study on hypospadias11. All 1000 controls were 
boys without major birth defects, but with persistent middle ear infection treated with 
ventilation tubes, and born between 1996 and 2004. This hospital-based control group was 
chosen to avoid selective non-response and information bias. Because middle ear infection is a 
very common disease in childhood, we expected the control group to be representative of the 
general population. The study protocol was approved by the regional Committee on Research 
Involving Human Subjects and written informed consent was obtained from the parents of all 
cases and controls.  
 
Data collection    
Between February 2005 and October 2008, the parents of every case and control child received 
questionnaires with questions about demographic factors, family history of birth defects, and 
pregnancy history. Questions about health status, prescribed medication, and lifestyle 
pertained to the three months before conception and during pregnancy for mothers and the 
three months before conception for fathers. Variables included in the analyses were age at 
childbirth for mothers (< or ≥ 35 years) and fathers (< or ≥ 40 years); ethnicity; educational 
level (intermediate and below vs. higher education); maternal and paternal body mass index 
(BMI) at conception (< or ≥ 30 kg/m2); family history of hypospadias or cryptorchidism (one or 
more 1st or 2nd degree relatives); time to pregnancy (TTP) without fertility treatment (≤ or > 6 
months); maternal and paternal subfertility diagnosed by a medical doctor; primiparity;  twin 
or triplet pregnancy; preeclampsia; hormone-containing contraceptive use after conception; 
maternal use of cigarettes and alcohol during the first four months of pregnancy; paternal use 
of cigarettes and alcohol in the three months prior to conception; preterm delivery (<37 
weeks); and being small for gestational age (SGA) (birth weight < 10th percentile using Dutch 
reference curves for birth weight by gestational age12. 
 
Statistical analyses 
Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for potential 
maternal and paternal risk factors comparing cases with controls using unconditional logistic 
regression analyses. Next, multivariable logistic regression analyses were performed to 
calculate adjusted ORs, including all relevant potential confounders. Variables considered as 
potential confounders were previously reported risk factors for hypospadias and those 
identified in this study, excluding factors that share their causal pathway with the risk factor of 
interest. Variables that changed the ORs by at least 10% upon removal were retained in the 
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multivariable models. All associations were adjusted for year of birth to account for potential 
trends in exposure levels or exposure probabilities over time. Multinomial logistic regression 
analyses were used to calculate effect estimates for the anterior, middle, and posterior 
phenotypes using the same strategy to adjust for confounders. These analyses were restricted 
to risk factors with two or more exposed subjects per group. SPSS 17.0 was used as statistical 
software. 
 
 
Results 
 
The parents of 275 of the 490 boys in the first case group (56%) filled out the questionnaires, 
while 156 cases and parents participated through AGORA, with a response rate of at least 62%. 
Fourteen cases were excluded because of syndromes, associations, or known causes, and 12 
hypospadias brothers (youngest) were excluded, leaving 405 cases for analyses. Parents of 650 
controls filled out the questionnaires (65%). Twenty-three controls with cryptorchidism were 
excluded because of potentially shared risk factors with hypospadias, leaving 627 controls for 
analyses.  
 
Hypospadias was subdivided into three phenotypes based on anatomical location: anterior 
(glandular and coronal) n=225 (59%), middle (penile) n=111 (29%), and posterior (penoscrotal, 
scrotal and perineal) n=45 (12%). The phenotype was unknown for 24 cases. Most case and 
control parents originated from the Netherlands or other parts of Europe (95% and 96%, 
respectively). Sixty-one percent of both case and control mothers had a low education, 
whereas slightly more control fathers were low educated (61%) compared to case fathers 
(53%).  
 
Family history of hypospadias in increased the hypospadias risk almost ten-fold (Table 1). 
Separate analyses for different phenotypes displayed a similar picture for anterior and middle 
forms of hypospadias, but a much lower risk estimate for posterior cases. Family history of 
cryptorchidism was not clearly associated with hypospadias, although it was slightly more 
often reported for all case groups except for posterior cases. No substantial differences for 
high maternal or paternal age at childbirth were observed between cases or case subgroups 
and controls.  
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Table 1.  Associations between hypospadias and family history of hypospadias and 
cryptorchidism and parental age in all cases and divided by phenotypes.  
 
Demographic 
factors 
 
 
Total group of hypospadias 
cases (n=405) 
N      (%) 
 
Controls   
(n=627) 
 N      (%) 
 
 
   ORcrude (95%CI) 
 
 
ORadjusted
a (95%CI) 
 
 
Family history of 
hypospadias  48   (12.9)   9   (1.6)    9.4  (4.6-19.4)    9.9   (4.5-21.7) 
Family history of 
cryptorchidism  38   (10.3) 40   (6.9)    1.5    (1.0-2.5)    1.5     (0.9-2.4) 
Maternal age (≥35 
years) at childbirth 54   (13.4) 99 (16.0)    0.8    (0.6-1.2)    1.0     (0.7-1.5) 
Paternal age (≥40 
years) at childbirth 28     (7.3) 42   (7.2)    1.0    (0.6-1.7)    1.2     (0.7-2.0) 
 
Divided by 
hypospadias 
phenotype 
 
           Anterior (n=225) 
 
  N    (%)   ORadjusted
a (95%CI) 
 
          Middle (n=111) 
 
  N   (%)    ORadjusted
a (95%CI) 
 
       Posterior (n=45) 
 
N    (%)     ORadjusted
a (95%CI) 
 
 
Family history of 
hypospadias  29  (13.6) 10.3  (4.5-23.7) 13  (13.0) 9.2  (3.5-24.2) 2    (5.3) 3.2  (0.7-15.8)b 
Family history of 
cryptorchidism  23  (10.9)   1.6     (0.9-2.8) 11  (11.0) 1.6    (0.8-3.4) 1    (2.6)   -c 
Maternal age (≥35 
years) at childbirth 23  (10.3)   0.8    (0.5-1.2) 20  (18.2) 1.5    (0.9-2.6) 9  (20.0) 1.4   (0.7-3.0) 
Paternal age (≥40 
years) at childbirth 13    (6.0)   1.2    (0.6-2.4)d 10     (9.5) 1.7    (0.8-3.6) 5  (12.5) 1.9   (0.7-5.0) 
Odds ratio (OR); Confidence Interval (CI). Proportions of missing data were < 10% per variable, except 
for family history of hypospadias in the posterior group (15.5%). The percentages presented for the 
cases and controls are calculated without these missing values. 
a
Adjusted for year of birth; 
b
also 
adjusted for primiparity; 
c
not calculated because of < 2 exposed subjects; 
d
also adjusted for maternal 
age at childbirth. 
 
 
Our results regarding parental fertility were inconsistent (Table2). Maternal subfertility was 
more frequent in posterior cases only (ORposterior:1.9, 95%CI:0.8-4.5), whereas paternal 
subfertility was not clearly associated with hypospadias and a TTP > 6months only increased 
the risk of anterior hypospadias (ORanterior:1.5, 95%CI:1.0-2.3). Being part of a twin or triplet and 
being the first-born were both associated with hypospadias, and these associations were 
strongest in posterior cases. The same was true for the occurrence of preterm delivery and 
SGA, with the latter not being associated with anterior hypospadias at all. Preeclampsia 
seemed to be associated with all hypospadias phenotypes, but numbers were too small to be 
conclusive. 
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Table 2.   Associations between hypospadias and pregnancy-related factors in all cases  
and divided by phenotypes.  
 
Pregnancy-related 
factors 
 
 
Total group of hypospadias 
cases (n=405) 
N      (%) 
 
Controls   
(n=627) 
 N      (%) 
 
 
   ORcrude (95%CI) 
 
 
ORadjusted
a (95%CI) 
 
 
Subfertility of mother 
Subfertility of father 
        32    (8.0) 
        17    (4.5) 
  60   (9.7) 
  16   (2.7) 
  0.8  (0.5-1.3) 
  1.7  (0.8-3.4) 
0.9  (0.6-1.5) 
1.6  (0.8-3.3)b 
TTP > 6 monthsc   75  (21.5)   98  (17.2)   1.3  (0.9-1.8) 1.3  (0.9-1.9)d 
Twin or triplet   27    (6.8)   20    (3.5)   2.0  (1.1-3.7) 2.3  (1.2-4.4) 
Primiparity 218  (55.3) 252  (40.2)   1.8  (1.4-2.4) 1.8  (1.4-2.4) 
Preeclampsia   19    (4.8)   15    (2.4)   2.0  (1.0-4.0) 2.1  (1.0-4.5) 
Preterm delivery 
(<37 weeks)   68  (17.5)   57    (9.4)   2.0  (1.4-3.0) 2.1  (1.4-3.2) 
Small for 
gestational age   77  (20.3)   81  (13.8)   1.6  (1.1-2.2) 1.6  (1.1-2.3) 
 
Divided by 
hypospadias 
phenotype 
 
           Anterior (n=225) 
 
        N  (%)  ORadjusted
a (95%CI) 
 
          Middle (n=111) 
 
N   (%)    ORadjusted
a (95%CI) 
 
       Posterior (n=45) 
 
N  (%)    ORadjusted
a (95%CI) 
 
 
Subfertility of mother 
Subfertility of father 
16    (7.2) 
10    (4.7) 
0.8  (0.5-1.5) 
1.5  (0.6-3.4) 
  7    (6.4) 
  4    (3.9) 
0.8   (0.3-1.8) 
1.4   (0.4-4.3)b 
  7  (16.3) 
  2    (5.1) 
1.9  (0.8-4.5) 
1.6  (0.3-7.5)e 
TTP > 6 monthsc      46  (23.1) 1.5  (1.0-2.3) 15  (16.9) 1.1   (0.6-2.0)   8  (21.1) 0.9  (0.4-2.1)d 
Twin or triplet     14    (6.3) 2.1  (1.0-4.4)   5    (4.6) 1.5   (0.5-4.3)   5  (11.4) 3.8  (1.4-10.9) 
Primiparity   110  (50.0) 1.5  (1.1-2.0) 60  (56.1) 1.9   (1.2-2.8) 36  (81.8) 6.7  (3.1-14.7) 
Preeclampsia     10    (4.5) 1.9  (0.8-4.6)   6    (5.5) 2.2   (0.8-6.4)   3    (7.0) 2.6  (0.7-9.7)d 
Preterm delivery 
(<37 weeks)     35  (15.8) 1.8  (1.1-2.9) 14  (13.7) 1.5   (0.8-2.9)  13  (29.5) 3.3  (1.6-6.7)d 
Small for 
gestational age     29  (13.5) 1.0  (0.6-1.6) 23  (22.8) 1.8   (1.0-3.1) 18  (42.9) 4.8  (2.5-9.2) 
Odds ratio (OR); Confidence Interval (CI); Time-To-Pregnancy (TTP). Proportions of missing data were 
< 10% per variable, except for subfertility of father in the posterior group (13.3%). The percentages 
presented for the cases and controls are calculated without these missing values. 
a
Adjusted for year 
of birth; 
b
also adjusted for family history of hypospadias; 
c
conception with fertility treatment 
excluded (n=91, 41 cases and 50 controls); 
d
also adjusted for primiparity; 
e
also adjusted for paternal 
age at childbirth. 
 
 
Maternal obesity (BMI ≥ 30 kg/m2) at time of conception doubled the risk of having a child with 
hypospadias, whereas paternal obesity proved not to be a risk factor (Table 3). Hormone-
containing contraceptives were not frequently used by women after conception, but more case 
than control mothers did, increasing the hypospadias risk especially for middle (ORmiddle:8.5, 
95%CI:1.5-47.9) and posterior (ORposterior:11.5, 95%CI:1.9-72.0) phenotypes. Parental smoking 
seemed not to influence hypospadias risk substantially. No overall associations were found 
between hypospadias and parental alcohol use either, but the risk of posterior hypospadias 
was increased when the mother used alcohol and decreased when the father drank alcohol.   
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Table 3.  Associations between hypospadias and lifestyle factors in all cases and 
divided by phenotypes.  
 
Lifestyle factors 
 
Total group of hypospadias 
cases (n=405) 
N      (%) 
 
Controls 
 (n=627) 
  N     (%) 
 
 
ORcrude (95%CI) 
 
 
ORadjusted
a (95%CI) 
 
 
Maternal BMI ≥30 
kg/m2 at conception     27    (7.3)   36    (6.0)   1.2  (0.7-2.1)   1.8  (1.0-3.1) 
Paternal BMI ≥30 kg/m2    31    (8.5)   47    (8.4)   1.0  (0.6-1.6)   1.1  (0.7-1.9) 
Hormone-containing contraceptive  
    7    (1.1)   2.5  (1.0-6.5)   6.6  (1.6-27.2)b     use after conception     11    (2.8) 
During the first 4 months of pregnancy: 
    Smoking mother     84  (21.8) 110  (18.2)   1.3  (0.9-1.7)   1.0  (0.7-1.4) 
    Alcohol use mother     80  (20.6)   95  (16.3)   1.3  (1.0-1.9)   1.3  (0.9-1.8) 
In the 3 months prior to conception: 
183  (32.4)   1.3  (1.0-1.7) 
 
  1.3  (0.9-1.7)c     Smoking father   141  (38.2) 
    Alcohol use father   299  (80.8) 449  (81.3)   1.0  (0.7-1.4)   0.8  (0.6-1.2) 
 
 
Divided by 
hypospadias 
phenotype 
 
 
           Anterior (n=225) 
 
        N   (%)  ORadjusted
a (95%CI) 
 
 
          Middle (n=111) 
 
N   (%)    ORadjusted
a (95%CI) 
 
 
       Posterior (n=45) 
 
N   (%)    ORadjusted
a (95%CI) 
 
 
 
Maternal BMI ≥30 
kg/m2 at conception 17   (8.1) 2.0 (1.0-3.8)   7   (7.1) 1.8 (0.7-4.3)   3    (7.5)   1.5 (0.4-5.5)d 
Paternal BMI ≥30 kg/m2 20   (9.6) 1.3 (0.7-2.3)   7   (6.9) 0.9 (0.4-2.2)   4  (10.5)   1.3 (0.4-3.8) 
Hormone-containing contraceptive  
3.8 (0.7-20.9)b   4   (3.7) 8.5 (1.5-47.9)b,d   2    (4.5) 11.5 (1.9-72.0)b     use after conception   4   (1.8) 
During the first 4 months of pregnancy: 
    Smoking mother    35 (16.4) 0.7 (0.5-1.1) 29 (27.1) 1.3 (0.8-2.2) 12  (28.6)   1.4 (0.6-3.3)e 
    Alcohol use mother    47 (21.8) 1.3 (0.9-2.0) 18 (16.8) 0.9 (0.5-1.7) 12  (27.9)   3.0 (1.3-6.5)f 
In the 3 months prior to conception:      
    Smoking father    80 (37.7) 1.3 (0.9-1.8)c 36 (35.3) 1.0 (0.6-1.6) 17  (48.6)   1.7 (0.8-3.4)d 
    Alcohol use father  169 (79.7) 0.8 (0.5-1.2) 87 (85.3) 1.2 (0.6-2.2) 24  (66.7)   0.5 (0.2-0.9) 
Odds ratio (OR); Confidence Interval (CI); Body Mass Index (BMI). Proportions of missing data were < 
10% per variable, except for alcohol use of father in the total group (12%), and maternal BMI at 
conception (11.1%) and smoking father (22.2%) in the posterior group. The percentages presented 
for the cases and controls are calculated without these missing values. 
a
Adjusted for year of birth; 
b
also adjusted for family history of hypospadias;
 c
also adjusted for paternal educational level; 
d
also 
adjusted for primiparity; 
e
also adjusted for paternal smoking in the 3 months prior to conception; 
f
also adjusted for paternal alcohol use in 3 months prior to conception. 
 
 
Discussion 
 
This study revealed different risk factors for the various phenotypes of hypospadias. In general, 
our data suggest genetic predisposition for anterior and middle hypospadias, illustrated by 
large effect estimates for familial occurrence of hypospadias. In contrast, the posterior 
phenotype was more often and stronger associated with pregnancy-related factors, such as 
multiple pregnancies, primiparity, preterm delivery, and SGA. Using hormone-containing 
contraceptives after conception increased the risk of middle and posterior hypospadias.  
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The fact that we found associations with some factors in specific phenotypes, which were not 
found in the total group of hypospadias cases, stresses the importance of studying these 
associations at the most detailed level possible, which has rarely been performed so far. 
Another strength of our study is the well-characterized group of cases with different 
phenotypes in proportions similar to those in earlier Dutch studies2,11. Furthermore, the wide 
range of risk factors allowed a thorough adjustment for potential confounders. A limitation was 
the self-reported nature of the data with a long time lag between childbirth and filling out the 
questionnaires for some parents. However, we do not expect many problems to have occurred 
with remembering factors such as age at childbirth, subfertility diagnosed by a medical doctor, 
twin pregnancy, parity, preeclampsia, birth weight, and gestational age. Moreover, as control 
parents were not aware of their control status, recall bias is not very likely, except for family 
history of hypospadias, which may have caused overestimation of the OR. 
  
Our finding that family history of hypospadias is more often seen in anterior and middle 
hypospadias confirms two earlier reports in Sweden and the Netherlands11,13, but contradicts 
an American study from 197914. Family history suggests involvement of genetic components, 
which was emphasized by a genome-wide association study identifying the DGKK gene as an 
important risk factor for the anterior and middle phenotypes, but less clearly for posterior 
hypospadias15.  
 
The well-recognized association of hypospadias with low birth weight, especially for posterior 
hypospadias11,16, is further supported by our results on SGA. Similarly, we found associations 
between preeclampsia and hypospadias, but these were not as strongly differentiated between 
the phenotypes as demonstrated in an earlier study showing a pronounced increased risk for 
posterior hypospadias11. The underlying mechanisms for the associations between hypospadias 
and preeclampsia or SGA may be found in a shared pathogenesis, such as placental 
insufficiency. Early placental malfunction may result in inadequate fetal human chorionic 
gonadotropin (hCG) provision and thus in reduced stimulation of fetal testicular 
steroidogenesis before the fetus’ own pituitary-gonadal axis is established. This may influence 
the male external genitalia development. Supportive evidence for this hypothesis is provided 
by studies showing an association between hypospadias and low placental weight17 and 
placental infarction in extremely low birth weight infants with hypospadias18. 
 
For twins and first-born children, the overall risk of having hypospadias was doubled, with 
almost four- and seven-fold increased risks, respectively, for posterior cases. Twinning and 
primiparity have been associated with hypospadias before9,19,20, and primiparity with posterior 
forms in particular16. For twinning, etiologic heterogeneity has not previously been described. 
Our results for maternal BMI are in accordance with those of others10,21. All of these factors 
(twinning, primiparity, and obesity) may be related to a disturbed androgen/estrogen balance, 
as endogenous levels of free estradiol rise with increasing BMI22,23 and are elevated in first and 
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twin pregnancies24. Increased estrogen exposure in utero has been hypothesized to produce 
male reproductive abnormalities such as hypospadias, due to impairment of Leydig cell 
development, or suppression of testosterone production or androgen receptor expression25. 
Oral contraceptives probably cause the highest exogenous estrogen exposure in humans. In 
contrast to what most other researchers found9,12,26,27, we demonstrated strong associations 
between post-conception use of hormone-containing contraceptives and hypospadias, 
especially for middle and posterior hypospadias. 
     
Unlike other studies investigating subgroups of hypospadias16,28, we did not find high maternal 
age to influence hypospadias risk, neither in the subgroups, nor in the total group. The latter is 
in accordance with other reports not distinguishing between phenotypes8,9. Our results on 
lifestyle factors, such as smoking and alcohol use, were divergent, ranging from an increased 
risk of posterior hypospadias for maternal alcohol use to a risk reduction for posterior cases for 
paternal alcohol use. Most previous studies did not find associations with maternal smoking 
and alcohol use 8,10,11, but paternal lifestyle exposures have rarely been investigated.  
 
The background of the seemingly diverse pathogenesis among the different phenotypes is 
unknown. Why do the anterior and middle phenotypes seem to have a more genetically based 
etiology, while posterior types of hypospadias are associated with risk factors implying 
placental insufficiency and a disbalance between androgens and estrogens? During 
development, the labioscrotal swellings fuse to form the scrotum, the urethral folds close to 
form the penile urethra, and several hypotheses exist about the formation of the glandular 
portion of the urethra. A disturbance in one of these embryonic processes may result in 
specific phenotypes of hypospadias. Genetic and/or environmental factors may influence these 
dissimilar processes in different time windows or through different levels or types of exposure. 
Therefore, more fundamental research is needed to disentangle this intriguing puzzle.    
 
 
Conclusions 
 
Our study provides strong indications for etiologic heterogeneity of hypospadias, separating 
the posterior phenotype from anterior and middle phenotypes. Future research should be 
stratified by hypospadias phenotypes to provide more insight into specific risks and 
pathophysiologic mechanisms.  
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The main objective of the research project described in this thesis was to obtain more 
knowledge about the genetic and environmental risk factors contributing to the development 
of hypospadias. Although this issue has received a substantial amount of attention in previous 
research efforts, we used several novel approaches that were expected to enhance knowledge 
significantly and to have a considerable impact on this field of research. First of all, we 
collected and used the largest sample of hypospadias cases described in genetic studies thus 
far. In addition, we were one of the first to investigate gene-environment interactions involved 
in hypospadias aetiology, and we performed the first genome-wide association study (GWAS) 
for this malformation. Finally, we collected detailed phenotypic information and used this to 
stratify the analyses for different subgroups of hypospadias. In this chapter, I will first consider 
some methodological issues. Thereafter, I will discuss our results, give some directions for 
future research, and consider potential clinical implications. 
 
 
Discussion of the methods used 
 
Study design and populations 
All studies described in this thesis were performed retrospectively, meaning that information 
about risk factors was obtained after the outcome was established, and most studies had a 
case-control design, implying that affected patients were compared to unaffected individuals. 
Because of the relatively low prevalence of hypospadias, this is an efficient design, but one has 
to be aware of potential biases.  
 
Genetic association studies with a case-control design (Chapter 2.1 and Chapter 2.3) are prone 
to bias due to population stratification. This is a specific form of selection bias, which occurs 
when cases and controls are drawn from subgroups that differ in disease prevalence and 
frequency of the genetic variant studied. Although the fear of population stratification has 
probably been exaggerated1, we further reduced the chance of this type of bias by selecting 
cases and controls of European descent only and living in the same area of the Netherlands. 
Although the controls were clearly older than the cases, we do not expect that the different 
birth cohorts would have caused bias due to time effects either, as this is unlikely to occur for 
genetic factors within one generation. More importantly, we excluded such effects as the case-
control results for the four candidate genes were confirmed using a case-parent triad design in 
the gene-environment interaction analyses (Chapter 2.2), and the association with DGKK from 
the GWAS was validated in the transmission disequilibrium test using the genotypes of the 
parents (Chapter 2.3). Both of these methods are insensitive to population stratification.  
 
Although the case-parent triad design used in the gene-environment interaction analyses 
(Chapter 2.2) is robust to population stratification, a drawback is that associations with 
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environmental risk factors cannot be identified. Therefore, this design was only used to study 
associations with the genotypes and interactions between genotypes and environmental 
factors. The design is based on the assumption that exposure to the environmental factor 
studied is independent of the genotype at the candidate locus. Furthermore, it assumes that 
offspring genotypes follow Mendelian proportions for each parental mating type. These 
assumptions are violated if the genotype modifies behaviour or survival, but this is unlikely for 
the frequently occurring single nucleotide polymorphisms (SNPs) we investigated.  
 
Selection bias could also be an issue in our case-control studies on environmental risk factors 
(Chapter 3.1 and 3.2). For these studies, we selected a control population with the same age 
and from the same geographical area as the cases to minimise the chance of this type of bias. 
We used a hospital-based control population of boys with otitis media with effusion (OME) 
who received ear ventilation tubes, which we consider to be an appropriate control group. First 
of all, OME is a very common disease in childhood, suggesting that the control group is 
representative for the general population. Secondly, the causal mechanism leading to OME is 
different from that leading to hypospadias, and the disorders do not seem to share any risk 
factors2,3. Nevertheless, OME may be associated with some of the exposures under study (e.g. 
maternal use of antibiotics), but this was taken into account in the interpretation of our 
findings. Because the two studies on environmental factors used the same control population, 
spurious results due to the selection of the control population may have been observed in both 
studies. However, the second study focused specifically on differences between the 
hypospadias subgroups, which are independ of the control population.  
 
Data collection 
Genotyping 
We used  5’ nuclease TaqMan SNP genotyping assays for all individual genotyping. These 
assays generate high-confidence results, are fast and easy to use, and do not need post-PCR 
processing, which minimises the chance of sample swops. As genotyping errors can seriously 
affect the power of genetic association studies4, we used stringent criteria to call the 
genotypes and repeated each genotyping of which we were not completely sure. In addition, 
we loaded five wells of each 96-well plate with randomly selected duplicate DNA samples from 
the same and other plates, and we included four blanks in each plate. All duplicate samples 
had to match, and plates with more than one positive blank were repeated. Furthermore, 
genotype frequencies in controls or parents were tested for accordance with Hardy-Weinberg 
equilibrium to identify systematic genotyping errors, which were not discovered. Eventually, 
genotyping was completed with a high success rate of at least 98% in all samples, except for 
the Dutch replication sample of the GWAS in Chapter 2.3, which was genotyped with a lower, 
but still adequate, success rate of more than 95%. This lower rate can be attributed to the 
poorer DNA quality of part of the samples, which resulted in their exclusion from the DNA 
pools in the discovery phase, earlier.   
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DNA pooling 
In the discovery phase of the GWAS (Chapter 2.3), we used DNA pools instead of individual 
DNA samples. While this design reduces the costs for such a hypothesis-generating study 
substantially, which enabled our group to perform the GWAS, it also decreases power for gene-
identification. Pool construction is sensitive to variations in DNA amounts among individuals 
contributing to the pool, and microarray measurement can introduce variation in the 
estimation of luminescence intensities, both leading to less accurate allele frequency 
estimates. Because of this, we might have missed interesting associations that we would have 
found with a GWAS based on genotyping of individual samples.  
 
Next to introducing an additional source of error, the use of DNA pools had some other 
drawbacks. First of all, it required tedious laboratory work in the preparatory phase as DNA 
concentrations had to be determined very precisely. We used triplicate PicoGreen 
quantifications, for which DNA needed to be diluted 1000-fold in two dilution steps followed by 
two days of homogenisation. Having determined the DNA concentrations, equal quantities of 
DNA from each sample were added to the pools. Accuracy of the pools was tested by 
comparing the allele frequencies of individually genotyped SNPs in the individuals contributing 
to a pool with the allele frequencies of these SNPs determined in the pool. These preparations 
took over half a year of laboratory work. 
 
An additional drawback is that, while analysis techniques for individual GWAS data are widely 
available, and consensus is reached about the best approach, this is not the case when using 
pooled DNA. A few GWASs had been carried out using pooled DNA, but the investigators all 
used different analysis techniques, so it took quite some effort to determine the optimal 
approach. In addition, many quality control steps cannot be performed in the pooled design 
(e.g. exclusion of individuals whose GWA data reveal substantial differences in genetic 
background, setting thresholds for the calling of genotypes, and exclusion of SNPs not in Hardy-
Weinberg equilibrium), while the analyses are limited to comparing allele frequency 
differences between predefined groups. Haplotype assessment cannot be performed, analyses 
cannot be corrected for other known risk factors, and gene-gene and gene-environment 
interactions cannot be studied. Despite these drawbacks, I still consider the use of DNA pools a 
sensible alternative approach if insufficient finances are available for a GWAS with individual 
samples, but only for traits that have not been the subject of a GWAS yet. 
 
Questionnaires 
We used self-administered questionnaires to collect environmental data. This is a fast and 
relatively easy way to obtain information, but self-report may result in recall bias, arising when 
cases remember or report past events differently from controls. To minimise the chance of this 
type of bias, we used hospital-based case and control populations unaware of their 
case/control status. Still, the time lag between birth of the affected child and filling out the 
General discussion 
 
171 
questionnaires may have resulted in misclassification. The use of composite exposure 
parameters derived from several items in the questionnaire for foetal human chorionic 
gonadotropin (hCG) provision and maternal oestradiol levels (Chapter 2.2), instead of 
measuring these factors directly, further increases the chances of misclassification. These 
forms of misclassification are most likely non-differential, however, and may have resulted in 
attenuation of some results rather than in bias. 
 
Power 
We used the largest sample of hypospadias cases described in genetic studies so far. The SNP 
replication study (Chapter 2.1) was performed in a sample of approximately 600 cases and 600 
controls, which provided us - based on the odds ratios and allele frequencies in the original 
studies - with enough power to detect the previously reported associations had they been 
present in our population. Similarly, the sample used in the gene-environment interaction 
analyses (Chapter 2.2) was, with more than 700 cases, large enough to identify these genetic 
associations as well. However, numbers of cases having a specific genotype ánd being exposed 
to a particular environmental risk factor were in some instances too small to convincingly 
detect or discard interactions, especially with the low prevalence of some risk factors. 
Therefore, these results need confirmation. The discovery phase of the GWAS (Chapter 2.3) 
included 450 cases and 500 controls, providing limited power for a GWAS due to the correction 
that needs to be made for multiple testing. Therefore, we likely missed some interesting 
associations. The studies on environmental risk factors (Chapter 3.1 and 3.2) included 305 and 
405 cases, respectively and 629 or 627 controls, which was enough to identify risk factors in 
the total group, but the analyses in the posterior subgroup in particular had limited power. The 
fact that most associations did show similar trends in both studies, however, strengthens these 
findings. Some other results from these studies still need independent replication. 
 
 
Inferences from the main findings 
 
Genetic studies 
We aimed to replicate the most interesting genetic associations reported for hypospadias, and 
genotyped 4 SNPs in SRD5A2, ESR1, ESR2, and ATF3. SRD5A2 encodes an enzyme that converts 
testosterone to dihydrotestosterone, and the SNP that we examined results in an approxi-
mately 30% decrease in enzyme activity5,6. The other SNPs are intronic haplotype-tagging SNPs, 
not likely to be causal themselves, but rather a marker for an unknown, linked variant. ESR1 
and ESR2 encode nuclear hormone receptors that act as transcription factors to regulate genes 
involved in homeostasis, development, and metabolism. Studies in mice show that Esr1 
mediates oestrogen signalling in classic oestrogen target tissues such as the uterus, the 
mammary gland, and the skeleton, whereas Esr2 regulates signalling in the ovary, immune 
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system, prostate, gastrointestinal tract, and hypothalamus7. Both receptors are expressed in 
male reproductive organs, also during development8. ATF3 is an oestrogen-responsive gene 
showing strong up-regulation in hypospadias9. In vitro studies showed that the ATF3 
homodimer is a transcriptional repressor, whereas ATF3 may activate transcription when co-
expressed with its heterodimeric partners10.  
 
While all four genes are considered valid hypospadias candidate genes from a gene function 
point of view, our results did not confirm previously reported associations with the SNPs in 
SRD5A2, ESR2, and ATF3. The association with the variant in ESR1 showed a trend in the same 
direction as reported, although much less strong. The lack of consistency between our study 
and previously performed studies might have been caused by several factors, as we elaborated 
on in Chapter 2.1. We hypothesized that real differences between the populations studied, 
such as differences in environmental exposures, could be causing the different findings. 
Therefore, we tested the presence of gene-environment interactions in Chapter 2.2. Of the two 
interactions that we identified, the one between foetal exposure to cytokines and the SNP in 
ATF3 did not reconcile our findings with the previously reported results, whereas the one 
between exogenous oestrogen exposure and the variant in SRD5A2 did. The SNP showed an 
association with hypospadias in exposed cases only, suggesting that the decreased enzyme 
activity caused by the variant increases hypospadias risk in the presence of additional 
oestrogen exposure. The studies that initially reported the association were performed in 
Chinese and Swedish populations, which may experience higher phyto-oestrogen exposures 
due to the consumption of soy products, rye bread, and berries. As a result, I think that this 
SNP increases hypospadias risk in specific populations only, based on interaction with 
population-specific exposure to environmental risk factors.  
 
In addition to gene-environment interactions, other (epi)genetic mechanisms may be involved 
in the aetiology of hypospadias, such as effects of the maternal genotype or gene imprinting. 
Therefore, we also examined maternal effects of these four genes and whether risks differed 
depending on the parental origin of the risk allele. We did not find associations between 
maternal genotype of the investigated SNPs and hypospadias risk. Nevertheless, I want to 
emphasise the potential role of maternal genotypes in the pathogenesis of congenital 
malformations, because their products may affect the intrauterine environment and thus the 
development of the foetus. For example, maternal polymorphisms in PON1 seem to increase 
the risk of spina bifida-affected offspring11, the A1298C SNP in maternal MTHFR was associated 
with a higher risk of schizophrenic descendants12, and for children of mothers carrying TPH1 
mutations, higher ADHD scores were reported than for controls or for progeny of fathers with 
the corresponding mutations13.  
 
In the parent-of-origin analyses, we found that only a maternally derived copy of the variant in 
ESR1 seemed to be associated with increased hypospadias risk, suggesting that the paternally 
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derived allele may be imprinted. As ESR1 is not one of the currently known imprinted genes, I 
would like to reflect on whether or not it is likely that the maternally derived allele of ESR1 is 
more fully expressed. Moore and Haig summarised the explanation for the evolution of 
imprinting as follows: “The more resources an embryo acquires from its mother, the larger it is 
at birth, and the more likely it is to survive and reproduce. However, the greater the nutrient 
demand of the pregnancy, the greater the cost to the mother's potential future reproduction. 
This creates a conflict between the interests of the maternal and paternal genes within an 
embryo because the mother's future offspring will sometimes have a different father”14. 
Following this hypothesis and our results, I would expect ESR1 to reduce growth of the foetus, 
but epididymal fat pad weights were similar in Esr1 knockout and wild-type male mice five days 
after birth15. In line with my expectation, however, large increases in white adipose tissue were 
seen in the knockout mice at subsequent ages15. In addition, introduction of exogenous ESR1 
results in growth inhibition in cultured colon carcinoma cells16. This confirms the hypothesis 
that the paternally derived allele may be imprinted, but does not explain how the variant 
would influence the occurrence of hypospadias. 
 
In general, our results suggest that genes involved in endocrine processes may be less 
important in hypospadias aetiology than previously assumed. To identify new variants that 
would increase hypospadias risk, we subsequently performed a hypothesis-free search by 
undertaking the first GWAS for this malformation and replicating the results in two additional 
samples. Unlike GWASs for many other diseases or traits, our results clearly pointed towards 
one major risk gene for hypospadias, diacylglycerol kinase κ (DGKK). We found odds ratios 
(ORs) of 2.5 when we individually genotyped two SNPs in this gene, which is exceptionally high 
for results from a GWAS where the largest effect estimates are often between 1.2 and 1.5 (see 
GWAS catalog on www.genome.gov).  
 
DGKK encodes a human type II diacylglycerol kinase. Diacylglycerol kinases modulate the 
balance between diacylglycerol and phosphatidic acid, two signalling lipids, thereby playing an 
important role in signal transduction. Diacylglycerol regulates cell growth and differentiation. A 
fraction of another member of the DGK family (DGKζ) is found in the nucleus, where it reduces 
the amount of nuclear diacylglycerol, attenuating cell growth17. If DGKK would have the same 
function, it could induce hypospadias by affecting growth and differentiation of cells forming 
the genital tubercle, if overactive in those cells. We indeed showed expression of DGKK in 
preputial tissue, but in contrast to the assumption made, this expression was lower in 
individuals with the risk allele. In addition, DGKK was shown to be persistently localised at the 
cell periphery, probably at the plasma membrane, instead of in the nucleus18. Therefore, it 
seems unlikely that DGKK causes hypospadias by an effect on cell growth. However, many 
other processes are involved in the development of the male external genitalia, including cell 
migration, differentiation, and apoptosis.   
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Searching the KEGG database for pathways involving diacylglycerol and phosphatidic acid 
revealed that diacylglycerol also plays an important role in the production and release of 
luteinizing hormone (LH) and follicle stimulating hormone (FSH) by the anterior pituitary. LH 
stimulates testosterone production in the Leydig cells, but during embryogenesis, placental 
hCG stimulates testicular steroidogenesis. According to Larsen’s Human Embryology19, pituitary 
gonadotropin release begins during the second and third trimester of foetal development, and 
LH receptors on Leydig cells begin to appear at 12 weeks. If DGKK influences the production of 
LH and LH is required for the production of enough testosterone and DHT to finish the 
formation of the male external genitalia, this could be a causal mechanism in the aetiology of 
hypospadias. In addition, it could explain why the SNPs in DGKK had less effect on the 
occurrence of posterior hypospadias, which arises earlier during development. Because DGKK 
phosphorylates diacylglycerol to form phosphatidic acid, it would need to be more active in 
developing brain tissue of carriers of the varant. The fact that DGKK is not expressed in adult 
brain tissue18 and DGKK expression is lower in preputial tissue of individuals with the risk allele, 
however,  does not support this hypothesis, although we do not know anything about DGKK in 
foetal brain.   
 
For 8 out of the other 9 variants that we genotyped in individual samples of the GWAS 
discovery cohort, the associations with hypospadias were confirmed. None of these 
associations were statistically significant in the replication samples, but the meta-analysis 
showed associations with the variants in GRID1, KIAA2022, PPARGC1B, and SLCO3A1. The 
association with the SNP in SLCO3A1 had a lower level of significance in the meta-analysis than 
in the discovery sample, indicating that the replication studies did not add evidence for this 
variant. GRID1 encodes a subunit of glutamate receptor channels in the central nervous system 
(NCBI) and is not an obvious candidate for the aetiology of hypospadias. The function of 
KIAA2022 is not clear. We only know that KIAA2022 mRNA is highly expressed in the foetal and 
adult brain, and that an inversion on the X-chromosome that disrupts this gene plus a G-
protein coupled purinergic receptor gene located in the pseudoautosomal region has been 
associated with X-linked mental retardation20. PPARGC1B is a co-activator of ESR1, enhancing 
its activity. This makes it an interesting candidate for hypospadias aetiology, although it shows 
low expression in the testis21. However, nothing is known about the expression of all of these 
genes in developing penile tissue. 
 
DGKK and hypospadias heritability 
Falconer proposed a liability threshold model for multifactorial diseases in which all factors 
influencing the development of a disorder can be considered as a single entity known as 
liability. The liabilities of all individuals in a population form a continuous variable with a 
normal distribution, and a threshold exists above which the disease develops (Figure 1)22. A 
small twin study estimated the heritability of hypospadias to be 77%, which means that 77% of 
the variation in liability can be attributed to genetic factors. This does not imply that 77% of 
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hypospadias cases are due to genetic factors, which is a common misunderstanding caused by 
the difference between variation and causation. Vineis and Pearce illustrated this difference 
with phenylketonuria (PKU), which is caused by a combination of a mutation and a diet rich in 
phenylalanine, as an example23. If nobody had the mutation, there would be no PKU, so 100% 
of cases are attributable to the genetic factor. But all cases would also be prevented if 
phenylalanine would be removed from the diet, so 100% of cases are attributable to the 
environment. In other words, attributable proportions sum up to more than 100%. The 
heritability estimate is highly dependent on the population studied: in a population where 
everybody has a phenylalanine-rich diet, 100% of the variation in liability is attributable to 
genetic factors, whereas in a population where everybody has the mutation, 100% of the 
variation is attributable to environmental factors. 
 
 
Figure 1.  Liability threshold model proposed by Falconer et al. 
 
 
 
 
 
To calculate the amount of heritability of hypospadias explained by rs1934179 in DGKK, I used 
a logistic regression model with the SNP as independent and hypospadias as dependent 
variable, which I applied to the Swedish replication sample because discovery samples often 
overestimate the effect of the genetic variant identified. The Nagelkerke R2 of the model, a 
pseudo R2, was 6.2%. Although there is debate about the correctness and interpretation of 
pseudo R2s, they can be interpreted as the amount of variation in a continuous latent variable 
that is explained by the model. In our case, this means that 6.2% of the variation in liability can 
be attributed to the SNP in DGKK. If we assume that the heritability estimate of 77% would 
apply to the Swedish situation, we can calculate that the variant explains 8% of the heritability. 
Although this is a high percentage to be explained by a single variant, it also implies that there 
must be many other genetic variants contributing to hypospadias.  
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The issue of ‘missing heritability’ applies to most multifactorial disorders, as shown by Manolio 
et al. who listed a number of diseases for which the heritability currently explained by the loci 
detected in GWASs ranges from 1.5% (fasting glucose) to 50% (age-related macular 
degeneration)24. Many explanations have been suggested for missing heritability, such as large 
numbers of variants with small effects yet to be found, rare variants (possibly with large 
effects) poorly detected by the current microarrays, or structural variations inadequately 
captured. These explanations are also very likely in our case, especially with the low power of 
our GWAS to detect variants with small effects. Other hypotheses are that the risks observed 
for the markers may underestimate the actual risk associated with the causal variant, that 
other mechanisms, such as epigenetics or parent-of-origin effects, contribute to the disorders, 
or that the heritability estimates are overestimated due to inadequate accounting for shared 
environment among relatives. Again, all of these issues could contribute to our missing 
heritability, and in addition, the estimate of 77% may not be representative for the heritability 
in the Swedish population. The suggestion that gene-gene interactions play a role in missing 
heritability is not likely in our case, since the estimate of 77% is the ‘narrow sense’ heritability, 
which is usually interpreted as the amount of variation attributable to additive genetic factors.  
 
Environmental studies 
In 2001, Skakkebæk et al. suggested that poor sperm quality, testicular cancer, undescended 
testes, and hypospadias are symptoms of one underlying entity, the Testicular Dysgenesis 
Syndrome (TDS)25. Although we could not study the occurrence of multiple TDS components in 
our cases, we did show an increased hypospadias risk with the occurrence of hypospadias or 
testicular cancer in first or second degree relatives. A longer time to pregnancy and paternal 
subfertility increased the risk of hypospadias in the first study (Chapter 3.1), but these effects 
were much less clear in the second study (Chapter 3.2). Clear-cut associations with familial 
occurrence of cryptorchidism were not observed, but our findings provide some support for 
shared susceptibility among the TDS component disorders.  
 
We found associations with low birth weight or being small for gestational age, preterm 
delivery, and maternal hypertension and preeclampsia, suggesting that placental insufficiency 
is involved in hypospadias aetiology. Inadequate provision of hCG to the foetus, which controls 
foetal Leydig cell growth and stimulates foetal testicular steroidogenesis before the foetus’ 
own pituitary-gonadal axis is established, may play an important role in the development of 
hypospadias. Oestradiol levels are thought to be increased in dizygotic twin pregnancies 
involving two placentas and in first pregnancies26. In addition, serum oestradiol levels increase 
with increasing body mass index (BMI)27. The associations with primiparity and twin or triplet 
pregnancies, as well as the association with high maternal body mass index found in one 
(Chapter 3.2), but not in the other study (Chapter 3.1), suggest a role for endogenous 
hormones in the aetiology of hypospadias.  
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Parental age was not associated with hypospadias risk, and neither were the majority of 
maternal and paternal lifestyle factors examined (e.g. prescriptive drug use, use of folate 
supplementation, having a vegetarian diet, intake of soy or seafood, occupational exposure, 
alcohol use, or smoking). Specifically, our results provided little evidence for an increased risk 
of hypospadias due to maternal or paternal exposure to endocrine disrupting chemicals (EDCs), 
except for the strongly increased risk associated with the use of oral contraceptives during 
pregnancy observed in our second study only (Chapter 3.2). The fact that EDCs can induce 
hypospadias in murine models28 and that several mechanisms exist by which EDCs could 
influence male reproductive function29 suggests that these substances have the potential to 
induce hypospadias in humans. In my opinion, however, exposure levels in humans are not 
high enough to exert this effect. 
 
Hypospadias subgroups 
A factor that we found to be potentially of great importance when performing studies on 
hypospadias was the location of the urethral opening. The development of the various forms of 
hypospadias in different time windows, possibly through disturbances of dissimilar processes 
could be an explanation. The labioscrotal swellings fuse to form the scrotum, while closure of 
the urethral folds contributes to the formation of the penile urethra. The mechanism behind 
the development of the glandular portion of the urethra is not exactly clear yet. Most likely, 
these different processes are influenced by specific risk factors.  
 
Therefore, the location of the urethral opening was taken into account in all studies. Maternal 
and offspring genotypes of the four SNPs examined in the replication study and in the gene-
environment interaction analyses showed no clear differences between the forms of 
hypospadias. Because of these equal results, the analyses for interactions and parent-of-origin 
effects were not conducted separately for the different subgroups. The GWAS was performed 
in anterior and middle hypospadias cases only, but an additional analysis of the SNPs in DGKK 
in posterior cases showed weaker associations. In addition, familial clustering of hypospadias 
was much more pronounced in the anterior and middle hypospadias cases than in the 
posterior forms, whereas primiparity, preeclampsia, low birth weight or being small for 
gestational age, and in utero exposure to oral contraceptives showed a more obvious risk 
increase for posterior hypospadias.  
 
Based on these results, I suggest that anterior and middle forms of hypospadias have an 
oligogenic or polygenic multifactorial aetiology, including a crucial role for DGKK, with 
involvement of other genes and environmental factors. Posterior forms of hypospadias are 
more likely the result of a strong single causal factor, such as a mutation in a single gene or 
inadequate hCG provision following placental insufficiency.  
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Directions for future research 
 
To investigate the contribution of genetic factors to the aetiology of multifactorial disorders, 
such as hypospadias, candidate gene-based approaches are becoming outdated. The more 
recent procedure of screening the whole genome for common variants using GWASs is 
currently being caught up by yet newer techniques such as exome or even whole-genome 
sequencing. The advantage of the latter techniques is that rare variants, variable number 
tandem repeats (VNTRs), and copy number variants (CNVs) are also detected. A disadvantage 
of these methods is that the statistical analysis methods for such enormous amounts of data 
are not yet sufficiently developed, and neither is our understanding of the functional 
consequences of the majority of variants found in the genome. Moreover, sequencing is as yet 
too expensive to be applied to the large cohorts that are needed for association studies. 
 
In my opinion, there are several promising prospects for the future of multifactorial genetic 
research. The sequencing efforts in patients with monogenic disorders that are currently 
ongoing will identify many novel sequence features of the human genome, including millions of 
moderately rare variants (0.1-5% frequency). The identification of such additional low-
frequency alleles will, however, further increase the sample sizes needed to identify 
associations of genome-wide significance. Large-scale international collaborations and 
extensive biobanking efforts are the only solutions to meet this requirement. Furthermore, 
sequencing techniques may be applied to pooled samples of patients with multifactorial 
disorders to reduce costs. However, the costs of the sequencing techniques are already coming 
down rapidly, and bioinformatics and statistics are catching up fast. So eventually, whole 
genomes of thousands of patients and controls will be sequenced. 
  
In addition to purely genetic studies, gene-environment interaction analyses are needed to 
unravel the aetiology of multifacorial disorders. These analyses would best be performed using 
cases and controls instead of cases and their parents, as we did. The case-parent triad design 
only enables exploration of SNP effects in the presence or absence of environmental factors, 
without the possibility of making inferences about risks associated with the exposures. It is 
more intuitive, however, to assume that genetic background increases or decreases 
susceptibility for an environmental exposure, and to investigate the effect of this exposure 
separately for people with and without the genetic variant.  
 
Based on our own results, some more specific leads for further research can be provided as 
well. The fact that the SNP in SRD5A2 showed an increased hypospadias risk only when the 
mother was exposed to oestrogens, shown in Chapter 2.2, needs to be verified, and functional 
studies may shed light on the mechanism leading to this result. For example, to evaluate 
whether oestrogen exposure influences SRD5A2 expression, mouse genital tubercles could be 
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cultured in vitro in hormone-free medium and in the presence of oestradiol, followed by 
examination of SRD5A2 expression using quantitative RT-PCR30. In the same chapter, we 
hypothesized that the paternally derived allele of ESR1 may be imprinted in the male external 
genitalia during embryogenesis. To confirm this assumption, ideally, we would need tissue 
from the developing human genital tubercle of an eight to 14 weeks old foetus. Alternatively, 
prepuce tissue from circumcised boys or foetal tissue from an animal model (such as the 
mouse or pig) could be used, although imprinting status may change over time or may not be 
conserved among species. The material would need to be heterozygous at a polymorphic locus 
in ESR1 and at least one of the parents would need to be homozygous in order to determine 
which allele is derived from which parent. RT-PCR reactions could generate DNA from the RNA 
present in the tissue. Genotyping the polymorphic locus would then establish whether both 
alleles or only one allele is expressed and, in the latter case, which one.  
 
The GWAS described in Chapter 2.3 also provides leads for further research. In addition to the 
SNPs in DGKK, variants in GRID1, KIAA2022, and PPARGC1B may be associated with 
hypospadias; results that need more definite confirmation. In addition, targeted resequencing 
efforts may enable the identification of the causal variant underlying the association of 
rs1934179 in DGKK with hypospadias, which may be a variant regulating DGKK expression. 
Furthermore, functional studies for DGKK in experimental animal models, such as knockdown 
or overexpression studies in mice, may help to determine the function of the gene and provide 
novel insights about pathways leading to hypospadias.  
 
To confirm the hypotheses that endogenous maternal hormone levels and reduced foetal 
provision of hCG play a role in the aetiology of hypospadias, studies artificially influencing 
oestradiol and hCG levels in pregnant mice may be performed. Prospective studies determining 
oestrogenic activity in maternal plasma and measuring maternal hCG levels during pregnancy 
may further increase knowledge on this subject. 
 
Based on our results and previously published data, we advise that in all future studies, 
stratified analyses will be performed for the different subgroups of hypospadias. 
 
 
Clinical implications 
 
Although the identification of DGKK as a major risk gene for hypospadias is only a first step 
towards improving hypospadias prediction, treatment, or prevention, I would like to discuss 
the possible clinical implications that our findings may have in the future. Prof. Slatkin from the 
University of California calculated for us the genotype-specific hypospadias recurrence risks for 
rs1934179 in DGKK, using the method described in one of his articles31. If a mother has a son 
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with hypospadias, the chance that her second son will also be affected is 13%. This is 8% if the 
second son has the normal DGKK allele and 20% if he has the SNP. This difference, although 
quite large, is probably not discriminative enough to be used in preconceptional genetic 
counselling. Since there is no intervention to improve the outcome (yet), prenatal screening for 
DGKK is not clinically useful either.  
 
 
Figure 2.  Three causal mechanisms of disease according to the model of causation 
proposed by Rothman et al. 
 
 
 
 
Since the aetiology of hypospadias is multifactorial, we may at some point find an environ-
mental factor that could influence DGKK. Using the model of causation introduced by Rothman 
et al.33, we can calculate what the impact would be if it were possible to ‘repair’ the causal 
variant underlying the association with the SNPs in DGKK. In this model, a disease can be 
caused by more than one causal mechanism, while every causal mechanism involves the action 
of a multitude of component causes (Figure 2)32. Most component causes are neither 
necessary, implying that they are not present in every causal mechanism, nor sufficient, 
meaning that they must interact with other component causes to produce disease. Still, 
removal of a component cause may prevent a substantial proportion of the disease. We 
calculated the population attributable fraction (PAF) for hypospadias of rs1934179 in DGKK for 
the Swedish population, again because discovery samples often overestimate the effect of the 
genetic variant identified. The PAF was 31.5%, meaning that the variant underlying the 
association is a component cause of the causal mechanism in nearly one third of hypospadias 
cases. This means that we could prevent one third of hypospadias cases if it were possible to 
‘repair’ DGKK.  
 
As shown in the calculation in Figure 3, we would need to provide treatment to 168 woman 
pregnant of a boy in order to prevent one hypospadias case. Before that, we would need to 
screen all unborn boys for the presence of the variant and treat all boys with the variant early 
in pregnancy, without the certainty that hypospadias would develop without the remedy. As 
yet, we do not know which variant underlies the association of rs1934179 with hypospadias, 
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Figure 3. Calculation of the number needed to treat. 
 
 
 
and the actual causal variant is likely to be less frequent with a larger effect, which means that 
the number needed to treat will be somewhat lower than the number calculated here. Still, a 
substantial number of boys who would not have developed hypospadias would need to be 
treated, so the remedy would need to be cheap and non-invasive without side effects. This 
may seem unrealistic at the moment, but in the future, a preventive advise may perhaps be 
given regardless of the presence of the variant. The recommendation to use folate 
supplementation during pregnancy is a good example of such a preventive measure, which 
turned out to be effective for prevention of neural tbe defects. 
 
Prevention of environmental exposures contributing to hypospadias is more straightforward in 
this regard. This would require education of couples that are planning a pregnancy or 
regulatory actions regarding the chemical content of all kinds of products. The findings in our 
and other studies on environmental risk factors, however, do not form a strong foundation for 
such preventive measures yet.  
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Summary 
 
Hypospadias is a common congenital malformation of the male external genitalia, with 
displacement of the urethral opening on the ventral aspect of the penis accompanied by other 
malformations of the corpora, subcutaneous tissue, and skin. There is a large diversity in 
manifestations of hypospadias, with the opening being located glandular, penile, penoscrotal, 
scrotal, or even in the perineal region. In a small percentage of cases, especially in posterior 
cases, monogenic causes for the malformation can be identified, such as a steroid-5-alpha-
reductase type II deficiency or a partial androgen insensitivity due to androgen receptor 
mutations. The aetiology of the majority of hypospadias cases, however, is as yet unknown and 
likely to be multifactorial, implicating both genes and environmental factors.  
 
The aim of this research project was to obtain more knowledge about the genetic and 
environmental risk factors contributing to the development of hypospadias. We hypothesized 
that the various hypospadias subgroups may have a different aetiology.  
 
Part 1: Introduction and literature review 
After a short general introduction in Chapter 1.1, we describe an extensive review of the 
literature on hypospadias in Chapter 1.2. In this review, we summarised all current knowledge 
about the aetiology of hypospadias, both on genetic and environmental factors.  
 
Different study designs have been used to study genetic factors implicated in the aetiology of 
hypospadias, and several genes have been identified. Screening hypospadias patients for single 
gene-defects identified mutations in the genes WT1, SF1, BMP4, BMP7, HOXA4, HOXB6, FGF8, 
FGFR2, AR, HSD3B2, SRD5A2, ATF3, MAMLD1, MID1, and BNC2. In addition, case-reports listed 
mutations in CYP11A1, CYP17A1, and HSD17B3, while association studies found polymorphisms 
in FGF8, FGFR2, AR, HSD17B3, SRD5A2, ESR1, ESR2, ATF3, MAMLD1, DGKK, MID1, CYP1A1, 
GSTM1, and GSTT1 to be risk factors for hypospadias. Additional candidate genes for 
hypospadias aetiology include genes involved in syndromes commonly associated with the 
disorder, such as HOXA13, HOXD13, ZEB2, and EFNB2, and genes that cause hypospadias when 
deleted or mutated in animal models, such as Ephb2. Lastly, gene expression studies 
indentified CTGF, CYR61, and EGF as candidate genes. 
 
Much of the research on environmental risk factors for hypospadias has been focused on 
environmental endocrine disrupting chemicals (EDCs), which are substances that have the 
potential to interfere with the natural hormones in the human body. The fact that EDCs can 
induce hypospadias in murine models and may influence male reproductive function by several 
mechanisms suggests that these substances may also induce hypospadias in humans, but the 
question remains whether exposure levels are high enough to exert this effect. Given that even 
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strong hormonal exposures, such as from hormonal stimulation to induce pregnancy and use of 
oral contraceptives while pregnant, do not show consistent associations with hypospadias, 
exogenous hormones and EDCs may not be as important in the aetiology of hypospadias as has 
previously been assumed. 
 
The consistent associations of hypospadias with low birth weight, maternal hypertension, and 
preeclampsia suggests that placental insufficiency may be a major risk factor for hypospadias, 
possibly through inadequate provision of human chorionic gonadotrophin (hCG) to the foetus. 
Direct proof of a link between placental insufficiency and hypospadias was provided by 
research showing associations between hypospadias and low placental weight or placental 
infarctions. A role for endogenous hormones is suggested by increased free oestradiol levels 
linked to high maternal BMI, primiparity, and multiple pregnancies that appear to contribute to 
hypospadias susceptibility.  
 
Maternal intrauterine exposure to diethylstilbestrol (DES), use of anti-epileptic drugs, pre-
existing diabetes, prolonged time to pregnancy, and ICSI-induced pregnancies have also been 
associated with hypospadias in most studies. Suggested protective factors, such as maternal 
use of folate supplementation, and other potential risk factors, such as maternal exposure to 
water disinfection by-products, occupational exposure, use of alcohol or medical drugs, 
smoking, gestational diabetes, parental age, and IVF-induced pregnancies, were not or not 
consistently associated with hypospadias.   
 
Part 2: Genetic studies 
In the second part of this thesis, we focus on genetic factors contributing to the aetiology of 
hypospadias. Chapter 2.1 describes our efforts to replicate the most important genetic 
associations reported for hypospadias at the start of our study. We genotyped 4 SNPs in 
SRD5A2, ESR1, ESR2, and ATF3. Our results did not confirm the previously reported 
associations with SNPs in SRD5A2, ESR2, and ATF3, whereas the association with the variant in 
ESR1 showed a trend in the same direction, but much less strong. The lack of consistency 
between our study and previously performed studies might be caused by spurious results or 
chance findings, differences in the criteria used to select cases and/or controls, or a real 
difference between the populations. As we tried to prevent spurious results due to population 
stratification by careful selection of cases and controls, had a large study population, and found 
comparable results for the separate subgroups of hypospadias, real differences between the 
populations seem likely. This may be differences in the aetiology of hypospadias, due to other 
underlying trait loci or their alleles, differences in environmental exposures between 
populations, or differences in genetic background affecting the associations, if these are 
dependent on interactions with other SNPs or on linkage disequilibrium (LD) with a causal 
allele.  
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In Chapter 2.2, we examined whether the lack of replication could be due to differences in 
environmental exposures between the populations, by testing the presence of gene-
environment interactions. We identified two possible interactions. One was an interaction 
between foetal exposure to cytokines and the SNP in ATF3, which did not reconcile our findings 
with the previously reported results. The other was an interaction between exogenous 
oestrogen exposure and the variant in SRD5A2, with the SNP being associated with 
hypospadias in exposed cases only. The studies that initially reported the association were 
performed in Chinese and Swedish populations, which experience higher phyto-oestrogen 
exposures due to consumption of soy products, rye bread, and berries. The SNP causes a 
decrease in enzyme activity, and additional oestrogen exposure may cause an androgen-
oestrogen imbalance in carriers of this variant, resulting in hypospadias. Because other 
(epi)genetic mechanisms may also be involved in the aetiology of hypospadias, we examined 
whether hypospadias risk was influenced by maternal genotype or differed depending on the 
parental origin of the risk allele. We did not find an association between maternal genotype of 
the investigated SNPs and hypospadias risk, but we did find that only the maternally derived 
copy of the variant in ESR1 was associated with an increased hypospadias risk, suggesting that 
this allele of ESR1 may be more fully expressed than the paternally derived allele in the 
developing embryo.  
 
Chapter 2.3 describes the genome-wide association study (GWAS) that we performed using 
pooled DNA from anterior and middle hypospadias cases. Seven of the 20 highest ranked SNPs 
were located in one X-chromosomal gene encoding diacylglycerol kinase κ, DGKK. Individual 
genotyping of two SNPs in this gene showed that they were strongly associated with 
hypospadias in the discovery sample and in the two replication samples, with odds ratios of 
around 2.5. An additional analysis of the SNPs in cases with posterior hypospadias showed 
weaker associations. Expression studies showed expression of DGKK in preputial tissue of cases 
and controls, which was lower in carriers of the risk allele of the strongest associated SNP. Of 
the other 9 high ranked variants that we genotyped in the individual samples, 8 showed 
associations in the discovery sample, but none of these associations were statistically 
significant in the replication samples. The meta-analysis showed associations with the variants 
in GRID1, KIAA2022, PPARGC1B, and SLCO3A1, but the association with the SNP in SLCO3A1 
was less significant in the meta-analysis than in the discovery sample. 
 
Part 3: Environmental studies 
In the studies described in the third part of this thesis, we aimed to obtain more knowledge 
about the environmental risk factors contributing to the development of hypospadias. Chapter 
3.1 describes a case-control study in which we explored a wide range of potential risk factors. 
Low birth weight, twin or triplet pregnancies, maternal preeclampsia or hypertension, paternal 
subfertility, and familial occurrence of hypospadias were associated with hypospadias in 
general, confirming most previous studies. In addition, the increased risks previously found for 
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diethylstilbestrol-daughters and IVF- or ICSI-induced pregnancies were replicated, although not 
statistically significant. A new finding was the association with familial occurrence of testicular 
cancer. Regarding familial occurrence of hypospadias, high risk estimates were observed for 
anterior and middle hypospadias, but not for posterior cases, whereas the associations with 
low birth weight and preeclampsia seemed much stronger for posterior hypospadias. Most 
maternal factors examined (e.g. age, body mass index, occupational exposures, smoking, use of 
prescriptive drugs or oral contraceptives, folate supplementation, having a vegetarian diet, and 
intake of soy or seafood) were not associated with hypospadias, and neither were the majority 
of paternal factors.  
 
In Chapter 3.2, we specifically focused on risk factors in hypospadias subgroups. Again, family 
history of hypospadias was shown to strongly increase the risk of having a son with 
hypospadias, especially in anterior and middle hypospadias cases. Being part of a twin or 
triplet, primiparity, preeclampsia, preterm delivery, and being small for gestational age were 
associated with hypospadias overall, but particularly in posterior cases. The fact that use of oral 
contraceptives after conception showed a trend towards stronger associations with more 
posterior forms of hypospadias was a rather new finding. This study provides clear indications 
for etiologic heterogeneity of hypospadias, with genetic predisposition being more pronounced 
for anterior and middle hypospadias, and posterior hypospadias being predominantly 
associated with pregnancy-related factors.   
 
Part 4: General discussion 
In the general discussion (Chapter 4.1), we consider several methodological issues, such as the 
study designs and populations used, the methods of data collection, and the power of the 
studies. We also briefly summarise the inferences that can be made from the studies presented 
in this thesis. In addition, we provide several suggestions for future research, such as exome or 
whole-genome sequencing studies to identify new variants involved in the aetiology of 
hypospadias, gene-environment interaction analyses to study the multifactorial character of 
the disorder, or prospective studies measuring oestrogenic activity or hCG levels in maternal 
plasma during pregnancy. In addition, targeted resequencing efforts may identify the causal 
variant underlying the association of the SNPs in DGKK with hypospadias, functional studies for 
DGKK in experimental animal models may help to determine the function of the gene, and in 
vitro culturing of mouse genital tubercles may determine whether oestrogen exposure 
influences SRD5A2 expression. Finally, we discuss the possible clinical implications of the 
identification of DGKK as a major risk gene for hypospadias and the possibilities for prevention. 
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Nederlandse samenvatting 
 
Hypospadie is een veelvoorkomende aangeboren afwijking aan het mannelijke geslachts-
orgaan, die bij 0.3 tot 0.7% van de jongens voorkomt. Bij hypospadie is de plasbuis verkeerd 
aangelegd, waardoor deze niet op de top van de penis uitkomt, maar aan de onderkant. Vaak 
zijn ook de huid, het onderliggende weefsel, en de corpora aangedaan. Hypospadie kent 
verschillende vormen, omdat de opening van de plasbuis in het glandulaire, peniele, 
penoscrotale, scrotale, of zelfs het perineale gebied kan uitkomen. In een klein percentage van 
de gevallen is er een monogene oorzaak, zoals een steroid-5-alpha-reductase type II deficiëntie 
of een gedeeltelijke androgeen ongevoeligheid door een androgeen receptor mutatie. Maar 
meestal kan de oorzaak van hypospadie niet achterhaald worden. Hoogstwaarschijnlijk is de 
etiologie in deze gevallen multifactorieel, wat betekent dat hypospadie door een combinatie 
van genen en omgevingsfactoren veroorzaakt wordt.   
 
Het doel van het onderzoek beschreven in dit proefschrift was om meer kennis te verwerven 
over de genetische en omgevingsfactoren die bijdragen aan het ontstaan van hypospadie. We 
hadden hierbij de hypothese dat de verschillende vormen van hypospadie een andere oorzaak 
zouden kunnen hebben. 
 
Deel 1: Inleiding en overzicht van de literatuur 
Na een korte algemene inleiding in Hoofdstuk 1.1, bevat Hoofdstuk 1.2 een uitgebreide review 
van de literatuur over hypospadie. In deze review vatten we de huidige kennis over de etiologie 
van hypospadie samen, zowel ten aanzien van de genetische als de omgevingsfactoren. 
 
Er zijn verschillende soorten studies gebruikt om de genetische factoren die betrokken zijn bij 
het ontstaan van hypospadie te identificeren. Bij het screenen van hypospadie patiënten op 
defecten in een enkel gen zijn mutaties geïdentificeerd in WT1, SF1, BMP4, BMP7, HOXA4, 
HOXB6, FGF8, FGFR2, AR, HSD3B2, SRD5A2, ATF3, MAMLD1, MID1 en BNC2. Verder zijn 
mutaties gevonden in CYP11A1, CYP17A1 en HSD17B3 in studies die een enkele patiënt 
beschrijven, terwijl associatie studies aantoonden dat polymorfismen in FGF8, FGFR2, AR, 
HSD17B3, SRD5A2, ESR1, ESR2, ATF3, MAMLD1, DGKK, MID1, CYP1A1, GSTM1 en GSTT1 het 
risico op hypospadie verhogen. Andere kandidaatgenen voor hypospadie zijn onder andere 
genen die syndromen veroorzaken waarbij vaak hypospadie voorkomt, zoals HOXA13, HOXD13, 
ZEB2 en EFNB2 en genen die hypospadie veroorzaken als ze gemuteerd zijn in diermodellen, 
zoals EphB2. Tenslotten hebben genexpressie studies CTGF, CYR61 en EGF geïdentificeerd als 
kandidaatgenen.  
 
Veel onderzoek naar omgevingsfactoren die betrokken zouden kunnen zijn bij het ontstaan van 
hypospadie was gericht op hormoonverstorende stoffen die de potentie hebben te 
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interfereren met de natuurlijke hormonen in het menselijk lichaam. Het feit dat deze stoffen 
hypospadie kunnen veroorzaken in diermodellen en dat er verschillende manieren zijn waarop 
deze stoffen het mannelijke voortplantingsstelsel kunnen beïnvloeden, suggereert dat deze 
stoffen hypospadie zouden kunnen veroorzaken in mensen, maar het is de vraag of de 
blootstellingsniveaus hoog genoeg zijn om dit effect teweeg te brengen. Aangezien zelfs sterke 
hormonale blootstellingen, zoals door hormoonstimulerende middelen om een zwangerschap 
te induceren of door pilgebruik tijdens de zwangerschap, geen consistente associatie met 
hypospadie laten zien, zouden exogene hormonen en hormoonverstorende stoffen minder 
belangrijk kunnen zijn in de etiologie van hypospadie dan tot nu toe aangenomen werd. 
 
De consistente associatie van hypospadie met laag geboortegewicht, maternale hypertensie en 
preeclampsie suggereert dat placenta insufficiëntie een belangrijke risicofactor is voor 
hypospadie. Dit zou veroorzaakt kunnen worden doordat de foetus van onvoldoende humaan 
choriongonadotrofine (hCG) wordt voorzien. Onderzoek dat een associatie liet zien tussen 
hypospadie en een laag gewicht van de placenta of placenta-infarcten geeft direct bewijs voor 
een link tussen placenta insufficiëntie en hypospadie. Ook endogene hormonen zouden een rol 
kunnen spelen. Oestradiol niveaus zijn namelijk verhoogd bij een hoge maternale BMI, bij de 
eerste zwangerschap en bij meerlingzwangerschappen, terwijl deze factoren de kans op 
hypospadie verhogen. 
 
Andere factoren die in de meeste studies een associatie lieten zien met hypospadie zijn 
maternale intra-uteriene blootstelling aan diethylstilbestrol (DES), vóór de zwangerschap aan-
wezige diabetes, verlengde tijd tot zwangerschap, ICSI-geïnduceerde zwangerschap en gebruik 
van anti-epileptica vroeg in de zwangerschap. Mogelijk beschermende factoren, zoals 
maternaal gebruik van foilumzuur supplementen, en mogelijke andere risicofactoren, zoals 
maternale blootstelling aan bijproducten van waterzuivering, beroepsblootstellingen, gebruik 
van alcohol of medicijnen, roken, zwangerschapsdiabetes, IVF-geïnduceerde zwangerschap en 
leeftijd van de ouders waren niet of niet consistent geassocieerd met hypospadie. 
 
Deel 2: Genetische studies 
In het tweede deel van dit proefschrift hebben we ons gericht op genetiche factoren die bij 
zouden kunnen dragen aan de etiologie van hypospadie. Hoofdsuk 2.1 beschrijft onze poging 
om de op dat moment belangrijkste genetische associaties gevonden voor hypospadie te 
repliceren. We hebben 4 SNPs (veranderingen in het DNA waarbij een nucleotide vervangen is 
door een ander nucleotide) gegenotypeerd in SRD5A2, ESR1, ESR2 en ATF3. Onze resultaten 
konden de associatie met de SNPs in SRD5A2, ESR2 en ATF3 niet bevestigen. De variant in ESR1 
liet wel een associatie zien in dezelfde richting, maar veel minder sterk. Het verschil tussen 
onze studie en de eerdere studies zou veroorzaakt kunnen worden door verkeerde resultaten, 
door kansbevindingen, door het gebruik van verschillende criteria om de cases en controles te 
selecteren of door een echt verschil tussen de populaties. Omdat we hebben geprobeerd om 
Chapter 4.2 
 
 
192 
incorrecte resultaten middels populatie-stratificatie te voorkomen door de cases en controles 
zorgvuldig te selecteren, een grote studiepopulatie hadden en vergelijkbare resultaten vonden 
voor de verschillende vormen van hypospadie, lijkt het erop dat er echte verschillen zouden 
kunnen zijn tussen de populaties. Dit kunnen verschillen zijn in de etiologie van hypospadie, 
doordat hypospadie in de ene populatie door andere genetische veranderingen veroorzaakt 
wordt dan in een andere populatie, verschillen in de omgevingsblootstellingen tussen 
populaties of verschillen in de genetische achtergrond. Deze kunnen de associaties 
beïnvloeden als deze associaties afhankelijk zijn van interacties met andere SNPs of van linkage 
disequilibrium (LD) met de oorzakelijke variant. 
 
In Hoofdstuk 2.2 hebben we gekeken of het gebrek aan replicatie verklaard kon worden door 
verschillen in omgevingsblootstellingen tussen de populaties, door de aanwezigheid van gen-
omgevingsinteracties te testen. We hebben twee interacties geïdentificeerd. De ene was een 
interactie tussen foetale blootstelling aan cytokines en de SNP in ATF3, die niet kon verklaren 
waarom wij andere resultaten vonden dan de eerdere studie. De andere was een interactie 
tussen exogene blootstelling aan oestrogenen en de SNP in SRD5A2. De SNP was alleen 
geassocieerd met hypospadie in blootgestelde cases. De studies die de associatie initieel 
gevonden hadden waren uitgevoerd in Chinese en Zweedse populaties, die meer blootgesteld 
worden aan fyto-oestrogenen door hogere consumptie van soyaproducten, roggebrood en 
bessen. De SNP veroorzaakt een verminderde enzymactiviteit en additionele oestrogeen-
blootstelling kan een androgeen-oestrogeen disbalans veroorzaken in dragers van de variant, 
hetgeen kan resulteren in hypospadie. Omdat ook andere (epi)genetische processen betrokken 
kunnen zijn in de etiologie van hypospadie, hebben we onderzocht of het risico op hypospadie 
afhankelijk is van de ouder waar het allel vandaan komt of dat het beïnvloed wordt door het 
maternale genotype. We vonden geen associatie tussen het maternale genotype van de SNPs 
en het risico op hypospadie, maar we vonden wel dat de variant in ESR1 alleen het risico op 
hypospadie verhoogde als deze afkomstig was van de moeder. Dit suggereert dat het 
maternale allel van ESR1 sterker tot expressie komt dan het paternale allel in het zich 
ontwikkelende embryo. 
 
Hoofdstuk 2.3 beschrijft de genoombrede associatie studie (GWAS) die we uitgevoerd hebben 
met gepooled DNA van hypospadie cases met een relatief kleine verplaatsing van de urthrale 
opening. Zeven van de 20 hoogst gerankte SNPs lagen in een X-chromosomaal gen dat codeert 
voor diacylglycerol kinase κ, DGKK. Individuele genotyperingen van twee SNPs in dit gen lieten 
zien dat ze sterk met hypospadie geassocieerd waren in de onderzoekspopulatie waarin het 
gen ontdekt was en in twee replicatie populaties, met odds ratio’s van 2.5. In een extra analyse 
van de SNPs in cases met een grotere verplaatsing van de urthrale opening vonden we een 
zwakkere associatie. Expressiestudies lieten zien dat DGKK tot expressie komt in de voorhuid 
van cases en controles en dat deze expressie lager is in dragers van het risico-allel van de 
sterkst geassocieerde SNP. Van de andere 9 hoog gerankte varianten die we in de individuele 
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samples gegenotypeerd hebben, lieten er 8 een associatie zien in de eerste onderzoeks-
populatie, maar geen van deze associaties was statistisch significant in de replicatie populaties. 
In de meta-analyse vonden we associaties met de varianten in GRID1, KIAA2022, PPARGC1B en 
SLCO3A1, maar de associatie met de SNP in SLCO3A1 was minder significant in de meta-analyse 
dan in de eerste onderzoekspopulatie. 
 
Deel 3: Omgevings studies 
In de studies die beschreven worden in het derde deel van dit proefschrift, hadden we als doel 
meer te weten te komen over de omgevingsrisicofactoren die bijdragen aan de ontwikkeling 
van hypospadie. Hoofdstuk 3.1 beschrijft een patiënt-controle onderzoek waarin we een breed 
scala aan risicofactoren bestudeerden. Laag geboortegewicht, twee- of drieling zwanger-
schappen, maternale preeclampsie of hypertensie, paternale subfertiliteit en het voorkomen 
van hypospadie in de familie waren geassocieerd met hypospadie. Deze bevindingen 
bevestigen de meeste eerdere studies. Verder werden de verhoogde risico’s die eerder 
gevonden werden voor diethylstilbestrol-dochters en IVF- of ICSI-geïnduceerde zwanger-
schappen gerepliceerd, maar niet statistisch significant. Een nieuwe bevinding was de 
associatie met familiair voorkomen van testiskanker. Wat betreft familiair voorkomen van 
hypospadie werden hoge risicoschattingen gevonden voor de vormen van hypospadie met een 
kleine verplaatsing van de urthrale opening, maar niet voor de vormen met een grote 
verplaatsing. De associaties met laag geboortegewicht en preeclampsie leken juist veel sterker 
voor vormen van hypospadie met een grote verplaatsing. De meeste maternale factoren die 
onderzocht werden (bv. leeftijd, body mass index, beroepsblootstellingen, roken, gebruik van 
voorgeschreven medicijnen of orale anticonceptie, foliumzuursuppletie, een vegetarisch dieet 
en inname van soya, vis of schaaldieren) waren niet geassocieerd met hypospadie. Ook de 
meeste paternale factoren waren niet geassocieerd. 
 
In Hoofdstuk 3.2 hebben we ons specifiek gericht op de risicofactoren voor de verschillende 
vormen van hypospadie. Weer vonden we een sterk verhoogd risico voor een familie-
geschiedenis van hypospadie, vooral voor de vormen met een kleine verplaatsing van de 
urethrale opening. Maternale preeclampsie, primipariteit, vroeggeboorte, behoren tot een 
twee- of drieling of klein zijn voor de zwangerschapsduur waren geassocieerd met hypospadie 
in het algemeen, maar vooral met een grote verplaatsing van de urethrale opening. Het feit dat 
het gebruik van orale anticonceptie na de bevruchting ook sterker geassocieerd leek te zijn met 
deze vorm van hypospadie was een nieuwe bevinding. Onze studie liet een duidelijke 
etiologische heterogeniteit van hypospadie zien, waarbij genetische factoren een duidelijkere 
rol spelen in vormen met een kleine verplaatsing van de urethrale opening, terwijl de vormen 
met een grotere verplaatsing juist vooral geassocieerd zijn met zwangerschapsgerelateerde 
factoren. 
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Deel 4: Algemene discussie 
In de algemene discussie (Hoofdstuk 4.1) gaan we in op verschillende methodologische 
aspecten, zoals de study designs en populaties die we gebruikt hebben, de methoden van 
dataverzameling, en de power van de studies. We vatten ook kort de conclusies samen die uit 
de studies die gepresenteerd worden in dit proefschrift getrokken kunnen worden. Verder 
geven we verschillende suggesties voor verder onderzoek, zoals exoom of whole-genome 
sequencing studies om nieuwe varianten die betrokken zijn bij het ontstaan van hypospadie te 
identificeren, gen-omgeving interactie analyses om het multifactoriële karakter van de 
aandoening te bestuderen of prospectieve studies om de oestrogene activiteit of de hCG 
niveaus in het maternale plasma te meten tijdens de zwangerschap. Verder kunnen gerichte 
resequencing pogingen de causale variant identificeren die ten grondslag ligt aan de associatie 
van de SNPs in DGKK met hypospadie, kunnen functionele studies naar DGKK in diermodellen 
helpen om de functie van het gen te achterhalen en kunnen in vitro technieken waarbij het 
genitale tuberkel van muizen gekweekt wordt bepalen of oestrogeenblootstelling SRD5A2 
expressie kan beïnvloeden. Tot slot bespreken we de mogelijke klinische gevolgen van de 
identificatie van DGKK als een risicogen voor hypospadie en de mogelijkheden voor preventie.  
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List of abbreviations 
 
AGORA Aetiologic research into Genetic and Occupational / environmental Risk factors 
for Anomalies in children 
AMH anti-Müllerian hormone 
AR androgen receptor 
ART assisted reproductive technique 
ATF3 activating transcription factor 3 
BMI body mass index 
BMP bone morphogenetic protein (BMP2, BMP4, BMP7) 
BSN2 basonuclin 2 
Chr chromosome 
CI confidence interval 
Ct cycle treshold 
CTGF connective tissue growth factor 
CXorf6 chromosome X open reading frame 6 
CYP1A1 cytochrome P450 (CYP1A1, CYP11A1, CYP17A1)  
CYR61 cysteine-rich, angiogenic inducer, 61 
DBP di-n-butyl phthalate 
DDE dichlorodiphenyldichloroethane 
DDT dichlorodiphenyltrichloroethane 
DES diethylstilbestrol 
DGKK diacylglycerol kinase kappa 
DHCR7 7-dehydrocholesterol reductase 
DHT dihydrotestosterone 
DNA deoxyribonucleic acid 
DSD disorders of sex development 
EDC endocrine disrupting chemical 
EDTA ethylenediaminetetraacetic acid 
EFNB2 Ephrin-B2 
EGF epidermal growth factor 
EPHB2 EPH receptor B2 
ESR oestrogen receptor (ESR1, ESR2) 
EUROCAT European Concerted Action on Congenital Anomalies and Twins 
FGF fibroblast growth factor (FGF8, FGF10) 
FGFR fibroblast growth factor receptor (FGFR2) 
FKBP4 FK506 binding protein 4 
FSH follicle stimulating hormone 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
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GLI1 GLI family zinc finger 1 
GRID1 glutamate receptor, ionotropic, delta 1 
GST glutathione S-transferases (GSTM1, GSTT1) 
GT genital tubercle 
GWAS genome-wide association study 
hCG human chorionic gonadotropin 
HOX homeobox (HOXA4, HOXA13, HOXB6, HOXD13) 
HSD17B3 hydroxysteroid (17-beta) dehydrogenase 3 
HSD3B2 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 
HSH hypospadias sine hypospadias 
ICSI intracytoplasmic sperm injection 
INSL3 insulin-like 3 
IUGR intrauterine growth retardation 
IVF in vitro fertilisation 
kb kilobases 
KIAA2022 KIAA2022 
LD linkage disequilibrium 
LH luteinizing hormone 
LRT likelihood ratio test 
MAF minor allele frequency 
MAMLD1 mastermind-like domain containing 1 
MID1 midline 1 
mRNA messenger ribonucleic acid 
MSX1 msh homeobox 1 
MTHFD1L methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like 
NBS Nijmegen Biomedical Study 
NCBI National Centre for Biotechnology Information 
OME otitis media with effusion 
OR odds ratio 
PAF population attributable fraction 
PAIS partial androgen insensitivity syndrome 
PCB polychlorinated biphenyl 
PCR polymerase chain reaction 
PO-LRT parent-of-origin likelihood ratio test 
PPARGC1B peroxisome proliferator-activated receptor gamma, coactivator 1 beta 
PTCH1 patched 1 
RAFk k-corrected raw allele frequency 
RAS relative allele signal 
RNA ribonucleic acid 
RR relative risk 
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RT-PCR reverse transcription polymerase chain reaction 
RUNMC Radboud University Nijmegen Medical Centre 
SD standard deviation 
s.e.m. standard error of the mean 
SF1 splicing factor 1 
SGA small for gestational age 
SHH sonic hedgehog 
SLC16A12 solute carrier family 16, member 12 (monocarboxylic acid transporter 12) 
SLCO3A1 solute carrier organic anion transporter family, member 3A1 
SMO smoothened, frizzled family receptor 
SNP single nucleotide polymorphism 
SOS1 son of sevenless homolog 1 (Drosophila) 
SOX9 sex determining region Y -box 9 
SRBD1 s1 RNA binding domain 1 
SRD5A2 steroid-5-alpha-reductase 
SRY sex determining region Y 
TAT transmission asymmetry test 
TDS testicular dysgenesis syndrome 
TMEM70 transmembrane protein 70 
Tris-HCL tris(hydroxymethyl)aminomethane 
TTC28 tetratricopeptide repeat domain 28 
TTP time to pregnancy 
UCSC University of California, Santa Cruz  
UDT undescended testes 
Wnt5A wingless-type MMTV integration site family member 5A 
WT1 Wilms tumour 1 
ZEB2 zinc finger E-box binding homeobox 2 
ZOON Zoon Ouder Onderzoek Nijmegen 
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Dankwoord 
 
Eindelijk! Het serieuze deel van mijn proefschrift is af! Nu alleen nog het minder weten-
schappelijke, maar daarmee niet minder belangrijke deel… het dankwoord! Over het algemeen 
het meest gelezen deel van een proefschrift, op de stellingen na. En zo’n boekje schrijf je niet 
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endless conversations in the car. Thanks to you, I loved the home visits! Stephan en Rogier, 
dankzij jullie was ook mijn vrije tijd in Indonesië geweldig! Sporten en eten bij S2, internetten 
in DP mall en rennen en bier drinken met de Hash. Bedankt dat jullie mij op sleeptouw hebben 
genomen! 
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En dan zijn er die 3 vriendinnen waar ik alles mee deel. 
Reggy, bij jou voel ik me op mijn gemak. Wat wil je ook; ik ken je al bijna 20 jaar! En al 
die tijd al ‘beste vriendinnen’. Maatjes in alles. Zonder ons gaan feestjes niet door en ‘naar 
huis’ kennen wij niet. Verder zijn we eigenlijk tegenpolen, maar misschien dat dat nu juist de 
kracht is. Dankzij jou zie ik dat niet altijd alles snel hoeft en dat niks doen ook lekker is.  
Dorien, al tijdens de scheikunde practica op Beekvliet was duidelijk dat wij allebei van 
efficiënt houden. Het klikte dan ook meteen en later als huisgenoten gebeurde zelfs het bood-
schappen doen op de meest efficiënte wijze. Best bijzonder tijdens de studie; alles deden we 
samen en toch waren we vrijdagmiddag op de terugweg in de trein nog steeds niet uitgekletst! 
Loes, jou ken ik sinds de 1e werkgroep van de studie. Jij kwam voor mij binnen en 
stelde je voor. Dus ik volgde: “Hoi, ik ben ook Loes.” Het ijs was meteen gebroken en we zijn 
steeds meer naar elkaar toe gegroeid. Wat hebben wij vaak gefilosofeerd over de wetenschap 
en onze carrières. Heerlijk om daar met iemand over te praten die ‘in hetzelfde schuitje’ zit. 
Dorien en Loes, bedankt dat jullie mijn paranimfen willen zijn! Jammer dat ik er geen 3 mag… 
 
Pa, ma, en Wies, fijn dat jullie zo trots op me zijn! Het is een heel andere wereld dan jullie 
gewend zijn, die wetenschap. Maar toch proberen jullie altijd mee te leven met alles wat ik 
vertel. Wies, fijn dat onze band de laatste tijd weer wat hechter wordt. Ik heb ontzettend veel 
zin in Thailand! 
 
En last but not least; Tim! Ook voor jou is het soms lastig de cultuur van de wetenschaps-
wereld te begrijpen en jouw geduld wordt af en toe dan ook flink op de proef gesteld. Fijn dat 
je altijd geïnteresseerd bent in mijn verhalen, ook al begin ik vaak ergens halverwege. En dank 
je wel voor de vrijheid die je me geeft om dat te doen wat ik leuk vind, niet alleen op werk-
gebied. Ikvinjoulief!  
Dankwoord 
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PhD theses Human Reproduction, Nijmegen Centre for 
Evidence Based Practice (NCEBP) 2000-2012 
 
 
2000 
1. 07-02-2000 Els van der Molen 
 Disturbed homocysteine metabolism endothelial dysfunction and placental vasculopathy 
2. 29-06-2000 Willianne Nelen 
Risk factors for recurrent early pregnancy loss. Hyperhomocysteinaemia, thrombophilia 
and impaired detoxification 
3. 05-09-2000 Ina Beerendonk 
 Sodium and ovarian hyperstimulation. Some clinical and psychological aspects 
4. 04-12-2000 Anne-Marie van Cappellen van Walsum 
 Cerebral metabolism of hypoxic fetal sheep by NMR spectroscopy 
5. 18-12-2000 Friso Delemarre 
Vascular aspects of human pregnancy. Clinical studies on sodium restriction and 
angiotensin infusion 
 
2001 
6. 10-1-2001 Way Yee Wong 
 Male factor subfertility. The impact of lifestyle and nutritional factors 
7. 5-6-2001 Petra Zusterzeel 
 Biotransformation enzymes and oxidative stress in preeclampsia 
8. 5-10-2001 Cathelijne van Heteren 
 Development of habituation and memory in the human fetus 
9. 10-10-2001 Michael Gaytant 
 Cytomegalovirus and herpes simplex virus infections in pregnancy 
 
2002 
10. 25-1-2002 Ron van Golde 
 Male subfertility and genetics 
11. 21-5-2002 Tanja de Galan-Roosen. 
 Perinatal Mortality 
 
2003 
12. 08-01-2003 Maarten Raijmakers 
Oxidative stress and detoxification in reproduction with emphasis on glutathione and 
preeclampsia 
13. 18-2-2003 Sabine de Weerd 
 Preconception counselling. Screening & periconceptional health 
14. 22-4-2003 Iris van Rooij 
 Etiology of Orofacial Clefts. Gene-environment interactions and folate 
15. 17-12-2003 Chris Verhaak 
 Emotional impact of unsuccessful fertility treatment in women 
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2004 
16. 14-01-2004 Liliana Ramos 
 The quality of epididymal sperm in azoospermia 
17. 04-10-2004 Pascal Groenen 
Nutritional and environmental factors in human spina bifida. An emphasis on myo-
inositol 
18. 24-11-2004 Tanya Bisseling 
Placental function in maternal disease. Ex vivo assessment of foetoplacental vascular 
function and transport in diabetes and preeclampsia 
19. 15-12-2004  Eva Maria Roes  
 Oxidant-antioxidant balance and maternal health in preeclampsia and HELLP syndroom 
 
2005 
20. 01-06-2005 Marieke Rijnsaardt-Lukassen  
 Single Embryo Transfer: clinical and immunological aspects 
21. 10-11-2005 Ingrid Krapels 
 The etiology of orofacial clefts. An emphasis on lifestyle and nutrition other than folate 
 
2006 
22. 14-06-2006 Reini Bretveld 
 Fertility among greenhouse workers 
23. 09-11-2006 Jesper Smeenk 
 Stress and IVF. Clinical consequences 
 
2007 
24. 08-02-2007 Inge Ebisch 
Human subfertility: explorative studies on some pathophysiologic factors in semen and 
follicular fluid 
25. 01-11-2007 Alwin Derijck  
 The transmission of chromatin and DNA lesions by sperm and their fate in de zygote (1) 
26. 01-11-2007 Godfried van der Heijden 
 The transmission of chromatin and DNA lesions by sperm and their fate in de zygote (2) 
27. 03-12-2007 Kirsten Kluivers 
 On the measurement of recovery following hysterectomy 
28. 10-12-2007 René Kok 
 Proton Magnetic Resonance Spectroscopy of Human fetal brain 
 
2008 
29. 10-12-2008 Trudie Gerrits  
 Clinical encounters: Dynamics of patient-centred practices in a Dutch fertility clinic 
30. 12-12-2008 Wouter Tuil 
 IVF and Internet 
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2009 
31. 06-03-2009 Ineke Krabbendam 
 Venous reserve capacity & autonomic function in formerly preeclamtic women 
32. 03-09-2009 Arno van Peperstraten 
 Implementation of single embryo transfer 
 
2010 
33. 10-03-2010 Suzanne Broekhuis 
 Dynamic MR imaging in female pelvic floor disorders 
34. 12-03-2010 Bea Lintsen  
 IVF in the Netherlands: success rates, lifestyle, psychological factors and costs 
35. 21-04-2010 Selma Mourad  
 Improving fertility care: the role of guidelines, quality indicators and patients 
 
2011 
36. 24-02-2011 Monique Brandes 
 Observational studies in reproductive medicine 
37. 04-04-2011 Marijn Brouwers 
Why foetal development of male reproductive structures sometimes fails. An 
epidemiologic study on hypospadias and undescended testis with a focus on endocrine 
disruptors 
38. 22-06-2011 Marian Spath 
Risk estimate for fragile X-associated primary ovarian insufficiency: genetic, 
environmental and reproductive factors 
39. 30-06-2011 Inge van Empel 
Patient-centredness in fertility care 
40. 18-11-2011 Gwendolyn Woldringh 
ICSI children. Follow-up after ICSI with ejaculated or non-ejaculated sperm 
 
2012 
41. 20-01-2012 Esther Haagen 
Guidelines in IUI, implications for quality improvement 
42. 17-02-2012 Loes van der Zanden 
Aetiology of hypospadias: from genes to environment and back 
 
 
